JOURNAL OF

# Pharmaceutical Sciences

A publication of the American Pharmaceutical Association

*Published monthly under the supervision of the Committee on Publications with the approval of the Board of Trustees*

*Editor*
EDWARD G. FELDMANN

*Associate Editor*
DURWARD F. DODGEN

*Associate Editor*
MARY H. HUDSON

*Production Editor*
EVELYN KILSHEIMER

*Contributing Editor*
SAMUEL W. GOLDSTEIN

*Contributing Editor*
RHEA LORIS TALLEY

*Committee on Publications*

ROBERT C. JOHNSON, *chairman*
WILLIAM S. APPLE
GROVER C. BOWLES, JR.
GEORGE P. HAGER
JOHN H. NEUMANN

*Editorial Advisory Board*

JOSEPH P. BUCKLEY
JACK COOPER
EDWARD R. GARRETT
W. LEWIS NOBLES
GORDON H. SVOBODA
JOSEPH V. SWINTOSKY

VOLUME 57

INDEX TO AUTHORS
INDEX TO SUBJECTS

JANUARY TO DECEMBER, 1968

© Copyright 1968 by the American Pharmaceutical Association

# Author Index


A

**Abou-Moustafa, A.,** and Khalifa, M., new compounds: synthesis of some phosphorus–nitrogen compounds for pharmacological study. II, 532; III, 1625

**Abou-Zeid, Y. M.,** *see* Alpad, L. R., 1068

**Abraham, D. J.,** *see* Maloney, E. M., 1035

**Acharya, R. N.,** and Chaubal, M. G., essential oil of *Anemopsis californica*, 1020

**Adams, H. J.,** *see* Dittert, L. W., 774; 1146; 1269

——*see* Misher, A., 1128

**Advani, S. B.,** and Sam, J., potential antineoplastic agents: *N*-(2-benzoxazolyl)amino acid esters, 1693

**Agarwal, S. P.,** and Blake, M. I., determination of the pKa′ value for 5,5-diphenylhydantoin, 1434

**Agrawal, K. C.,** and Sartorelli, A. C., potential antitumor agents III. Sodium salts of α-(*N*)-heterocyclic carboxaldehyde thiosemicarbazones, 1948

**Aguiar, A. J.,** Wheeler, L. M., Fusari, S., and Zelmer, J. E., evaluation of physical and pharmaceutical factors involved in drug release and availability from chloramphenicol capsules, 1844

**Ahuja, S.,** paper chromatographic assay of glyceryl guaiacolate in a pharmaceutical formulation, 313

——Spitzer, C., and Brofazi, F. R., study on dosage variations of individual capsules and tablets of desipramine and imipramine hydrochloride, 1979

**Albert, K.,** and Windheuser, J. J., separation and determination of chlorpheniramine and its dealkylated metabolites from urine, 2085

**Alexander, F.,** *see* Dittert, L. W., 1146

**Allen, R. C.,** remarks on the synthesis of benzofurans, 192

**Alpad, L. R.,** Khalifa, M., Abou-Zeid, Y. M., and Gabali, E., new compounds: certain alkanolamine esters likely to possess anesthetic activity, 1068

**Amanat, M.,** *see* Weiner, N. D., 1398

**Amin, P. R.,** *see* Foye, W. O., 1793

**Amin, S. W.,** *see* Wahba, S. K., 1231

**Anderson, C. A.,** *see* Balazs, M. K., 2002

**Andrako, J.,** *see* Duncan, R. L., Jr., 979

——*see* Stubbins, J. F., 534

**Anello, J. A.,** *see* Levy, G., 101

**Angelino, N. J.,** *see* Levy, G., 1449

**Anschel, J.,** *see* Swartz, C. J., 1779

**Aparajithan, K.,** *see* Sam, J., 564

**Appelt, G. D.,** and Heim, H. C., effect of chronic poisoning by emetine on oxidative process in rat heart III. Effects on oxidation of pyruvate and lactate, 1428

——Walker, N. O., and Brown, R. G., effect of mescaline on nicotinamide adenine dinucleotide synthesis in the central nervous system, 527

**Apple, M. A.,** *see* Bulkacz, J., 1017

**Araujo, O. E.,** *see* Yakatan, G. J., 155

**Arnett, W. A.,** *see* Templeton, R. J., 1168

**Arranda, E. S.,** *see* Rader, B. R., 847

**Arret, B.,** and Eckert, J., new developments in antibiotic interference thresholds of microbial assays, 871

**Arrigoni, E.,** *see* Benzi, G., 1031; 1301

**Ascione, P. P.,** Zagar, J. B., and Chrekian, G. P., quantitative determination of gallamine triethiodide, 1768

**Augsburger, L. L.,** and Shangraw, R. F., bubble size analysis of high consistency aerosol foams and its relationship to foam rheology. Effects of container emptying, propellent type, and time, 624

**Autian, J.,** *see* Jones, A. B., 293

——*see* O'Leary, R. K., 1552

**Avis, K. E.,** *see* Ray, M. D., 609

——*see* Turnbull, R. T., 1409

**Awad, A. T.,** *see* Tomko, J., 329

B

**Back, N.,** *see* Nagashima, R., 68

**Bafna, S. L.,** *see* Bhat, C. V., 1195

——*see* Hegde, R. S., 598

——*see* Kanhere, S. S., 342

**Bahal, C. K.,** *see* Poole, J. W., 1945

**Bailey, J. V.,** *see* Wagman, G. H., 1319

**Balazs, M. K.,** Anderson, C. A., and Lim, P., rapid assay method for the determination of methotrexate, 2002

**Ballard, B. E.,** biopharmaceutical considerations in subcutaneous and intramuscular drug administration, 357

**Banes, D.,** deterioration of nitroglycerin tablets, 893

**Banker, G. S.,** *see* Gore, A. Y., 1850

——*see* McClintock, W. J., 1649

——*see* Willis, C. R., Jr., 1598

**Barbier, F.,** and DeWeerdt, G. A., thin-layer chromatography and IR spectrophotometry of commercial sodium sulfobromophthalein solutions, 819

**Bardos, T. J.,** *see* Datta-Gupta, N., 300

——*see* Mukherjee, S. L., 516

**Barfknecht, C. F.,** and Chih Peng, H., antifertility factors from plants I. Preliminary extraction and screening, 1607

**Barrett, J.,** Puckett, R., and Poe, R. D., a spectrophotometric method for the analysis of strychnine phosphate in the presence of magnesium stearate, 1249

**Barry, H., III,** *see* Watzman, N., 1572; 2089

**Bates, T. R.,** *see* Gibaldi, M., 708

**Bauer, L.,** *see* Conway, T. T., 455

**Beal, J. L.,** *see* Tomko, J., 329

**Beasley, J. G.,** *see* Christian, S. T., 1025

**Becker, B. A.,** Hindman, K. L., and Gibson, J. E., enhanced mortality of selected central nervous system depressants in hypoexcretory mice, 1010

**Becker, C. H.,** *see* Cusimano, A. G., 1104

——*see* John, P. M., 584

——*see* Raghunathan, Y., 1748

——*see* Robinson, I. C., 49

**Beckett, A. H.,** *see* Wilkinson, G. R., 1933

**Beckstead, H. D.,** Kaistha, K. K., and Smith, S. J., determination and thin-layer chromatography of phenylbutazone in presence of decomposition products, 1952

**Beebe, A. J.,** *see* Stubbins, J. F., 534

**Beirwaltes, W. H.,** *see* Counsell, R. E., 1958

**Bejnarowicz, E. A.,** and Smolenski, S. J., gas chromatographic analysis of the essential oil from *Achillea millefolium* L., 2160

**Belcastro, P.,** *see* Rifino, C. B., 351

**Below, L. E.,** Leung, A. Y., McLaughlin, J. L., and Paul, A. G., cactus alkaloids IV. Macromerine from *Coryphantha runyonii*, 515; erratum, 2184

**Benedict, R. G.,** *see* Neal, J. M., 1661

**Bennett, J. W.,** *see* Orth, R. E., 1814

**Benzi, G.,** Berté, F., Crema, A., and Arrigoni, E., renal metabolizing activity studied in dog and monkey by the isolated perfused kidney *in situ*, 1301

——Berté, F., Crema, A., and Arrigoni, E., uterine-placental-fetal preparation *in situ* on the dog. Investigation of metabolizing activity and tissue distribution, 1031

**Bergen, A.,** *see* Commons, K. C., 1253

**Bernardo, P. D.,** *see* Ravin, L. J., 1075

**Berté, F.,** *see* Benzi, G., 1031; 1301

**Beyer, W. F.,** automated colorimetric analysis of ethinyl estradiol and mestranol in pharmaceutical tablets, 1415

——and Zipple, K. G., comparison of iron assays in multivitamin products using an automated chemical procedure and an X-ray emission method, 653

**Bhansali, K. G.,** *see* Huang, C. L., 1511

**Bhargava, U. C.,** and Westfall, B. A., antitumor activity of *Juglans nigra* (black walnut) extractives, 1674

——Westfall, B. A., and Siehr, D. J., preliminary pharmacology of ellagic acid from *Juglans nigra* (black walnut), 1728

**Bhat, C. V.,** Kamath, B. R., Shar, R. S., Kanhere, S. S., and Bafna, S. L., studies with ion-exchange resins on cinchona alkaloids II. Effects of the ionic form and of the solvent medium, 1195

**Bhatt, R. A.,** *see* Hegde, R. S., 598

**Bhattacharya, A. K.,** *see* Finnegan, R. A., 1039

**Bhut, D. J.,** *see* Devani, M. B., 1051

**Bianchi, E.,** Caldwell, M. E., and Cole, J. R., antitumor agents from *Bursera microphylla* (*Burseraceae*) I. Isolation and characterization of deoxypodophyllotoxin, 696

**Bičan-Fišter, T.,** quantitative separation and estimation of steroid mixtures by thin-layer chromatography II. Determination of progesterone and estradiol benzoate and of progesterone, testosterone propionate, and estradiol benzoate in mixtures, 169

**Bickerton, R. K.,** *see* Halliday, R. P., 430

**Biles, J. A.,** *see* Koda, R. T., 2056

**Billman, J. H.,** and Khan, M. S., hexahydropyrimidines IX. Synthesis of 2-substituted-1,3-bis[2-methyl-4-[*N*,*N*-bis(2-chloroethyl)-amino]-benzyl]-hexahydropyrimidines as transport molecules for tumor inhibition, 1817

——and May, R. F., 1,3,2-dioxaphosphorinane 2-oxides III. The preparation and antitumor evaluation of some 3,9-disubstituted-2,4,8,10-tetraoxa-3,9-diphosphaspiro[5.5]-undecane 3,9-dioxide, 1812

——May, R. F., and Heard, J. E., 1,3,2-dioxaphosphorinane 2-oxides. I, Preparation of some 2-alkoxy, 2-acyl, and 2-hydroxy-5-alkyl-5-nitro-1,3,2-dioxaphosphorinane 2-oxides as potential antitumor agents, 1622; II, Preparation and antitumor activity of some 2-alkylamino and 2-arylamino-5-alkyl-5-nitro-1,3,2-dioxaphosphorinane 2-oxides, 1809

**Birner, J.,** determination of *p*-hydroxyphenoxy methyl penicillin in phenoxymethyl penicillin fermentation samples, 1606

**Bischoff, K. B.,** and Dedrick, R. L., thiopental pharmacokinetics, 1346

**Blake, M. I.,** *see* Agarwal, S. P., 1434

——*see* Mohammed, K., 2049

——*see* Nona, D. A., 975; 1993

——*see* Rhodes, H. J., 1706

**Blaug, S. M.,** *see* Wesolowski, J. W., 811

**Blodinger, J.,** *see* Jacob, J. T., 1854

**Blomster, R. N.,** *see* Farnsworth, N. R., 2174

——*see* Maloney, E. M., 1035

——*see* Masoud, A. N., 587

——*see* Tin-Wa, M., 2167
**Blondo, D.,** *see* Weiner, N. D., 1398
**Blunden, G.,** and Rhodes, C. T., stability of diosgenin, 602
**Boggs, P. P.,** *see* Quintana, R. P., 230
**Bolton, S.,** *see* Mario, E., 418
——*see* Pfeffer, M., 1375
**Bonkoski, S.,** and Perrin, J. H., measurement of the apparent dissociation constants of some betaine salts by spectropolarimetry, 1784
**Bonorden, R.,** *see* Wertalik, F., 530
**Booth, A. Z.,** Long, J. P., and Long, K. R., miotic activity produced by inhibitors of acetylcholinesterase, 172
**Borazan, H. N.,** *see* Goyan, F. M., 861
**Bordun, M.,** *see* Klutch, A., 524
**Borke, M. L.,** Madan, P. B., and Martin, B. D., neutron activation analysis of *l*-ephedrine and norephedrine silver complexes, 1788
**Bornstein, M.,** Lach, J. L., and Munden, B. J., iron-adjuvant interactions observed with diffuse reflectance spectroscopy, 1653
**Boudjouk, M. G.,** *see* Chafetz, L., 1000
**Bousquet, W. F.,** *see* Riñno, C. B., 351
**Bowles, W. H.,** stability of prednisolone in an organic vehicle, 1057
**Bowman, F. W.,** *see* White, M., 1061
**Bowman, P. B.,** and West, W. E., gas chromatographic assay for α-tocopheryl acetate in multivitamin products, 470
**Boylan, J. C.,** and Robison, R. L., rheological stability of a procaine penicillin G suspension, 1796
**Bracey, A.,** and Selzer, G., determination of microgram quantities of belladonna alkaloids in neomycin-kaolin-pectin suspension, 464
**Bradley, C. A.,** *see* Voldeng, A. N., 1053
**Brady, L. R.,** *see* Neal, J. M., 1661
**Brannon, W. L.,** *see* Hayden, A. L., 858
**Brashier, G. K.,** *see* Eickholt, T. H., 1431
**Breckinridge, C. E., Jr.,** *see* Spitznagle, L. A., 764
**Brenner, R. J.,** *see* Janicki, C. A., 451
**Briden, R. C.,** Smissman, E. E., and Creese, M. W., long-range spin-spin coupling in bicyclo[3.1.0]hexane systems, 1523
**Briggen, S.,** *see* Zoglio, M. A., 1877
**Briggs, G. G.,** *see* Martin, A. R., 166
**Brochmann-Hanssen, E.,** and Hirai, K., opium alkaloids VII. Isolation of a new benzylisoquinoline alkaloid. synthesis and NMR studies of papaveroline trimethyl ethers, 940
——Hirai, K., Nielsen, B., Pfeifer, S., Mann, I., and Kühn, L., opium alkaloids VI. Isolation of *N*-methyl-14-*O*-desmethylepiporphyroxine, 30
**Brofazi, F. R.,** *see* Ahuja, S., 1979
**Brook, D. B.,** and Marshall, K., "crushing strength" of compressed tablets I. Comparison of testers, 481
**Brooke, D.,** and Guttman, D. E., complex formation influence on reaction rate IV. Studies on the kinetic behavior of 3-carbomethoxy-1-methylpyridinium cation, 1677
——and Guttman, D. E., salt effects in the spectrophotometric examination of a complex of *N'*-methylnicotinamide cation, 1206
**Brown, M. R. W.,** survival of *Pseudomonas aeruginosa* in fluorescein solution. Preservative action of PMN and EDTA, 389
**Brown, N.,** *see* Lefar, M. S., 1442
**Brown, R. G.,** *see* Appelt, G. D., 527
——*see* Gomer, S. K., 1586
——*see* Schwartz, H. F., II, 1530
**Browning, R. S., Jr.,** Grego, J., and Warrington, H. P., Jr., gas chromatographic determination of hexachlorophene in blood and urine, 2165
**Bruce, R. B.,** and Maynard, W. R., Jr., fenfluramine metabolism, 1173; errata, 2184
**Brunnett, E. W.,** and McCarthy, W. C., heterocyclic amines V. Electrophilic substitution in some carbamate derivatives of 3-aminothiophene, 2003
**Bryant, R.,** Mantle, D. E., Timma, D. L., and Yoder, D. S., single-tablet assays. Automated assay of single tablets of isoxsuprine hydrochloride, 658
**Buckley, J. P.,** *see* Jandhyala, M. L., 1576
——*see* Watzman, N., 1572; 2089
**Budavari, S.,** *see* Urbányi, T., 1386
**Buisman, J. A. K.,** Hanewald, K. H., Mulder, F. J., Roborgh, J. R., and Keuning, K. J., evaluation of the effect of isomerization on the chemical and biological assay of vitamin D. Analysis of fat-soluble vitamins X, 1326
**Bulkacz, J.,** Apple, M. A., Craig, J. C., and Naik, A. R., thiophene analogs of sulfanilamide: bacterial growth inhibitors, 1017
**Burckhalter, J. H.,** *see* Sinsheimer, J. E., 333; 1938
**Burkman, A. M.,** Ringham, G. L., and Weinswig, M. H., some pharmacological and toxicological properties of several phthalimidoaldehydes, 815
——*see* Wiley, M. R., 2011

C

**Cadwallader, D. E.,** *see* Das Gupta, V., 112; 1199; 2140
**Caldwell, H. C.,** *see* Dittert, L. W., 774; 828
——*see* Swintosky, J. V., 752
**Caldwell, M. E.,** *see* Bianchi, E., 696
**Caliari, R. E.,** *see* Munies, R., 824
**Campbell, A. H.,** Stasse, J. A., Lord, G. H., and Willson, J. E., *in vivo* evaluation of local anesthetics applied topically, 2045
**Cantwell, F. F.,** *see* Hiskey, C. F., 2105
**Caprioli, R.,** *see* Weiner, N. D., 1398
**Carboni, S.,** Grothe, E., and Saettone, M. F., synthesis of imidazolthiones from 3,4-diphenyl-4-oxazolin-2-thione, 1063
**Carey, C. E.,** *see* Choulis, N. H., 1048
**Carroll, D. M.,** *see* Mathison, I. W., 1820
**Carstensen, J. T.,** apparatus for solution kinetics, 494
——Johnson, J. B., Spera, D. C., and Frank, M. J., equilibrium phenomena in solid dosage forms, 23
**Cartwright, F. D.,** *see* Haley, T. J., 321
**Castello, R. A.,** Jellinek, G., Konieczny, J. M., Kwan, K. C., and Toberman, R. O., dissolution apparatus with multiple testing stations, 485
**Cates, L. A.,** and Nelson, J. A., phosphorus-nitrogen compounds VIII. Urethan derivatives, 189
**Chafetz, L.,** Boudjouk, M. G., Tsilifonis, D. C., and Hom, F. S., validation of methanol–sulfuric acid colorimetry as a stability assay method for quinestrol by comparison with a gas chromatographic procedure, 1000
——and Daly, R. E., stability determination of homatropine hydrobromide by direct cerimetric titration, 1977
——Schriftman, H., and Kay, A. I., validity of the Doty reaction as a stability-indicating assay for isoproterenol in an aerosol preparation, 710
——*see* Talmage, J. M., 1073
**Chalmers, R. K.,** *see* Ghafghazi, T., 1690
**Chang, H.-H.,** *see* Wolff, M. E., 1450
**Chatten, L. G.,** and Racz, W. J., quantitative determination of some synthetic antiparkinsonism agents, 137
——*see* Yung, D. K., 2073
**Chaubal, M. G.,** *see* Acharya, R. N., 1020
**Chemburkar, P. B.,** *see* Garrett, E. R., 944; 949; 1401
**Cheng, C. C.,** *see* Podrebarac, E. G., 1438
——Robins, R. K., Cheng, K. C., and Lin, D. C., pyrazoles I. Synthesis of 4-hydroxypyrazolo [3,4-*d*]-*v*-triazine. A new analog of hypoxanthine, 1044
**Cheng, C. T.,** *see* Huang, J. T., 1620
**Cheng, K. C.,** *see* Cheng, C. C., 1044
**Cheng, S.-S.,** Piantadosi, C., and Irvin, J. L., structure and synthesis of 2-(4'-substituted phenyl)-Δ-pyrrolines from 4-phthalimidobutyryl chloride *via* Friedel-Crafts acylation, 1910
**Chiccarelli, F. S.,** determination of 6-demethyltetracycline HCl in 6-demethylchlortetracycline HCl, 1046
**Chih Peng, H.,** *see* Barfknecht, C. F., 1607
**Chin, T.-F.,** Chung, P.-H., and Lach, J. L., influence of cyclodextrins on ester hydrolysis, 44
——*see* Wesolowski, J. W., 811
**Chinn, C.,** *see* Dreyfuss, J., 1497
**Chmielewicz, Z. F.,** *see* Mukherjee, S. L., 516
**Chong, C. W.,** *see* Dittert, L. W., 780; 1146; 1269
——*see* Swintosky, J. V., 752
**Chou, U. T.,** *see* Huang, J. T., 1620
**Choulis, N. H.,** and Carey, C. E., quantitative thin-layer chromatography of sympathomimetic amines, 1048
**Chrekian, G. P.,** *see* Ascione, P. P., 1768
**Christenson, G. L.,** *see* Huber, H. E., 164
**Christian, J. E.,** *see* Ice, R. D., 399
——*see* Jarboe, R. H., Jr., 323
——*see* Spitznagle, L. A., 764
**Christian, S. T.,** and Beasley, J. G., Michaelis constants for isolated cholinesterase systems, 1025
**Chung, P.-H.,** *see* Chin, T.-F., 44
**Clayton, S. J.,** *see* Shealy, Y. F., 1562
**Clemente, E.,** and Lynch, V. P., *in vitro* action of mescaline. Possible mode of action, 72
**Clemson, H. C.,** Magarian, E. O., Fuller, G. C., and Langner, R. O., synthesis of derivatives of *N*-methyl-2-phenylsuccinimide involving a lithium salt condensation and a novel application of the Mannich reaction. Potential anticonvulsant agents, 384
**Cochran, E. M.,** Inskip, E. B., King, P., and Ziegler, H. W., the analysis of barium sulfate, 1215
**Cohen, A. I.,** *see* Dreyfuss, J., 1505
**Cohen, S.,** quantitative determination of volatile components in pressurized aerosols by gas chromatography, 966
**Cohn, R.,** *see* Reier, G., 660
**Colaizzi, J. L.,** *see* Poust, R. I., 2119
——*see* Stelzer, J. M., Jr., 1732
**Cole, J. R.,** *see* Bianchi, E., 696
**Coleman, E. C.,** *see* Lefar, M. S., 1442
**Colombo, C.,** Piliero, S. J., and Grosso, L., serum turbidity responses of anti-inflammatory drugs in endocrine-deficient rats, 1526
**Comer, I.,** *see* Stevenson, C. E., 1227
**Comer, J. P.,** Hartsaw, P., and Stevenson, C. E., unit tablet assay of 17α-ethynylestradiol-3-methyl ether (mestranol) by a direct colorimetric and an automated fluorometric method, 147
**Commons, K. C.,** Bergen, A., and Walker, G. C., influence of starch concentration on the disintegration time of tolbutamide tablets, 1253
**Conklin, J. D.,** *see* Hollifield, R. D., 325
**Connors, K. A.,** *see* Hong, W. H., 1789
——*see* Shah, A. A., 282
**Conway, T. T.,** Shoeb, A., and Bauer, L., synthesis of α-mercaptoacetamidinium chlorides *via* the corresponding phosphorothioates, 455
**Conway, W. D.,** Minatoya, H., Lands, A. M., and Shekosky, J. M., absorption and elimination profile of isoproterenol III. The metabolic fate of *dl*-isoproterenol-7-$^3$H in the dog, 1135
**Coquilla, V.,** *see* Poulsen, B. J., 928
**Cosgrove, F. P.,** *see* Valdez, C., 2093
**Counsell, R. E.,** Ranade, V. V., Pocha, P., Willette, R. E., and DiGuilio, W., tumor localizing agents VI. Radioiodinated analogs of dichlorodiphenyldichloroethane (DDD), 1657
——Smith, T. D., DiGuilio, W., and Beierwaltes, W. H., tumor-localizing agents VIII. Radioiodinated phenylalanine analogs, 1958
**Coutts, R. T.,** and Locock, R. A., identification of medicinal barbiturates by means of mass spectrometry, 2096
**Coviello, D. A.,** and Hines, N. L., α-alkyloximino acid thiol esters: new class of compounds showing antimalarial activity, 688
**Craig, J. C.,** *see* Bulkacz, J., 1017
**Craig, N. R.,** *see* Hayden, A. L., 858
**Crane, F. A.,** *see* Solomon, M. J., 2038
**Crawford, R. R.,** Naramore, D. C., and Esmerian, O. K., assay of vitamin E in multivitamin products using thin-layer chromatography, 1716
**Creese, M. W.,** *see* Briden, R. C., 1523
——*see* Smissman, E. E., 1520
**Crema, A.,** *see* Benzi, G., 1031; 1301
**Crespi, H. L.,** *see* Nona, D. A., 975; 1993
**Cullen, L. F.,** Rutgers, J. G., Lucchesi, P. A., and Papariello, G. J., fluorometric determination of norgestrel and structurally related steroids, 1857

**Culvenor, C. C. J.,** tumor-inhibitory activity of pyrrolizidine alkaloids, 1112
**Cummings, A. J., and Martin, B. K.,** interpretation of the kinetics of salicylic acid elimination, 891
**Cusimano, A. G., and Becker, C. H.,** spray-congealed formulations of sulfaethylthiadiazole (SETD) and waxes for prolonged-release medication. Effect of wax, 1104
**Czoncha, L.,** *see* May, M., 884

D

**Daly, R. E.,** *see* Chafetz, L., 1977
**Das Gupta, V.,** and Cadwallader, D. E., acid dye method for the analysis of thiamine, 112
——and Cadwallader, D. E., determination of first pKa′ value and partition coefficients of bromothymol blue, 2140
——Cadwallader, D. E., Herman, H. B., and Honigberg, I. L., effect of pH and dye concentration on the extraction of a thiamine dye salt by an organic solvent, 1199
**Data, J. B.,** *see* Jarboe, R. H., Jr., 323
**Datta-Gupta, N.,** and Bardos, T. J., synthetic porphyrins II. Preparation and spectra of some metal chelates of *para*-substituted-*meso*-tetraphenylporphines, 300
**Davis, C. S.,** *see* Halliday, R. P., 430
——*see* Schwan, T. J., 877
**Davis, E. J.,** *see* Kapoor, A., 1514
**DeAngelis, N. J.,** and Papariello, G. J., differential scanning calorimetry. Advantages and limitations for absolute purity determinations, 1868
**Dedrick, R. L.,** *see* Bischoff, K. B., 1346
**De Fabrizio, F.,** spectrophotometric determination of acetaminophen, phenylephrine hydrochloride, codeine phosphate, and pyrilamine maleate in tablets or powder, 644
**Delgado, J. N.,** *see* Gomer, S. K., 1586
——*see* Schwartz, H. F., II, 1530
**DeRitter, E.,** *see* Osadca, M., 309
**Desai, S. J.,** *see* Singh, P., 217; 959
**Deuble, J. L.,** *see* Salim, E. F., 311
**Devani, M. B.,** Shishoo, C. J., and Bhut, D. J., nonaqueous titration of theophylline combinations with acetous perchloric acid, 1051
**DeWeerdt, G. A.,** *see* Barbier, F., 819
**Diamond, L.,** bronchodilatory and cardiovascular effects of metaproterenol, 971
**DiGuilio, W.,** *see* Counsell, R. E., 1657; 1958
**Dinerman, N.,** *see* Weiner, N. D., 1398
**Dittert, L. W.,** Adams, H. J., Alexander, F., Chong, C. W., Ellison, T., and Swintosky, J. V., 4-acetamidophenyl 2,2,2-trichloroethyl carbonate: particle size studies in animals and man, 1146
——Adams, H. J., Chong, C. W., and Swintosky, J. V., trichloroethyl carbonate: influence of particle size on oral toxicity in mice, 1269
——Caldwell, H. C., Adams, H. J., Irwin, G. M., and Swintosky, J. V., acetaminophen prodrugs I. Synthesis, physicochemical properties, and analgesic activity, 774
——Caldwell, H. C., Ellison, T., Irwin, G. M., Rivard, D. E., and Swintosky, J. V., carbonate ester prodrugs of salicylic acid. Synthesis, solubility characteristics, *in vitro* enzymatic hydrolysis rates, and blood levels of total salicylate following oral administration to dogs, 828
——Irwin, G. M., Chong, C. W., and Swintosky, J. V., acetaminophen prodrugs II. Effect of structure and enzyme source on enzymatic and nonenzymatic hydrolysis of carbonate esters, 780
——*see* Swintosky, J. V., 752
**Dixon, R. L.,** effect of chlordan pretreatment on the metabolism and lethality of cyclophosphamide, 1351
——*see* Yamamura, H. I., 1132
**Doerge, R. F.,** *see* Harrell, W. B., 1989
**Doskotch, R. W.,** *see* Tomko, J., 329
**Doyle, A. B.,** *see* Oleniacz, W. S., 2136
**Doyle, J. E.,** and Ernst, R. R., influence of various pretreatments (carriers, desiccation, and relative cleanliness) on the destruction of *Bacillus subtilis* var. *niger* spores with gaseous ethylene oxide, 433
**Dreyfuss, J.,** Cohen, A. I., and Hess, S. M., metabolism of thiazesim, 5-(2-dimethyl - aminoethyl) - 2,3 - dihydro - 2 - phenyl - 1,5 - benzothiazepin-4(5*H*)-one, in the rat *in vivo* and *in vitro*, 1505
——Swoap, J. R., Chinn, C., and Hess, S. M., excretion and distribution of thiazesim-$^{14}$C with its biotransformation *in vivo* and *in vitro*, 1497
**Dudock, B. S.,** *see* Shamma, M., 262
**Duncan, R. L., Jr.,** and Andrako, J., synthesis of 2-(*N*,*N*-dialkylaminomethyl)-7-phenylthioindoles, 979
**Duvall, R. N.,** *see* Gold, G., 667; 2153

E

**Eckert, J.,** *see* Arret, B., 871
**Eickholt, T. H.,** Brashier, G. K., Higgins, M. D., and Martinez, U. B., synthesis, purification, and influence of chain length on toxicity of two quaternary ammonium compounds, 1431
**Eisdorfer, I. B.,** Warren, R. J., and Zarembo, J. E., spectroscopy of amines of pharmaceutical interest, 195
**Eisenmann, A.,** and Wolf, W., chemistry and biochemistry of polyvalent iodine compounds VII. The ARP (apparent reduction potential) of 1,3-dihydro-1-hydroxy-3-oxo-1,2-benziodoxole, 1435
**Elefant, M.,** *see* Talmage, J. M., 1073
**Eling, T. E.,** McOwen, J. M., and Schmidt, G. C., synthesis of tropine-labeled atropine IV. Labeling of the 2,3, and 4 positions of atropine from citric-$^{14}$C acid, 1357
——*see* Schmidt, G. C., 443
**Elkin, S.,** *see* Lieberman, H., 684
——*see* Shapiro, W., 1725
**Ellison, T.,** *see* Dittert, L. W., 828; 1146
**Elwasimi, M. T.,** *see* Nabih, I., 1202; 1609
**Epstein, W. L.,** *see* Rowland, M., 984
**Ernst, R. R.,** *see* Doyle, J. E., 433
**Esmerian, O. K.,** *see* Crawford, R. R., 1716
**Estevez, V.,** *see* Ho, B. T., 269

F

**Fales, H. M.,** *see* Kapadia, G. J., 2017
**Fang, V.,** Foye, W. O., Robinson, S. M., and Jenkins, H. J., hypoglycemic activity and chemical structure of the salicylates 2111
**Fantelli, S.,** *see* Setnikar, I., 671
**Farnsworth, N. R.,** Svoboda, G. H., and Blomster, R. N., antiviral activity of selected *Catharanthus* alkaloids, 2174
——Wagner, H., Hörhammer, L., and Hörhammer, H. P., *Aster pilosus* (*Compositae*) I. Isolation of hyperoside (quercetin-3-β-D-mono-galactoside) from the leaves, 1059
——Wagner, H., Hörhammer, L., Hörhammer, H. P., and Fong, H. H. S., *Euphorbia esula* L. (*Euphorbiaceae*) I. preliminary phytochemical and biological evaluation, 933
——*see* Maloney, E. M., 1035
——*see* Masoud, A. N., 587
——*see* Messmer, W. M., 1996
——*see* Tin-Wa, M., 2167
**Federici, N. J.,** *see* Wiseman, E. H., 1535
**Feldman, S.,** and Gibaldi, M., problem in the estimation of drugs in biologic tissue. Recovery of phenol red from the GI tract, 1234
——Wynn, R. J., and Gibaldi, M., effect of sodium deoxycholate on gastric emptying in the rat, 1493
——*see* Gibaldi, M., 708; 787; 1072
**Felmeister, A.,** *see* Shaubman, R., 178
——*see* Weiner, N. D., 1398
**Ferraro, F. M.,** *see* Rongone, E. L., 1962
**Fincher, J. H.,** particle size of drugs and its relationship to absorption and activity, 1825
**Finholt, P.,** and Solvang, S., dissolution kinetics of drugs in human gastric juice—the role of surface tension, 1322
**Finnegan, R. A.,** and Stephani, R. A., structure of hiptagin as 1,2,4,6-tetra-*O*-(3-nitropropanoyl)-β-D-glucopyranoside, its identity with endecaphyllin X, and the synthesis of its methyl ether, 353
——Stephani, R. A., Ganguli, G., Ganguly, S. N., and Bhattacharya, A. K., occurrence of mangiferin in *Hiptage madablota* Geartn., 1039
**Firestone, D.,** *see* Lefar, M. S., 1442
**Fisher, E. R.,** and Keverline, P. O., serotonin infusion in rats with experimental renovascular hypertension, 1966
**Fishler, J. J.,** *see* Misher, A., 1128
**Fitzgibbon, W. E.,** *see* Shealy, Y. F., 83
**Flanagan, D. R.,** *see* Simonelli, A. P., 1629
——*see* Singh, P., 959
**Flanigan, C. C., Jr.,** *see* Ray, M. D., 609
**Fletcher, H. P.,** Murray, H. M., and Weddon, T. E., absorption of lincomycin and lincomycin esters from rat jejunum, 2101
**Fong, H. H. S.,** *see* Frausworth, N. R., 933
——*see* Maloney, E. M., 1035
——*see* Tin-Wa, M., 2167
**Fooks, J. R.,** McGilveray, I. J., and Strickland, R. D., colorimetric assay and improved method for identification of vancomycin hydrochloride, 314
**Foreman, F.,** *see* Plaxco, J. M., Jr., 698
**Forist, A. A.,** *see* Taraszka, M. J., 1379
**Forlano, A. J.,** Farowski, C. I., and Hammer, H. F., preparation and stability of a new series of sterically hindered esters of vitamin A, I, 1184
**Fory, W.,** *see* McCormick, D. B., 841
**Foye, W. O.,** and Kay, D. H., antiradiation compounds IX. Dithiocarbamates of strongly basic pyridines and pyrimidines, 345
——Kay, D. H., and Amin, P. R., antiradiation compounds XII. Dithiocarbamates of strongly basic acridines and quinaldines, 1793
——and Kauffman, J. M., antiradiation compounds. X, Derivatives of 3,3-dimercaptoacrylonitrile, 1611; XI, Sulfur-containing derivatives and aminonitriles, 1614
——*see* Fang, V., 2111
**Frank, M. J.,** *see* Carstensen, J. T., 23
**French, L. L.,** and Swartz, H. A., radiosynthesis of 3′-chloro-3-nitrosalicylanilide and determination of its uptake by lamprey larvae, 2068
**French, W. N.,** *see* Kaistha, K. K., 459
**Freshwater, D. C.,** *see* Groves, M. J., 1273
**Fricke, F. L.,** Walters, S. M., and Lampkin, W. T., gas-liquid chromatographic determination of dienestrol in the presence of methyltestosterone, 868
**Fukuda, K.,** *see* Kuroda, K., 250
**Fuller, G. C.,** *see* Clemson, H. C., 384
**Fusari, S.,** *see* Aguiar, A. J., 1844

G

**Gábáldon, M.,** Sánchez, J., and Llombart, A., Jr., *in vitro* utilization of diethylstilbestrol by rat liver, 1744
**Gabali, E.,** *see* Alpad, L. R., 1068
**Gál, G.,** *see* Setnikar, I., 671
**Gallelli, J. F.,** *see* Gressel, P. D., 335
**Galpin, D. R.,** and Huitric, A. C., absolute configuration of *trans*- and *cis*-2-*o*-tolylcyclohexanols, 447
**Ganguli, G.,** *see* Finnegan, R. A., 1039
**Ganguly, S. N.,** *see* Finnegan, R. A., 1039
**Garnett, E. S.,** *see* Jouhar, A. J., 617
**Garrett, E. R.,** and Chemburkar, P. B., evaluation, control, and prediction of drug diffusion through polymeric membranes. I, Methods and reproducibility of steady-state diffusion studies, 944; II, Diffusion of aminophenones through silastic membranes: a test of the pH-partition hypothesis, 949; III, Diffusion of barbiturates, phenylalkylamines, dextromethorphan, progesterone, and other drugs, 1401
——and Yakatan, G. J., solvolysis of 5-halouridines and related nucleosides, 1478
——*see* Nestler, H. J., 1117
**Garrison, D. R.,** *see* May, M., 884
**Gautieri, R. F.,** *see* Harpel, H. S., Jr., 1590
——*see* Ward, C. O., 287
**Genest, K.,** Hughes, D. W., and Rice, W. B., muscarine in *Clitocybe* species, 331
——*see* Hughes, D. W., 1023; 1619

**Gerner, R. W.,** *see* Mario, E., 1243
**Ghafghazi, T.,** Miya, T. S., Mennear J. H., and Chalmers, R. K., chlorpromazine and epinephrine. Hyperglycemic mechanisms, 1690
**Gibaldi, M.,** Feldman, S., and Bates, T. R., correlation of pharmacologic activity and dissolution rates of reserpine–desoxycholic acid dispersions, 708
——Feldman, S., and Weiner, N. D., apparent nonsteady-state dissolution phenomenon in solutions of colloidal solubilizers, 1072
——Feldman, S., Wynn, R., and Weiner, N. D., dissolution rates in surfactant solutions under stirred and static conditions, 787
——and Nightingale, C. H., bile salt potentiation of pharmacologic effects and drug uptake in goldfish, 1354
——Nightingale, C. H., use of the overturn end point for the estimation of absorption and elimination kinetics in goldfish, 226
——and Weintraub, H., dissolution of salicylic acid and polyvinylpyrrolidone from compressed mixtures, 832
——*see* Feldman, S., 1234; 1493
——*see* Zatz, J. L., 1440
**Gibson, J. E.,** *see* Becker, B. A., 1010
**Gisvold, O.,** and Maulding, H. V., Jr., basically substituted dioxolanes and dioxanes, 784
**Gluck, N.,** *see* Pfeffer, M., 36
**Gold, G.,** Duvall, R. N., Palermo, B. T., and Slater, J. G., powder flow studies. III, Factors affecting the flow of lactose granules, 667; IV, uniformity of flow: instrumentation and applications, 2153
**Goldberg, A. H.,** and Higuchi, W. I., improved method for diffusion coefficient determinations employing the silver membrane filter, 1583
**Gomer, S. K.,** Isaacson, E. I., Brown, R. G., and Delgado, J. N., synthesis of xanthoxime and pyridine-3-aldoxime esters and ethers as potential anticholinergics, 1586
**Goodhart, F. W.,** Mayorga, G., Mills, M. N., and Ninger, F. C., instrumentation of a rotary tablet machine, 1770
**Goodman, A.,** *see* Kondritzer, A. A., 1142
**Gore, A. Y.,** Naik, K. B., Kildsig, D. O., Peck, G. E., Smolen, V. F., and Banker, G. S., significance of salicylic acid sublimation in stability testing of aspirin-containing solids, 1850
**Görög, S.,** analysis of steroids VIII. Determination of conjugated ketosteroids in pharmaceutical preparations using the sodium borohydride method, 1737
**Gorum, L.,** and Nobles, W. L., new compounds: synthesis of heterocyclic estrogens, 1265
**Goto, S.,** Kono, A., and Iguchi, S., kinetics of reaction of dehydroacetic acid II. Reaction with primary amines, 791
**Goyan, F. M.,** and Borazan, H. N., osmotic properties of aqueous solutions containing caffeine, 861
**Grab, F. L.,** and Reinstein, J. A., determination of caffeine in plasma by gas chromatography, 1703
**Graetzer, M. J.,** *see* Kapoor, A., 1514
**Grass, G. M.,** *see* Robinson, M. J., 1983
**Gratten, J. F.,** *see* Luts, H. A., 578
**Greenberg, L.,** antimicrobial activity of dermatomucosal agents, 1546
**Grego, J.,** *see* Browning, R. S., Jr., 2165
**Gressel, P. D.,** and Gallelli, J. F., quantitative analysis and alkaline stability studies of allopurinol, 335
**Grewal, R. S.,** *see* Kaul, C. L., 1741
**Griboff, S.,** *see* Pfeffer, M., 36
**Grosso, L.,** *see* Colombo, C., 1526
**Grothe, E.,** *see* Carboni, S., 1063
**Groves, M. J.,** and Freshwater, D. C., particle-size analysis of emulsion systems, 1273
**Grubb, T. C.,** *see* Munies, R., 824
**Gruber, M. P.,** and Klein, R. W., TLC determination of sulfanilamide as a degradation product in pharmaceutical preparations containing sodium sulfacetamide, 1212
**Gueldner, R. C.,** *see* Mathison, I. W., 1820
**Guess, W. L.,** *see* Jones, A. B., 293
——*see* O'Leary, R. K., 12; 1552
——*see* Watkins, W. D., 1968
**Guth, E. P.,** *see* Mansour, Z., 404
**Guttman, D. E.,** heterogeneous catalysis of aspirin degradation in chloroformic solution and its relationship to the determination of salicylic acid in buffered aspirin products, 1685
——*see* Brooke, D., 1206; 1677
——*see* Meyer, M. C., 245; 895; 1627

H

**Haidri, S. Z.,** *see* Luts, H. A., 578
**Haley, T. J.,** and Cartwright, F. D., pharmacology and toxicology of potassium perrhenate and rhenium trichloride, 321
**Hall, N. A.,** *see* Hayton, W. L., 158
——*see* Thakkar, A. L., 1394
**Haller, R. M.,** *see* Zoglio, M. A., 1877
**Halliday, R. P.,** Davis, C. S., Heotis, J. P., Pals, D. T., Watson, E. J., and Bickerton, R. K., allenic amines: a new class of nonhydrazine MAO inhibitors, 430
**Hammer, H. F.,** *see* Forlano, A. J., 1184
**Hammer, R. H.,** pyrrolo [2,3-*d*]pyrimidines, 1616
**Hamot, H.,** *see* Zoglio, M. A., 2080
**Hanewald, K. H.,** Mulder, F. J., and Keuning, K. J., thin-layer chromatographic assay of vitamin D in high-potency preparations. Analysis of fat-soluble vitamins IX, 1308
——*see* Buisman, J. A. K., 1326
**Hansch, C.,** *see* Lien, E. J., 1027
**Hanus, E. J.,** and King, L. D., thermodynamic effects in the compression of solids, 677
**Harpel, H. S., Jr.,** and Gautieri, R. F., morphine-induced fetal malformations I. Exencephaly and axial skeletal fusions, 1590
**Harrell, W. B.,** and Doerge, R. F., Mannich bases from 2-phenylindolizines III. 1,3-Bis(dialkylaminomethyl)-2-phenylindolizines, 1989
**Hartsaw, P.,** *see* Comer, J. P., 147
**Harwood, C. F.,** and Pilpel, N., granulation of griseofulvin, 478
**Hashizume, G.,** *see* Kuroda, K., 250
**Haussler, A.,** *see* Salim, E. F., 640
**Hayden, A. L.,** Brannon, W. L., and Craig, N. R., a micro-extraction technique with compounds isolated from thin-layer chromatograms, 858
**Hayton, W. L.,** and Hall, N. A., apparent pH dependence of ethanol absorption rate in the common guppy, 158
**Heard, J. E.,** *see* Billman, J. H., 1622; 1809
**Hebron, D. L.,** *see* Levan, H., 1033
**Hedge, R. S.,** Mehta, M. J., Bhatt, R. A., Patel, D. J., and Bafna, S. L., molecular sorption on ion-exchange resins: studies with coumarin, 598
**Heim, H. C.,** *see* Appelt, G. D., 1428
**Held, H. R.,** *see* Landi, S., 605
**Heotis, J. P.,** *see* Halliday, R. P., 430
**Herman, H. B.,** *see* Das Gupta, V., 1199
**Hess, S. M.,** *see* Dreyfuss, J., 1497; 1505
**Hiestand, E. N.,** and Wilcox, C. J., some measurements of friction in simple powder beds, 1421
**Higgins, M. D.,** *see* Eickholt, T. H., 1431
**Highet, R. J.,** *see* Kapadia, G. J., 191
**Higuchi, T.,** *see* Nakano, M., 183; 1865
——*see* Paulssen, R. B., 529
——*see* Pitman, I. H., 239
——*see* Rankell, A. S., 574
**Higuchi, W. I.,** *see* Goldberg, A. H., 1583
——*see* Ho, N. F. H., 436
——*see* Koizumi, T., 87; 93
——*see* Schwartz, J. B., 274; 278
——*see* Simonelli, A. P. 1629
——*see* Singh, P., 217; 959
**Hindman, K. L.,** *see* Becker, B. A., 1010
**Hines, N. L.,** *see* Coviello, D. A., 688
**Hirai, E.,** *see* Brochmann-Hanssen, E., 30; 940
**Hiskey, C. F.,** and Cantwell, F. F., ultraviolet spectrum correlations with the conjugate acid-base species of acetarsone and arsthinol, 2105
**Ho, B. T.,** McIsaac, W. M., Tansey, L. W., and Kralik, P. M., hydroxyindole-*O*-methyltransferase II. Inhibitory activities of some *N*-acyltryptamines, 1998
——McIsaac, W. M., and Walker, K. E., inhibitors of monoamine oxidase II. Synthesis of some *N*-2(9)-substituted tetrahydro-β-carbolines and evaluation of their inhibitory activities, 1364
——McIsaac, W. M., Walker, K. E., and Estevez, V., inhibitors of monoamine oxidase. Influence of methyl substitution on the inhibitory activity of β-carbolines, 269
**Ho, N. F. H.,** and Higuchi, W. I., preferential aggregation and coalescence in heterodispersed systems, 436
**Ho, W.,** *see* Wolff, M. E., 1450
**Hobbs, D. C.,** metabolism of thiothixene, 105
**Hohmann, J. R.,** *see* Moody, J. E., Jr., 634
**Hollifield, R. D.,** and Conklin, J. D., method specific for determination of furazolidone in urine: evidence for drug-related metabolites, 325
**Holum, L. B.,** *see* Shealy, Y. F., 83
**Hom, F. S.,** *see* Chafetz, L., 1000
**Hong, W. H.,** and Connors, K. A., identification of aliphatic amines from rates of cinnamoylation, 1789
**Honigberg, I. L.,** *see* Das Gupta, V., 1199
**Hörhammer, H. P.,** *see* Farnsworth, N. R., 933; 1059
**Hörhammer, L.,** *see* Farnsworth, N. R., 933; 1059
**Housholder, G. E.,** *see* Loo, T. L., 2126
**Houtman, R. L.,** morphine determination in kaolin pectin formulations, 1975
——Kaiser, D. G., and Taraszka, A. J., gas-liquid chromatographic determination of lincomycin, 693
**Hsiu, H. C.,** *see* Huang, J. T., 1620
**Huang, C. L.,** and Bhansali, K. G., nonpolar metabolites of trifluoperazine in rats, 1511
**Huang, J. T.,** Hsiu, H. C., Shih, T. B., Chou, U. T., Wang, K. T., and Cheng, C. T., polyamide layer chromatography of organophosphorus pesticides, 1620
**Huber, H. E.,** and Christenson, G. L., utilization of hydrophilic gums for the control of drug substance release from tablet formulations II. Influence of tablet hardness and density on dissolution behavior, 164
**Huettemann, R. E.,** *see* Shroff, A. P., 882
**Hudgins, P. N.,** *see* Stubbins, J. F., 534
**Hughes, D. W.,** Genest, K., and Skakum, W., alkaloids of *Peumus boldus*. Isolation of laurotetanine and laurolitsine, 1619
——Genest, K., and Skakum, W., alkaloids of *Peumus boldus*. Isolation of (+)-reticuline and isoboldine, 1023
——*see* Genest, K., 331
**Huitric, A. C.,** *see* Galpin, D. R., 447
**Humphreys, K. J.,** and Rhodes, C. T., effect of temperature upon solubilization by a series of nonionic surfactants, 79
**Hussain, A.,** Schurman, P., Peter, V., and Milosovich, G., kinetics and mechanism of degradation of echothiophate iodide in aqueous solution, 411

I

**Ice, R. D.,** Christian, J. E., and Plumlee, M. P., metabolic fate of orally administered 2,3,5-triiodobenzoic acid in lactating animals, 399
**Idson, B.,** topical toxicity and testing, 1
**Iguchi, S.,** *see* Goto, S., 791
**Imholte, R. D.,** and Schramm, L. C., chemically defined medium for the production of *Fusarium graminearum*, 97
**Ingram, J. T.,** and Lowenthal, W., mechanism of action of starch as a tablet disintegrant. II, Effect of pepsin and surfactants on swelling of starch grains at 37°, 187; III, Factors affecting starch grain damage and their effect on swelling of starch grains and disintegration of tablets at 37°, 393
**Inskip, E. B.,** *see* Cochran, E. M., 1215
**Iorio, T. L.,** *see* Krause, G. M., 1223
**Irvin, J. L.,** *see* Cheng, S.-S., 1910
**Irwin, G. M.,** *see* Dittert, L. W., 774; 780; 828
——*see* Swintosky, J. V., 752
**Isaacson, E. I.,** *see* Gomer, S. K., 1586
——*see* Schwartz, H. F., II, 1530

——*see* Valdez, C., 2093
**Isildatici, S.,** *see* Ulubelen, A., 1037
**Ivashkiv, E.,** separation and determination of polymyxin B in formulations, 642

J

**Jacob, J. T.,** Nessel, R. J., and Blodinger, J., stability of cyanocobalamin in film-coated multivitamin tablets, 1854
——and Plein, E. M., factors affecting the dissolution rates of medicaments from tablets. I, *In vitro* dissolution rate of commercial phenobarbital tablets, 798; II, Effect of binder concentration, tablet hardness, and storage conditions on the dissolution rate of phenobarbital from tablets, 802
**Jacobs, A.,** *see* Zoglio, M. A., 2080
**Jacobsen, R.,** *see* Pfeffer, M., 1375
**Jakovljevic, I. M.,** *see* Templeton, R. J., 1168
**Jandhyala, M. L.,** and Buckley, J. P., mechanisms of action of cryptenamine, 1576
**Janicki, C. A.,** Brenner, R. J., and Schwartz, B. E., specific assay methods for droperidol and fentanyl citrate in a pharmaceutical combination, 451
**Jarboe, R. H., Jr.,** Data, J. B., and Christian, J. E., photodisintegration studies of $^{14}$C-carboxyl 2,3,5-triiodobenzoic acid, 323
**Jarowski, C. I.,** *see* Forlano, A. J., 1184
**Jellinek, G.,** *see* Castello, R. A., 485
**Jenkins, H. J.,** *see* Fang, V., 2111
**Jindra, A.,** *see* Staba, E. J., 701
**John, P. M.,** and Becker, C. H., surfactant effects on spray-congealed formulations of sulfaethylthiadiazole–wax, 584
**Johnson, E.,** *see* Pratt, R., 1040
**Johnson, G. A.,** *see* Veldkamp, W., 613
**Johnson, J. B.,** *see* Carstensen, J. T., 23
**Johnston, E. J.,** *see* Maulding, H. V., 1873
**Jones, A. B.,** Guess, W. L., and Autian, J., mechanistic toxicology of triethyl citrate in cultured mammalian cells by cinematography, 293
**Jones, L. N.,** Seidman, M., and Southworth, B. C., quantitative determination of diethylstilbestrol by thin-layer chromatography, 646
**Jones, R. G.,** *see* Misher, A., 1128
**Jones, T. M.,** mechanism of flow improvement by the addition of fine particles to bulk solids, 2015
**Jorgensen, E. C.,** *see* Mulhauser, R. O., 151
**Jouhar, A. J.,** Garnett, E. S., and Wallington, J. S., potassium absorption—a comparison of *in vitro* and *in vivo* studies, 617
**Judis, J.,** *see* Starr, J. E., 768

K

**Kabasakalian, P.,** Taggart, M., and Townley, E., urinary excretion of chlorpheniramine and its *N*-demethylated metabolites in man, 856
——Taggart, M., and Townley, E., urinary excretion of pheniramine and its *N*-demethylated metabolites in man—comparison with chlorpheniramine and brompheniramine data, 621
**Kaiser, D. G.,** *see* Houtman, R. L., 693
**Kaistha, K. K.,** and French, W. N., selective determination of tolbutamide in pharmaceutical dosage forms by reaction with ninhydrin, 459
——*see* Beckstead, H. D., 1952
**Kamath, B. R.,** *see* Bhat, C. V., 1195
**Kanhere, S. S.,** Shah, R. S., and Bafna, S. L., ion-exchange resins and cinchona alkaloids I. Exchange equilibria, 342
——*see* Bhat, C. V., 1195
**Kantor, N.,** and Selzer, G., chromatographic separation and bioassay of the gentamicin complex, 2170
**Kapadia, G. J.,** and Fales, H. M., peyote alkaloids VI. Peyophorine, a tetrahydroisoquinoline cactus alkaloid containing an *N*-ethyl group, 2017
——and Highet, R. J., peyote alkaloids IV. Structure of peyonine, novel β-phenethylpyrrole from *Lophophora williamsii*, 191
——Shah, N. J., and Zalucky, T. B., peyote alkaloids II. Anhalotine, lophotine, and peyotine, the quaternary alkaloids of *Lophophora williamsii*, 254; errata, 2184
**Kaplan, G. B.,** *see* Moody, J. E., Jr., 634
**Kapoor, A.,** Davis, E. J., and Graetzer, M. J., further applications of pentachlorophenyl active esters in lengthening peptide chains from C- and N-terminal amino acids using dicyclohexylamine C-protection, 1514
**Karageorgiou, G.,** *see* Voyatzakis, V. A. E., 1255
**Kassapoglou, I. R.,** *see* Voyatzakis, V. A. E., 1255
**Katchen, B.,** *see* Symchowicz, S., 1383
**Katz, J. J.,** *see* Nona, D. A., 975; 1993
**Katz, M.,** *see* Poulsen, B. J., 928
**Kauffman, J. M.,** *see* Foye, W. O., 1611; 1614
**Kaul, C. L.,** and Grewal, R. S., effect of physostigmine upon the output of catecholamines from the adrenal gland of the rat, 1741
**Kay, A. I.,** *see* Chafetz, L., 710
**Kay, D. H.,** *see* Foye, W. O., 345; 1793
**Keasling, H. H.,** *see* Veldkamp, W., 613
**Kee, R. D.,** *see* Voldeng, A. N., 1053
**Kessler, W. V.,** *see* McClintock, W. J., 1649
**Keuning, K. J.,** *see* Buisman, J. A. K., 1326
——*see* Hanewald, K. H., 1308
**Keverline, P. O.,** *see* Fisher, E. R., 1966
**Khalifa, M.,** *see* Abou-Moustafa, A., 532; 1625
——*see* Alpad, L. R., 1068
**Khan, M. S.,** *see* Billman, J. H., 1817
**Kier, L. B.,** preferred conformation of serotonin and a postulate on the nature of its receptor from molecular orbital calculations, 1188
——*see* McClintock, W. J., 1649
**Kildsig, D. O.,** *see* Gore, A. Y., 1850
**King, E. L.,** *see* Voldeng, A. N., 1053
**King, L. D.,** *see* Hanus, E. J., 677
**King, P.,** *see* Cochran, E. M., 1215
**Kinget, R. D.,** and Schwartz, M. A., model catalysts which simulate penicillinase III. Structure-reactivity relationship in catalysis of penicillin hydrolysis by morpholinomethyl derivatives of catechol and pyrogallol, 1916
**Kinnard, W. J., Jr.,** *see* Watzman, N., 1572
**Kirshbaum, A.,** *see* White, M., 1061
**Kirschbaum, J.,** molecular association of the antibiotic prasinomycins, 690
**Klein, R. W.,** *see* Gruber, M. P., 1212
**Klutch, A.,** and Bordun, M., chromatographic methods for analysis of the metabolites of acetophenetidin (phenacetin), 524
**Knevel, A. M.,** *see* Rifino, C. B., 351
**Ko, J.-H. H.,** and Vanderwyk, R. W., membrane filter technique for testing the bactericidal activity of iodophors, 2013
**Koch, W. L.,** *see* Wesselman, H. J., 845
**Koda, R. T.,** Biles, J. A., and Wolf, W., synthesis of some iodopurine derivatives, 2056
**Koide, S. S.,** *see* Sunaga, K., 2116
**Koizumi, T.,** and Higuchi, W. I., analysis of data on drug release from emulsions. II, Pyridine release from water-in-oil emulsions as a function of pH, 87; III, Boundary effect of pyridine release from water-in-oil emulsion as a function of pH, 93
**Komae, H.,** *see* Nigam, I. C., 1029
**Kondo, T.,** and Tomizawa, M., hemolysis by nonionic surface-active agents, 1246
**Kondritzer, A. A.,** Zvirblis, P., Goodman, A., and Paplanus, S. H., blood plasma levels and elimination of salts of 2-PAM in man after oral administration, 1142
**Konieczny, J. M.,** *see* Castello, R. A., 485
**Kono, A.,** *see* Goto, S., 791
**Konzelman, L. M.,** *see* Topliss, J. G., 737
**Kooyers, W. M.,** method for testing the efficacy of topical sunscreen preparation, 1236
**Kornblum, S. S.,** *see* Zoglio, M. A., 2080
**Kowblansky, M.,** *see* Shane, N., 1218
**Kralik, P. M.,** *see* Ho, B. T., 1998
**Kram, T. C.,** and Turczan, J. W., determination of DMSO in solutions and ointments by NMR, 651
**Kraus, P.,** *see* Sancilio, L. F., 1248
**Krause, G. M.,** and Iorio, T. L., application of sugar coating to tablets and confections by means of an automated airless spray system I. Investigation of sweet coating by tablets, 1223
**Krauth, C. A.,** *see* Shealy, Y. F., 83; 1562
**Kriesel, D. C.,** and Menzie, J., synthesis and pharmacological evaluation of some tosylbiurets and tosylthiocarbamates as potential hypoglycemic agents, 1791
**Kubiak, E. J.,** determination of terpin hydrate by gas-liquid chromatography, 473
**Kühn, L.,** *see* Brochmann-Hanssen, E., 30
**Kurlansik, L.,** and Salim, E. F., observations concerning gas chromatography study of resorcinol monoacetate, 475
**Kuroda, K.,** Hashizume, G., and Fukuda, K., quantitative X-ray diffraction analysis of oral suspensions, 250
**Kuzel, N. R.,** automated analysis of tertiary amines, 852
**Kwan, K. C.,** *see* Castello, R. A., 485

L

**Lach, J. L.,** *see* Bornstein, M., 1653
——*see* Chin, T.-F., 44
——*see* Wesolowski, J. W., 811
**Lachman, L.,** and Lin, S. L., electrostatic characteristics of pharmaceutical solids and packaging materials I. Design of testing equipment and preliminary findings, 504
——*see* Lin, S.-L., 2143
**Lahiri, S. C.,** and Pathak, B., synthesis and pharmacology of some pyrroles and indan amines: hexahydro indeno(1,2-*c*)-pyrroles and indan amines, 1013
**Lampkin, W. T.,** *see* Fricke, F. L., 868
**Landi, S.,** and Held, H. R., interaction of 8-hydroxyquinoline sulfate with components present in a tuberculin PPD solution II. Effect of 8-hydroxyquinoline on metallic impurities, 605
**Lands, A. M.,** *see* Conway, W. D., 1135
**Lange, W. E.,** Theodore, J. M., and Pruyn, F. J., *in vivo* determination of certain aralkylamines, 124
**Langner, R. O.,** *see* Clemson, H. C., 384
**Lantz, R. J.,** *see* Robinson, M. J., 1983
**Lapidus, H.,** and Lordi, N. G., drug release from compressed hydrophilic matrices, 1292
**Lapidus, M.,** solubilization of aminopteridines, 878
**Lapoff, R.,** *see* Maulding, H. V., Jr., 1244
**Larson, D. L.,** *see* Portoghese, P. S., 711
**Lasslo, A.,** *see* Quintana, R. P., 230
**Laster, W. R., Jr.,** *see* Shealy, Y. F., 1562
**Leaffer, M. A.,** *see* Skinner, W. A., 338
**Lee, I. P.,** *see* Yamamura, H. I., 1132
**Lee, K. H.,** studies on the mechanism of action of salicylate. II, Retardation of wound healing by aspirin, 1042; III, Effect of vitamin A on the wound-healing retardation action of aspirin, 1238
——and Soine, T. O., coumarins VII. The coumarins of *Lomatium nuttallii*, 865
——and Soine, T. O., synthesis of (±)-norargemonine, 1922
——Thompkins, L., and Spencer, M. R., separation of acetylsalicylic acid and salicylic acid by Sephadex gel filtration, 1240
**Lefar, M. S.,** Firestone, D., Coleman, E. C., Brown, N., and Shaw, D. W., lipids from the seeds of *Abrus precatorius*, 1442
**Lemberger, A. P.,** *see* Mahrous, H. A. F., 1836
——see Torosian, G., 17
**Lemke, T. L.,** *see* Smissman, E. E., 1520
**Lerner, L. M.,** new compounds: nucleosides derived from D-*glycero*-D-*gulo*-heptose, 1263

**Leung, A. Y.,** and Paul, A. G., baeocystin and norbaeocystin: new analogs of psilocybin from *Psilocybe baeocystis*, 1667
——*see* Below, L. E., 515
**Levan, H.,** and Hebron, D. L., radioprotective effect of magnesium pemoline: a comparison with pemoline and dextroamphetamine, 1033
**Levine, J.,** and Weber, J. D., determination of free salicylic acid in buffered aspirin tablets, 631
**Levy, G.,** and Anello, J. A., effect of complex formation on drug absorption V. Studies on the mechanism of the secobarbital absorption-enhancing effect of polysorbate 80 in goldfish, 101
——and Angelino, N. J., hydrolysis of aspirin by rat small intestine, 1449
——and Mroszczak, E. J., effect of complex formation on drug absorption VI. Drug permeation through an artificial lipoid barrier, 235
——*see* Nagashima, R., 58; 68; 1881; 1888; 1991; 2000
——and Procknal, J. A., drug biotransformation interactions in man I. Mutual inhibition in glucuronide formation of salicylic acid and salicylamide in man, 1330
——*see* Reuning, R. H., 1335; 1342; 1556
**Lieberman, H.,** and Elkin, S., synthesis of several dibasic acid esters of 3-quinuclidinol as potential pharmacological agents, 684
**Lien, E. J.,** and Hansch, C., correlation of ratios of drug metabolism by microsomal subfractions with partition coefficients, 1027
**Lim, P.,** *see* Balazs, M. K., 2002
**Lin, D. C.,** *see* Cheng, C. C., 1044
**Lin, S.-L.,** Menig, J., and Lachman, L., interdependence of physiological surfactant and drug particle size on the dissolution behavior of water-insoluble drugs, 2143
——*see* Lachman, L., 504
**Liska, K. J.,** and Tadepalli, A. S., LSD analogs II. *N*-[2-(3-pyridyl)ethyl]-β-alanine derivatives, 2157
**Llombart, A., Jr.,** *see* Gábáldon, M., 1744
**Locock, R. A.,** *see* Coutts, R. T., 2096
**Long, J. P.,** *see* Booth, A. Z., 172
——*see* Magus, R. D., 594
——*see* Strycker, S. J., 1822
**Long, K. R.,** *see* Booth, A. Z., 172
**Loo, J.,** *see* Riegelman, S., 117; 128
**Loo, J. C. K.,** and Riegelman, S., new method for calculating the intrinsic absorption rate of drugs, 918
**Loo, T. L.,** Tanner, B. B., Housholder, G. E., and Shepard, B. J., some pharmacokinetic aspects of 5-(dimethyltriazeno)-imidazole-4-carboxamide in the dog, 2126
**Lopez, A. V.,** *see* Sam, J., 1755
**Lord, G. H.,** *see* Campbell, A. H., 2045
**Lordi, N. G.,** *see* Lapidus, H., 1292
**Lowenthal, W.,** multiregressional analysis of the Griffin HLB numbers for polyoxyethylene polyoxypropylene surfactants, 514
——*see* Ingram, J. T., 187; 393
**Lucchesi, P. A.,** *see* Cullen, L. F., 1857
**Luduena, F. P.,** and McKeon, W. B., Jr., effect of β-adrenergic blockade on the toxicity of bronchoconstrictors in guinea pigs, 1543
**Luts, H. A.,** Grattan, J. F., Haidri, S. Z., and Nobles, W. L., α-phenyl-α(2,3-cyclohexenyl) acetic acid derivatives as potential antispasmodics, 578
——and Yamashiro, D., new compounds: 5-chloro-2-(3-chloro-2-hydroxypropoxy)benzhydrylamine and related compounds, 1447
**Lynch, V. P.,** *see* Clemente, E., 72

## M

**Ma, O. H.,** *see* Orth, R. E., 1814
**Machatzke, H.,** Vaughan, W. R., Warren, C. L., and White, G. R., lawsone derivatives IV. 3-ω-Substituted alkyllawsones and related compounds, 520
**MacLeod, D. P.,** *see* Yung, D. K., 2073
**Madan, P. B.,** *see* Borke, M. L., 1788
**Magarian, E. O.,** *see* Clemson, H. C., 384
**Magus, R. D.,** and Long, J. P., mechanism of hypotensive action of 2-(2,6-dichlorophenylamino) - 2 - imidazoline hydrochloride (ST-155) in the cat, 594
**Mahn, F. P.,** Viswanathan, V., Plinton, C., Menyharth, A., and Senkowski, B. Z., determination of vitamin E in multivitamin products by gas-liquid chromatography, 2149
——Viswanathan, V., and Senkowski, B. Z., determination of terpin hydrate in elixirs containing codeine or dextromethorphan hydrobromide by gas-liquid chromatography, 145
**Mahrous, H. A. F.,** and Lemberger, A. P., relative stabilizing effects of several high molecular weight polymers on the stability of a 2% hexadecane in water emulsion, 1836
**Malone, M. H.,** *see* Marozzi, F. J., 989
**Maloney, E. M.,** Fong, H. H. S., Farnsworth, N. R., Blomster, R. N., and Abraham, D. J., catharanthus alkaloids XV. Isolation of vindolinine from *C. lanceus* leaves, 1035
**Manian, A. A.,** *see* Watzman, N., 2089
**Mann, I.,** *see* Brochmann-Hanssen, E., 30
**Mansour, Z.,** and Guth, E. P., complexing behavior of starches with certain pharmaceuticals, 404
**Mantle, D. E.,** *see* Bryant, R., 658
**Marshall, K.,** *see* Brook, D. B., 481
**Mario, E.,** and Bolton, S., inhibition of acetylcholinesterase by chelates III, 418
——and Gerner, R. E., determination of silicon in a commercial hand lotion by atomic absorption spectroscopy, 1243
**Marks, A. M.,** and Sciarra, J. J., effect of size on other physical properties of granules and their corresponding tablets, 497
**Marozzi, F. J.,** and Malone, M. H., analgesic and anti-inflammatory evaluation of thymotic acid and certain homologs, 989
**Marrelli, L. P.,** colorimetric method for the determination of 7-aminocephelosporanic acid (7-ACA) and related compounds, 2172
**Martin, A. N.,** *see* Rifino, C. B., 351
**Martin, A. R.,** Briggs, G. G., and Yale, T. J., tetracyclic phenothiazines I. Reinvestigation of the brominations of some pyrido [3,2,1-*kl*]phenothiazines, 166
**Martin, B. D.,** *see* Borke, M. L., 1788
**Martin, B. K.,** *see* Cummings, A. J., 891
**Martinez, U. B.,** *see* Eickholt, T. H., 1431
**Masoud, A. N.,** Sciuchetti, L. A., Farnsworth, N. R., Blomster, R. N., and Meer, W. A., effect of gibberellic acid on the growth, alkaloid production, and VLB content of *Catharanthus roseus*, 587
**Masterson, D. S., Jr.,** colorimetric assay for chloramphenicol using 1-naphthol, 305
**Mathison, I. W.,** Gueldner, R. C., and Carroll, D. M., application of *n*-butyl lithium in the synthesis of some methoxy-substituted aromatic carboxylic acids, 1820
**Mathur, P. P.,** *see* Mokler, C. M., 1304
**Matthews, B. A.,** and Rhodes, C. T., use of the Coulter counter and a digital computer for the evaluation of stability ratios in flocculating monodisperse systems, 557
——and Rhodes, C. T., some studies of flocculation phenomena in pharmaceutical suspensions, 569
**Mattocks, A. M.,** *see* Penzotti, S. C., 1192
**Maulding, H. V.,** Zoglio, M. A., and Johnston, E. J., pharmaceutical heterogeneous systems II. Study of hydrolysis of aspirin in combination with fatty acid tablet lubricants, 1873
——Zoglio, M. A., Turi, P., and Lapoff, R., Mannich bases of vanillin oxime, 1244
——*see* Gisvold, O., 784
——*see* Zoglio, M. A., 1877; 2080
**May, M.,** Czoncha, L., Garrison, D. R., and Triggle, D. J., the analgesic, hypothermic, and depressant activities of some *N*-substituted α-5,9-dimethyl-6,7-benzomorphans, 884
——and Triggle, D. J., cholinergic receptor I. Cholinomimetic activities of some analogs of *cis*-2-methyl-4-dimethylaminomethyl - 1,3 - dioxolane methiodide, 511
**May, R. F.,** *see* Billman, J. H., 1622; 1809; 1812
**Maynard, W. R., Jr.,** *see* Bruce, R. B. 1173
**Mayorga, G.,** *see* Goodhart, F. W., 1770
**McCarthy, W. C.,** *see* Brunett, E. W., 2003
**McClintock, W. J.,** Kildsig, D. O., Kessler, W. V., and Banker, G. S., nuclear *in vitro* method of continuously evaluating release rates of solid dosage forms, 1649
**McCormick, D. B.,** and Fory, W., base-catalyzed hydrolysis of flavins. Effect of amines and the particular role of position 3, 841
**McGilveray, I. J.,** *see* Fooks, J. R., 314
**McIsaac, W. M.,** *see* Ho, B. T., 269; 1364; 1998
**McKeon, W. B., Jr.,** *see* Luduena, F. P., 1543
**McLaughlin, J. L.,** *see* Below, L. E., 515
**McOwen, J. M.,** *see* Eling, T. E., 1357
——*see* Schmidt, G. C., 443
**Meer, W. A.,** *see* Masoud, A. N., 587
**Mehta, M. J.,** *see* Hegde, R. S., 598
**Melder, F. L.,** *see* Voldeng, A. N., 1053
**Menig, J.,** *see* Lin, S.-L., 2143
**Mennear, J. H.,** *see* Ghafghazi, T., 1690
**Menyharth, A.,** *see* Mahn, F. P., 2149
**Menzie, J.,** *see* Kriesel, D. C., 1791
**Messmer, W. M.,** Farnsworth, N. R., Persinos, G. J., and Wilkes, J. D., phytochemical investigation of the flowers of *Cassia reticulata* Willd. (*Leguminosae*), 1996
**Metri, J.,** *see* Nabih, I., 1609
**Meyer, M. C.,** and Guttman, D. E., the binding of drugs by plasma proteins, 895
——and Guttman, D. E., interactions of xanthine derivatives with bovine serum albumin III. Inhibition of binding, 245
——and Guttman, D. E., novel method for studying protein binding, 1627
**Miele, D.,** *see* Shane, N., 1260
**Mikkelson, T. J.,** and Robinson, J. R., identification of sugars from rates of oxime formation, 1180
**Miller, A. S.,** *see* Tansy, M. F., 1906
**Miller, M. M.,** *see* Wagman, G. H., 1319
**Mills, M. N.,** *see* Goodhart, F. W., 1770
**Milner, G.,** cumulative lethal dose of alcohol in mice given amitriptyline, 2005
——modified confinement motor activity test for use in mice, 1900
**Milosovich, G.,** *see* Hussain, A., 411
**Minatoya, H.,** *see* Conway, W. D., 1135
**Mirazaian, A. H.,** and Sommers, E. B., comparison of the absorption and excretion of calcium from precipitated calcium carbonate USP XVII and egg shells, 422
**Misher, A.,** Adams, H. J., Fishler, J. J., and Jones, R. G., pharmacology of the hexylcarbonate of salicylic acid, 1128
**Mitscher, L. A.,** biosynthesis of the tetracycline antibiotics, 1633
**Miya, T. S.,** *see* Ghafghazi, T., 1690
**Mohammed, K.,** Nona, D. A., and Blake, M. I., effect of deuteration on the growth and antibiotic production of a number of strains of *Penicillium*, 2049
**Mokler, C. M.,** and Mathur, P. P., influence of calcium and antiarrhythmic drugs on palmitate uptake by rabbit heart slices, 1304
**Mollica, J. A.,** *see* Urbányi, T., 1257
**Monte-Bovi, A. J.,** *see* Tuesley, S. P., 488
**Montfort, M. L.,** *see* Svoboda, G. H., 1720
**Montgomery, J. A.,** *see* Shealy, Y. F., 757
**Moody, J. E., Jr.,** Hohmann, J. R., and Kaplan, G. B., chemical determination of the potency of thyroid preparations, 634
**Mroszczak, E. J.,** *see* Levy, G., 235
**Mukherjee, S. L.,** Chmielewicz, Z. F., and Bardos, T. J., deoxyalloxazines (benzopteridines) II. Methylation of 2,4 - diamino - 6,7 - dimethylbenzo (*g*)pteridine, 516
**Mulder, F. J.,** *see* Buisman, J. A. K., 1326
——*see* Hanewald, K. H., 1308
**Mulhauser, R. O.,** and Jorgensen, E. C.,

properties of some phenyl pyridyl ethers with antifungal and antibacterial properties, 151
**Munden, B. J.,** *see* Bornstein, M., 1653
**Munies, R.,** Grubb, T. C., and Caliari, R. E., relationship between sputum viscosity and total sialic acid content, 824
**Murphy, J. E.,** *see* Salim, E. F., 649
**Murphy, P. J.,** and Wick, A. N., metabolism of β-phenethylbiguanide, 1125
**Murray, D. H.,** *see* Prokop, J., 1697
**Murray, H. M.,** *see* Fletcher, H. P., 2101
**Murray, R. B.,** new approach to the fusion method for preparing granular effervescent products, 1776
**Myers, C.,** *see* Sancilio, L. F., 1248

N

**Nabih, I.,** and Elwasimi, M. T., structure and activity relationships in molluscicides, 1202
——El-Wassimy, M. T., and Metri, J., structure and activity in molluscicides II. Activity assay of catalase and peroxidase in snails, 1609
**Nádor, K.,** *see* Pálosi, E., 709
**Nagashima, R.,** and Levy, G., effect of flow rate on the distribution kinetics of a drug from perfusate to a perfused organ, 2000
——and Levy, G., effect of perfusion rate and distribution factors on drug elimination kinetics in a perfused organ system, 1991
——Levy, G., and Back, N., comparative pharmacokinetics of coumarin anticoagulants II. Pharmacokinetics of bishydroxycoumarin elimination in the rat, guinea pig, dog, and rhesus monkey, 68
——Levy, G., and Nelson, E., comparative pharmacokinetics of coumarin anticoagulants I. Unusual interaction of bishydroxycoumarin with plasma proteins—development of a new assay, 58
——Levy, G., and O'Reilly, R. A., comparative pharmacokinetics of coumarin anticoagulants IV. Application of a three-compartmental model to the analysis of the dose-dependent kinetics of bishydroxycoumarin elimination, 1888
——Levy, G., and Sarcione, E. J., comparative pharmacokinetics of coumarin anticoagulants III. Factors affecting the distribution and elimination of bishydroxycoumarin (BHC) in isolated liver perfusion studies, 1881
**Naik, A. R.,** *see* Bulkacz, J., 1017
**Naik, K. B.,** *see* Gore, A. Y., 1850
**Nairn, J. G.,** *see* Sawchuk, R. J., 1896
**Nakano, M.,** and Higuchi, T., determination of molecular binding in aqueous solution from optical activity measurements. Interaction of tryptophan with alkylxanthines, 1865
——and Higuchi, T., effect of molecular conformation on interaction of organic species in water. Benzamides and anisamides with theophylline and riboflavin, 183
**Naramore, D. C.,** *see* Crawford, R. R., 1716
**Neal, J. M.,** Benedict, R. G., and Brady, L. R., interrelationship of phosphate nutrition, nitrogen metabolism, and accumulation of key secondary metabolites in saprophytic cultures of *Psilocybe cubensis*, *Psilocybe cyanescens*, and *Panaeolus campanulatus*, 1861
**Neely, W. B.,** White, H. C., and Rudzik, A., structure-activity relationship in an imidazoline series prepared for their analgesic properties, 1176
**Nelson, E.,** *see* Nagashima, R., 58
**Nelson, J. A.,** *see* Cates, L. A., 189
**Nessel, R. J.,** *see* Jacob, J. T., 1854
**Nestler, H. J.,** and Garrett, E. R., prediction of stability in pharmaceutical preparations XV. Kinetics of hydrolysis of 5-trifluoromethyl-2′-deoxyuridine, 1117
**Niebergall, P. J.,** and Sugita, E. T., utilization of the Guggenheim method in kinetics, 1805
**Nielsen, B.,** *see* Brochmann-Hanssen, E., 30
**Nigam, I. C.,** Radecka, C., and Komae, H., essential oils and their constituents XXXVII. Isolation and structure of khusenol, a new sesquiterpenic primary alcohol from oil of vetiver, 1029
**Nightingale, C. H.,** *see* Gibaldi, M., 226; 1354
**Ninger, F. C.,** *see* Goodhart, F. W., 1770
**Nobles, W. L.,** and Potti, N. D., studies on the mechanism of the Mannich reaction, 1097; erratum, 2184
——*see* Gorum, L., 1265
——*see* Luts, H. A., 578
——*see* Potti, N. D., 1487; 1785
——*see* Varma, R. S., 39; 1251; 1801
**Nona, D. A.,** Blake, M. I., Crespi, H. L., and Katz, J. J., effect of deuterium oxide on the culturing of *Penicillium janczewskii*. II, Isolation of fully deuterated griseofulvin, 975; III, Antifungal activity of fully deuterated griseofulvin, 1993
——*see* Mohammed, K., 2049
**Northam, J. I.,** *see* Wagner, J. G., 994
**Nuti, V.,** *see* Saettone, M. F., 1798

O

**Ogura, H.,** Shikiba, Y., and Yamazaki, Y., quantitative analysis of flavonoids, 705
**Ohlrogge, A. J.,** *see* Spitznagle, L. A., 764
**O'Leary, R. K.,** and Guess, W. L., toxicological studies on certain medical grade plastics sterilized by ethylene oxide, 12
——Guess, W. L., and Autian, J., effects of heat and ultraviolet radiation on the stability of a polypropylene-polyisobutylene alloy, 1552
**Oleniacz, W. S.,** Singer, E. J., Doyle, A. B., and Vinson, L. J., induction of photohemolysis by tetrachlorosalicylanilide, 2136
**Opliger, C. E.,** *see* Shealy, Y. F., 757
**O'Reilly, R. A.,** *see* Nagashima, R., 1888
**Orth, R. E.,** biologically active pyrazoles, 537
——Bennett, J. W., Ma, O. H., and Young, L., centrally acting isosteric Mannich bases, 1814
**Osadca, M.,** and De Ritter, E., modification of USP vitamin D assay to remove interference of vitamin E, 309
**Ozturk, S.,** *see* Ulubelen, A., 1037

P

**Packman, E. W.,** *see* Sample, R. G., 795
——*see* Sherman, G. P., 733
**Palermo, B. T.,** *see* Gold, G., 667; 2153
**Pálosi, E.,** Szporny, L., and Nádor, K., antidepressive effect of *N*-3,4,5-trimethoxybenzoyl heptamethyleneimine, 709
**Pals, D. T.,** *see* Halliday, R. P., 430
**Papariello, G.,** *see* Salim, E. F., 311
**Papariello, G. J.,** *see* Cullen, L. F., 1857
——*see* DeAngelis, N. J., 1868
**Paplanus, S. H.,** *see* Kondritzer, A. A., 1142
**Parkhurst, R. M.,** *see* Skinner, W. A., 338
**Patel, D. J.,** *see* Hegde, R. S., 598
**Patel, N. K.,** Sheen, P.-C., and Taylor, K. E., studies on protein binding I. Interaction of *para*-hydroxybenzoic acid esters with bovine serum albumin, 1370
**Pathak, B.,** *see* Lahiri, S. C., 1013
**Paul, A. G.,** *see* Below, L. E., 515
——*see* Leung, A. Y., 1667
**Paulssen, R. B.,** Pitman, I. H., and Higuchi, T., characterization of racemic-α-hydroxy- and β-hydroxysuccinanilic acids, 529
——*see* Pitman, I. H., 239
**Pavelek, J. J.,** *see* Theimer, E. E., 887
**Peck, G. E.,** *see* Gore, A. Y., 1850
**Penner, M. H.,** thin-layer chromatography of certified coal tar color additives, 2132
**Penzotti, S. C.,** and Mattocks, A. M., acceleration of peritoneal dialysis by surface-active agents, 1192
**Pernarowski, M.,** Woo, W., and Searl, R. O., continuous flow apparatus for the determination of the dissolution characteristics of tablets and capsules, 1410
**Perrin, J. H.,** *see* Bonkoski, S., 1784
**Persinos, G. J.,** *see* Messmer, W. M., 1996
**Peter, V.,** *see* Hussain, A., 411
**Pfeffer, M.,** Schor, J. M., Bolton, S., and Jacobsen, R., human urinary excretion of the quaternary ammonium compounds anisotropine methylbromide and propantheline bromide, 1375
——Schor, J. M., Gluck, N., Semmel, M. G., and Griboff, S., human urinary excretion of orally administered anisotripine methylbromide, 36
**Pfeifer, S.,** *see* Brochmann-Hanssen, E., 30
**Phares, R. E., Jr.,** complexation of sodium fluorescein with polyvinylpyrrolidone, 53
**Piantadosi, C.,** Semeniuk, F. T., and Rauch, R. K., mixed glycol acetal dimethylcarbamates *via* transacetalation of certain di- and trihydric alcohols, 161
——*see* Cheng, S.-S., 1910
**Piechocki, J. T.,** gas chromatographic determination of ethanol in pharmaceuticals. Comparison of polyethylene glycol 400 and divinylbenzene polymer columns, 134
**Piliero, S. J.,** *see* Colombo, C., 1526
**Pilpel, N.,** *see* Harwood, C. F., 478
**Pinchuk, G.,** *see* Wolkoff, H. N., 317
**Pitman, I. H.,** Paulssen, R. B., and Higuchi, T., interaction of acetic anhydride with di- and tricarboxylic acids in aqueous solution II. Acetic anhydride in malic, tartaric, and succinic acid buffers, 239
——*see* Paulssen, R. B., 529
**Pitzer, N. W.,** and Ray, F. E., new compounds: fluorene derivatives as potential carcinogens, 348
——and Ray, F. E., new compounds: *N*-hydroxy- and *N*-acetoxy-metabolites of *N*,*N*′-(2,7-fluorenylene) bisacetamide, 1065
**Plaxco, J. M., Jr.,** and Foreman, F., effect of some nonionic surfactants on the rate of absorption of aminophylline from suppositories in rabbits, 698
**Plein, E. M.,** *see* Jacob, J. T., 798; 802
**Plinton, C.,** *see* Mahn, F. P., 2149
**Plumlee, M. P.,** *see* Ice, R. D., 399
**Pocha, P.,** *see* Counsell, R. E., 1657
**Podrebarac, E. G.,** and Cheng, C. C., methylglyoxal bis(guanylhydrazone) analogs VI. Methylglyoxal bis-(guanylhydrazone) pamoate, 1438
**Poe, R. D.,** *see* Barrett, J., 1249
**Polesuk, J.,** *see* Turi, P., 2180
**Ponder, C.,** determination of phenylephrine hydrochloride in combination with other drugs, 467
**Poole, J. W.,** and Bahal, C. K., dissolution behavior and solubility of anhydrous and trihydrate forms of ampicillin, 1945
**Poore, G. A.,** *see* Svoboda, G. H., 1720
**Portoghese, P. S.,** and Larson, D. L., absolute stereochemistry and analgesic potency of prodine enantiomers, 711
**Poswalk, N. M.,** *see* Sinsheimer, J. E., 2007
**Potti, N. D.,** and Nobles, W. L., an improved method for preparing 3-azabicyclo[3.2.1]octane hydrochloride and the synthesis of its phenothiazine derivatives, 1785
——and Nobles, W. L., use of 3-azabicyclo[3.2.1]octane in the Mannich reaction, 1487
——*see* Nobles, W. L., 1097
**Poulsen, B. J.,** Young, E., Coquilla, V., and Katz, M., effect of topical vehicle composition on the *in vitro* release of fluocinolone acetonide and its acetate ester, 928
**Poust, R. I.,** and Colaizzi, J. L., copper-catalyzed oxidation of ascorbic acid in gels and aqueous solutions of polysorbate 80, 2119
**Powell, C. E.,** *see* Willard, P. W., 1390
**Pratt, R.,** and Johnson, E., deficiency of vitamin $B_{12}$ in *Chlorella*, 1040
**Procknal, J. A.,** *see* Levy, G., 1330
**Prokop, J.,** and Murray, D. H., synthesis of 3′-deoxynucleosides III. Synthesis of 9-(3-deoxyaldofuranosyl) adenines derived from 3-deoxy-D-mannose and 3-deoxy-D-galactose, 1697
**Prosser, A. R.,** and Sheppard, A. J., gas-liquid chromatography of niacin and niacinamide, 1004
**Pruyn, F. J.,** *see* Lange, W. E., 124
**Puckett, R.,** *see* Barrett, J., 1249

Q

**Quay, W. B.,** specificity of fluorometry of 5-hydroxytryptamine by means of products with ninhydrin, 1568
**Quintana, R. P.,** Lasslo, A., Boggs, P. P., and Yeaglin, E. D., effect of new synthetic grisan derivatives upon monomolecular films of stearic acid, 230

R

**Racz, W. J.,** *see* Chatten, L. G., 137
**Radecka, C.,** *see* Nigam, I. C., 1029
**Rader, B. R.,** and Arranda, E. S., quantitative determination of some single and multiple component drugs by gas-liquid chromatography, 847
**Raghunathan, Y.,** and Becker, C. H., spray-congealed formulations of sulfaethidole (SETD) and waxes for prolonged-release medication. Effects of modifier, 1748
**Ranade, V. V.,** *see* Counsell, R. E., 1657
**Rankell, A. S.,** and Higuchi, T., physics of tablet compression XV. Thermodynamic and kinetic aspects of adhesion under pressure, 574
**Rasmussen, S.,** correlation between *in vitro* and *in vivo* disintegration times of enteric-coated tablets, 1360
**Rauch, R. K.,** *see* Piantadosi, C., 161
**Ravin, L. J.,** and Bernardo, P. D., pharmaceutical sciences—1967. A literature review of pharmaceutics, 1075
**Ray, F. E.,** *see* Pitzer, N. W., 348; 1065
**Ray, M. D.,** Avis, K. E., and Flanigan, C. C., Jr., microbiological evaluation of PCMX complexes, 609
**Reier, G.,** Cohn, R., Rock, S., and Wagenblast, F., evaluation of factors affecting the encapsulation of powders in hard gelatin capsules I. Semiautomatic capsule machines, 660
**Reinstein, J. A.,** *see* Grab, F. L., 1703
**Reuning, R. H.,** and Levy, G., characterization of complex formation between small molecules by membrane permeation measurements, 1556
——and Levy, G., effect of complex formation on drug absorption. VII, Effect of complexation and self-association on the absorption of caffeine, 1335; VIII, Intestinal transfer characteristics of the salicylamide–caffeine system, 1342
**Rhodes, C. T.,** *see* Blunden, G., 602
——*see* Humphreys, K. J., 79
——*see* Matthews, B. A., 557; 569
**Rhodes, H. J.,** Shiau, R. P., and Blake, M. I., oxidation of organic compounds with xenon trioxide I. Stoichiometric and kinetic studies involving cinnamyl alcohol, cinnamaldehyde, and cinnamic acid, 1706
**Rice, W. B.,** *see* Genest, K., 331
**Richmond, C. W.,** *see* Sam, J., 1445; 1763
**Riegelman, S.,** Loo, J., and Rowland, M., concept of a volume of distribution and possible errors in evaluation of this parameter, 128
——Loo, J., and Rowland, M., shortcomings in pharmacokinetic analysis by conceiving the body to exhibit properties of a single compartment, 117
——*see* Loo, J. C. K., 918
——*see* Rowland, M., 984; 1313
**Rifino, C. B.,** Bousquet, W. F., Knevel, A. M., Belcastro, P., and Martin, A. N., effect of certain tetracycline analogs on phenylalanine-$^{14}$C incorporation by *Escherichia coli* B cell-free extracts, 351
**Ringham, G. L.,** *see* Burkman, A. M., 815
**Rivard, D. E.,** *see* Dittert, L. W., 828
**Robins, R. K.,** *see* Cheng, C. C., 1044
**Robinson, D. W.,** method for determining ethchlorvynol in urine and serum by gas chromatography, 185
**Robinson, I. C.,** and Becker, C. H., sulfaethylthiadiazole (SETD) release from synthetic wax prolonged-release particles I. Effect of dispersant concentration, 49
**Robinson, J. R.,** *see* Mikkelson, T. J., 1180
**Robinson, M. J.,** Grass, G. M., and Lantz, R. J., an apparatus and method for the coating of solid particles, 1983
**Robinson, S. M.,** *see* Fang, V., 2111
**Robison, R. L.,** *see* Boylan, J. C., 1796
**Roborgh, J. R.,** *see* Buisman, J. A. K., 1326
**Rock, S.,** *see* Reier, G., 660
**Rofael, N.,** *see* Wahba, S. K., 1231
**Roll, W. D.,** *N*-acyl analogs of *N*-(2-cyanoethyl) cyclohexylamine with CNS activity, 1671
**Rongone, E. L.,** and Ferraro, F. M., androst-4-ene-3,17-dione-4-$^{14}$C metabolism by the homogenates of the chicken uropygial gland I. Antibiotic concentrations necessary for inhibition of bacterial growth, 1962
**Roosemont, J. L.,** polarographic study of the interaction between the antimonyl ion and pyrazoline derivatives, 1056
**Rossi, G. V.,** *see* Sample, R. G., 795
——*see* Sherman, G. P., 733
**Rowe, E. J.,** *see* Seidler, W. M. K., 1007
**Rowland, M.,** and Riegelman, S., pharmacokinetics of acetylsalicylic acid and salicylic acid after intravenous administration in man, 1313
——Riegelman, S., and Epstein, W. L., absorption kinetics of griseofulvin in man, 984
——*see* Riegelman, S., 117; 128
**Rudzik, A.,** *see* Neely, W. B., 1176
**Rutgers, J. G.,** *see* Cullen, L. F., 1857

S

**Saettone, M. F.,** and Nuti, V., preparation of some 5-hydroxyimidazolidin-2-ones, 4-imidazolin-2-ones, and hydantoins from 3,4-diphenyl-4-oxazolin-2-one, 1798
——*see* Carboni, S., 1063
**Salim, E. F.,** Deuble, J. L., and Papariello, G., qualitative and quantitative tests for oxazepam, 311
——Haussler, A., and Vaughan, J. B., qualitative and quantitative tests for furosemide, 640
——and Murphy, J. E., qualitative and quantitative tests for allopurinol, 649
——*see* Kurlansik, L., 475
**Sam, J.,** preparation of 2,2-diethyl-3-(3,4,5-trimethoxybenzoyloxy)propyl carbamate, 707
——Aparajithan, K., and Shafik, R., 2-(4-biphenyl)ethylamines: potential cardiovascular and CNS agents, 564
——Lopez, A. V., and Shafik, R. M., preparation and properties of some relatives of noscapine, 1755
——Valentine, J. L., and Richmond C. W., reaction of 2-chlorobenzoxazole with anthranilic acids and 2-amino-1-naphthalenesulfonic acid, 1445
——Valentine, J. L., and Richmond, C. W., 3-substituted-2-benzoxazolinones, 1763
——*see* Advani, S. B., 1693
**Sample, R. G.,** Rossi, G. V., and Packman, E. W., thiry-vella dog as a biologic model for evaluation of drug absorption from the intestinal mucosa, 795
**Sánchez, J.,** *see* Gábáldon, M., 1744
**Sancilio, L. F.,** Kraus, P., Myers, C., and Wagner, L., simple method for resuscitating rats from ether overdosage, 1248
**Sarcione, E. J.,** *see* Nagashima, R., 1881
**Sartorelli, A. C.,** *see* Agrawal, K. C., 1948
**Saski, W.,** effect of a nonionic surface-active polymer on passage of hydrocortisone across rat intestine *in vitro*, 836
**Sawchuk, R. J.,** and Nairn, J. G., rate studies on the binding of bilirubin by ion-exchange resins, 1896
**Schaeffer, H. J.,** and Schwender, C. F., enzyme inhibitors XXII. Identity of inhibitor binding site on adenosine deaminase, 1070
**Schaubman, R.,** and Felmeister, A., interaction of a photosensitizer with dipalmitoyl lecithin, 178
**Scheline, R. R.,** drug metabolism by intestinal microorganisms, 2021
**Schmidt, G. C.,** Eling, T. E., and McOwen, J. M., synthesis of tropine-labeled atropine III. Synthesis of *N*-methyl-$^{14}$C-tropine and *N*-methyl-$^{14}$C-atropine, 443
**Schmidt, G. C.,** *see* Eling, T. E., 1357
**Schor, J. M.,** *see* Pfeffer, M., 36; 1375
**Schramm, L. C.,** *see* Imholte, R. D., 97
——*see* Sinner, G. T., 889
**Schriftman, H.,** analysis of pharmaceuticals by ultraviolet densitometry on thin-layer chromatograms I. Parabens in gels and creams, 1760
——*see* Chafetz, L., 710
**Schurman, P.,** *see* Hussain, A., 411
**Schwan, T. J.,** and Davis, C. S., more convenient syntheses of *o*-azidobenzaldehyde and 2-substituted indazoles, 877
**Schwartz, B. E.,** *see* Janicki, C. A., 451
**Schwartz, H. F., II,** Brown, R. G., Isaacson, E. I., and Delgado, J. N., structure-activity relationships among some selected substituted cyanoacetamides, 1530
**Schwartz, J. B.,** Simonelli, A. P., and Higuchi, W. I., drug release from wax matrices. I, Analysis of data with first-order kinetics and with the diffusion-controlled model, 274; II, Application of a mixture theory to the sulfanilamide–wax system, 278
**Schwartz, M. A.,** aminolysis of benzylpenicillin by aliphatic diamines, 1209
——*see* Kinget, R. D., 1916
**Schwender, C. F.,** *see* Schaeffer, H. J., 1070
**Sciarra, J. J.,** *see* Marks, A. M., 497
——*see* Tuesley, S. P., 488
**Sciuchetti, L. A.,** *see* Masoud, A. N., 587
**Searl, R. O.,** *see* Pernarowski, M., 1419
**Segal, A.,** and Taylor, E. H., conversion of griseophenone A to (±)-dehydrogriseofulvin in the presence of horseradish peroxidase and hydrogen peroxide, 874; erratum, 2184
**Seidler, W. M. K.,** and Rowe, E. J., influence of certain factors on the coating of a medicinal agent on core tablets, 1007
**Seidman, M.,** *see* Jones, L. N., 646
**Selzer, G.,** *see* Bracey, A., 464
——*see* Kantor, N., 2170
**Semeniuk, F. T.,** *see* Piantadosi, C., 161
**Semmel, M. G.,** *see* Pfeffer, M., 36
**Senkowski, B. Z.,** *see* Mahn, F. P., 145; 2149
**Setnikar, I.,** Gál, G., and Fantelli, S., rheologic studies on dermatologic lotions, 671
**Seydel, J. K.,** sulfonamides, structure-activity relationship, and mode of action. Structural problems of the antibacterial action of 4-aminobenzoic acid (PABA) antagonists, 1455
**Shafik, R.,** *see* Sam, J., 564; 1755
**Shah, A. A.,** Connors, K. A., alpha-chymotrypsin-catalyzed hydrolysis of some carbonate esters, 282
**Shah, M. A.,** and Wilson, R. G., some effects of humidity and heat on the tableting properties of microcrystalline cellulose formulations I, 181
**Shah, N. J.,** *see* Kapadia, G. J., 254
**Shah, R. S.,** *see* Kanhere, S. S., 342
**Shamma, M.,** and Dudock, B. S., thalictrum alkaloids V. Isolation, 262
**Shane, N.,** and Kowblansky, M., determination of acetylsalicylic acid, salicylamide, acetaminophen, and caffeine in tablets or powders by independent methods, 1218
——and Miele, D., potentiometric determination of fluoride ion in toothpastes by a specific ion-activity electrode, 1260
**Shangraw, R. F.,** *see* Augsburger, L. L., 624
——*see* Walkling, W. D., 1927
**Shapiro, P. H.,** *see* Wolkoff, H. N., 317
**Shapiro, W.,** Tansy, M. F., and Elkin, S., synthesis and preliminary evaluation of a new quinuclidine derivative as a radioprotective agent, 1725
**Shar, R. S.,** *see* Bhat, C. V., 1195
**Shaw, D. W.,** *see* Lefar, M. S., 1442
**Shealy, Y. F.,** Krauth, C. A., Clayton, S. J., Shortnacy, A. T., and Laster, W. R., Jr., imidazoles V. 5(or 4)-(3-Alkyl-3-methyl-1-triazeno)-imidazole-4(or 5)-carboxamides, 1562
——Krauth, C. A., Holum, L. B., and Fitzgibbon, W. E., synthesis and properties of the antileukemic agent 5 (or 4)-[3,3-bis(2-chloroethyl)-1-triazeno]imidazole-4 or (or 5)-carboxamide, 83
——Opliger, C. E., and Montgomery, J. A., synthesis of D- and L-thalidomide and related studies, 757

**Sheen, P.-C.,** *see* Patel, N. K., 1370
**Shefter, E.,** crystal and molecular structure of 6-thiopurine riboside, 1157
——crystal structure of thiolphthalide, 175
——structural studies on complexes. I, Postulation of polarization bonding in xanthine complexes, 350; II, crystal and molecular structure of a 1:1 caffeine and 5-chlorosalicylic acid complex, 1163
**Shekosky, J. M.,** *see* Conway, W. D., 1135
**Shepard, B. J.,** *see* Loo, T. L., 2126
**Sheppard, A. J.,** *see* Prosser, A. R., 1004
**Sherman, G. P.,** Packman, E. W., and Rossi, G. V., electrolyte alterations in vascular smooth muscle and hypotensive activity of a new chalcone derivative, 733
**Shiau, R. P.,** *see* Rhodes, H. J., 1706
**Shih, T. B.,** *see* Huang, J. T., 1620
**Shikiba, Y.,** *see* Ogura, H., 705
**Shipchandler, M.,** and Soine, T. O., coumarins. V, Mass spectra of columbianetin and its esters, 741; VI, A revised structure of columbianin and pertinent mass spectral studies, 747; VIII, Mass spectra of lomatin and some of its derivatives, 2062
**Shishoo, C. J.,** *see* Devani, M. B., 1051
**Shoeb, A.,** *see* Conway, T. T., 455
**Shortnacy, A. T.,** *see* Shealy, Y. F., 1562
**Shroff, A. P.,** and Huettemann, R. E., gas chromatographic determination of anagestone acetate in fertility control tablets, 882
**Shtacher, G.,** X-ray contrast media. Glutaric and iminodiacetic acids as carriers of iodinated phenyl ring, 1710
**Siegel, F. P.,** *see* Smolen, V. F., 378
**Siehr, D. J.,** *see* Bhargava, U. C., 1728
**Silva, M.,** triterpenic constituents of *Lepechinia chamaedryoides*, 864
**Simonelli, A. P.,** Flanagan, D. R., and Higuchi, W. I., apparent discrepancy between theory and experimental data for dissolution from the rotating disk under stirred and unstirred conditions, 1629
——*see* Schwartz, J. B., 274; 278
——*see* Singh, P., 217; 959
**Singer, E. J.,** *see* Oleniacz, W. S., 2136
**Singh, P.,** Desai, S. J., Flanagan, D. R., Simonelli, A. P., and Higuchi, W. I., mechanistic study of the influence of micelle solubilization and hydrodynamic factors on the dissolution rate of solid drugs, 959
——Desai, S. J., Simonelli, A. P., and Higuchi, W. I., role of wetting on the rate of drug release from inert matrices, 217
**Sinner, G. T.,** and Schramm, L. C., preliminary phytochemical investigation of wild rice ergot, 889
**Sinsheimer, J. E.,** and Poswalk, N. M., pharmaceutical applications of the near infrared determination of water, 2007
——and Smith, R. V., 4,4′-dihydroxybibenzyl, a reduction metabolite of *trans*-stilbene, 713
——Stewart, J. T., and Burckhalter, J. H., fluorometric determinations comparable to eye response, 333
——Stewart, J. T., and Burckhalter, J. H., stilbene isothiocyanates as potential fluorescent tagging agents, 1938
**Skakum, W.,** *see* Hughes, D. W., 1023; 1619
**Skinner, W. A.,** Leaffer, M. A., and Parkhurst, R. M., investigation of the use of derivative neutron activation analysis for drug assay, 338
**Slater, J. G.,** *see* Gold, G., 667; 2153
**Smissman, E. E.,** Lemke, T. L., and Creese, M. W., novel preparation of bicyclo[3.1.0]hex-2-ene-4-one-1-carboxylic acid and related compounds, 1520
——*see* Briden, R. C., 1523
**Smith, R. V.,** *see* Sinsheimer, J. E., 713
**Smith, S. J.,** *see* Beckstead, H. D., 1952
**Smith, T. D.,** *see* Counsell, R. E., 1958
**Smolen, V. F.,** and Siegel, F. P., procaine interaction with the corneal surface and its relation to anesthesia, 378
——*see* Gore, A. Y., 1850
**Smolenski, S. J.,** *see* Bejnarowicz, E. A., 2160
**Soine, T. O.,** *see* Lee, K.-H., 865; 1922
——*see* Shipchandler, M., 741; 747; 2062
**Solomon, M. J.,** and Crane, F. A., isolation and characterization of some UV-induced mutants of *Chlorella vulgaris* Prings., 2038
**Solvang, S.,** *see* Finholt, P., 1322
**Sommers, E. B.,** *see* Mirazaian, A. H., 422
**Sorby, D. L.,** effect of adsorbents on drug absorption: importance of preequilibrating drug and adsorbent, 1604
**Southworth, B. C.,** *see* Jones, L. N., 646
**Spencer, M. R.,** *see* Lee, K. H., 1240
**Spera, D. C.,** *see* Carstensen, J. T., 23
**Spitzer, C.,** *see* Ahuja, S., 1979
**Spitznagle, L. A.,** Christian, J. E., Ohlrogge, A. J., and Breckinridge, C. E., Jr., study of absorption, translocation, and residue properties of 2,3,5-triiodobenzoic acid in field-grown soybeans, 764
**Srivastava, M. C.,** *see* Tewari, J. P., 328
**Staba, E. J.,** and Jindra, A., datura tissue cultures: production of minor alkaloids from chlorophyllous and nonchlorophyllous strains, 701
**Starr, J. E.,** and Judis, J., mechanism of action of phenolic disinfectants VIII. Association of phenolic disinfectants with proteins, 768
**Stasse, J. A.,** *see* Campbell, A. H., 2045
**Stein, A.,** *see* Tansy, M. F., 1906
**Stelzer, J. M., Jr.,** Colaizzi, J. L., and Wurdack, P. J., influence of dimethyl sulfoxide (DMSO) on the percutaneous absorption of salicylic acid and sodium salicylate from ointments, 1732
**Stephani, R. A.,** *see* Finnegan, R. A., 353; 1039
**Stevenson, C. E.,** and Comer, I., semiautomated assay for the simultaneous determination of propoxyphene hydrochloride and paramethasone acetate in coated single tablets, 1227
——*see* Comer, J. P., 147
**Stewart, J. T.,** *see* Sinsheimer, J. E., 333; 1938
**Straw, R. N.,** effect of paralyzation with dimethyltubocurarine on cortical after-discharge duration, 1782
**Strickland, R. D.,** *see* Fooks, J. R., 314
**Strycker, S. J.,** and Long, J. P., remarks on the synthesis of quaternary cocaine compounds, 1822
**Stubbins, J. F.,** Hudgins, P. N., Andrako, J., and Beebe, A. J., anticholinergic agents based on Arien's dual receptor theory, 534
**Sugita, E. T.,** *see* Neibergall, P. J., 1805
**Sullivan, G.,** occurrence of norcaperatic acid in *Polyporus fibrillosus*, 1804
**Sunaga, K.,** and Koide, S. S., identification of a prednisolone derivative interacting with calf thymus histones, 2116
**Svoboda, G. H.,** Poore, G. A., and Montfort, M. L., alkaloids of *Ochrosia maculata* Jacq. (*Ochrosia borbonica* Gmel.) isolation of the alkaloids and study of the antitumor properties of 9-methoxyellipticine, 1720
——*see* Farnsworth, N. R., 2174
**Swartz, C. J.,** and Anschel, J., evaluation of tableting tool life records, 1779
**Swartz, H. A.,** *see* French, L. L., 2068
**Swintosky, J. V.,** Caldwell, H. C., Chong, C. W., Irwin, G. M., and Dittert, L. W., 4-acetamidophenyl 2,2,2-trichloroethyl carbonate: synthesis, physical properties, and *in vitro* hydrolysis, 752
——*see* Dittert, L. W., 774; 780; 828; 1146; 1269
**Swoap, J. R.,** *see* Dreyfuss, J., 1497
**Symchowicz, S.,** and Katchen, B., griseofulvin absorption in man after single and repeated treatments and its correlation with dissolution rates, 1383
**Szporny, L.,** *see* Palosi, E., 709

T

**Tadepalli, A. S.,** *see* Liska, K. J., 2157
**Taggart, M.,** *see* Kabasakalian, P., 621; 856
**Talmage, J. M.,** Chafetz, L., and Elefant, M., observations on the instability of cyclamate in hydroalcoholic solution, 1073
**Tanner, B. B.,** *see* Loo, T. L., 2126
**Tansey, L. W.,** *see* Ho, B. T., 1998
**Tansy, M. F.,** Miller, A. S., and Stein, A., effect of vagal stimulation on enterochromaffin cell granulation in the guinea pig small intestine, 1906
——*see* Shapiro, W., 1725
**Taraszka, A. J.,** *see* Houtman, R. L., 693
**Taraszka, M. J.,** and Forist A. A., significance of kinetic aspects in the simultaneous administration of drugs, 1379
**Taylor, E. H.,** *see* Segal, A., 875
**Taylor, K. E.,** *see* Patel, N. K., 1370
**Templeton, R. J.,** Arnett, W. A., and Jakovljevic, I. M., comparative study of a new fluorometric assay of a 17α-ethinylestradiol-3-methyl ether in tablets with GLC and colorimetric assays, 1168; erratum, 2184
**Tewari, J. P.,** and Srivastava, M. C., fractionation of fatty acids of *Cucurbita maxima* seed oil with urea, 328
**Thakkar, A. L.,** and Hall, N. A., micellar solubilization of testosterone II. In aqueous solutions of some ionic surfactants, 1394
**Theimer, E. E.,** and Pavelek, J. J., titration of residual moisture in lyophilized vials, 887
**Theodore, J. M.,** *see* Lange, W. E., 124
**Thompkins, L.,** *see* Lee, K. H., 1240
**Thompson, B. B.,** the Mannich reaction. Mechanistic and technological considerations, 715
**Timma, D. L.,** *see* Bryant, R., 658
**Tin-Wa, M.,** Fong, H. H. S., Blomster, R. N., and Farnsworth, N. R., *Catharanthus* alkaloids XXI. Isolation of lochneriniae, one of the cytotoxic principles of *C. pusillus*, 2167
**Toberman, R. O.,** *see* Castello, R. A., 485
**Tomizawa, M.,** *see* Kondo, T., 1246
**Tomko, J.,** Awad, A. T., Beal, J. L., and Doskotch, R. W., isolation of candicine chloride, laurofoline chloride, and xanthoxyletin from the bark of *Zanthoxylum elephantiiasis*, 329
**Topliss, J. G.,** and Konzelman, L. M., cyclic α,β-unsaturated ketones related to ethacrynic acid, 737
**Torosian, G.,** and Lemberger, A. P., surface films of soybean lecithin II. Interactions between lecithin and lipid substances in mixed monomolecular films, 17
**Townley, E.,** *see* Kabasakalian, P., 621; 856
**Triggle, D. J.,** *see* May, M., 511; 884
**Tsilifonis, D. C.,** *see* Chafetz, L., 1000
**Tuesley, S. P.,** Sciarra, J. J., and Monte-Bovi, A. J., development and evaluation of a sampling device for the analysis of pharmaceutical aerosols, 488
**Turczan, J. W.,** gas chromatographic determination of trisulfapyrimidines in tablets, 142
——*see* Kram, T. C., 651
**Turi, P.,** *see* Maulding, H. V., Jr., 1244
**Turi, P.,** and Polesuk, J., determination of impurities in phenacetin by thin-layer chromatography II, 2180
**Turnbull, R. T.,** and Avis, K. E., effect of dimethylpolysiloxane fluid on the stability of menadione, 1409

U

**Ulubelen, A.,** Ozturk, S., and Isildatici, S., a new flavone from *Salvia triloba L. f* (*Labiatae*), 1037
**Urbányi, T.,** and Budavari, S., further applications of diazotized 4-amino-6-chloro - *m* - benzenedisulfonamide. Colorimetric determination of pyridoxine hydrochloride, 17β-hydroxy-7αα - 17α - dimethyl - B - homo - A-norestrane-3,6-dione and morphine sulfate, 1386
——and Mollica, J. A., potential diazo reagents for colorimetric determination, 1257

V

**Valdez, C.,** Isaacson, E. I., and Cosgrove, F. P., interaction of methyl and propyl parabens with selected sucrose esters, 2093
**Valentine, J. L.,** *see* Sam, J., 1445; 1763

**Vanderwyk, R. W.,** *see* Ko, J.-H. H., 2013
**Van Rossum, J. M.,** pharmacokinetics of accumulation, 2162
**Varma, R. S.,** and Nobles, W. L., antibacterial and antifungal activity of certain β-aminoketones, 1801
——and Nobles, W. L., synthesis and antibacterial activity of certain β-aminoketones, 1251
——and Nobles, W. L., synthesis and antibacterial activity of certain 3-substituted benzoxazolinones, 39
**Vasilikiotis, G. S.,** *see* Voyatzakis, V. A. E., 1255
**Vatti, R.,** *see* Zoglio, M. A., 2080
**Vaughan, J. B.,** *see* Salim, E. F., 640
**Vaughan, W. R.,** *see* Machatzke, H., 520
**Veldkamp, W.,** Johnson, G. A., and Keasling, H. H., studies on the effects of reserpine in mice as influenced by its diluent, 613
**Venturella, V.,** selective acid-catalyzed hydrolyses of methoxysulfanilamidodiazines, 1151; errata, 2184
**Vinson, L. J.,** *see* Oleniacz, W. S., 2136
**Viswanathan, V.,** *see* Mahn, F. P., 145; 2149
**Voldeng, A. N.,** Bradley, C. A., Kee, R. D., King, E. L., and Melder, F. L., synthesis of adamantyl analogs of analgesics, 1053
**Voyatzakis, V. A. E.,** Vasilikiotis, G. S., Karageorgiou, G., and Kassapoglou, I. R., influence of metallic ions on the antituberculous activity of isonicotinoyl hydrazones, 1255

W

**Wagenblast, F.,** *see* Reier, G., 660
**Wagman, G. H.,** Bailey, J. V., and Miller, M. M., differential ninhydrin chromatographic assay for the gentamicin complex, 1319
**Wagner, H.,** *see* Farnsworth, N. R., 933; 1059
**Wagner, J; G.,** and Northam, J. I., lag time before essentially constant urinary excretion rate is attained, 994
**Wagner, L.,** *see* Sancilio, L. F., 1248
**Wahba, S. K.,** Amin, S. W., and Rofael, N., study of the degradation of dexamethasone in certain pharmaceutical preparations, 1231
**Walker, G. C.,** *see* Commons, K. C., 1253
**Walker, K. E.,** *see* Ho, B. T., 269; 1364
**Walker, N. O.,** *see* Appelt, G. D., 527
**Walkling, W. D.,** and Shangraw, R. F., rheology of microcrystalline cellulose-carboxymethylcellulose gels, 1927
**Wallace, J. E.,** determination of phenaglycodol in biologic specimens by ultraviolet spectrophotometry, 426
——ultraviolet spectrophotometric determination of phenylbutazone in biologic specimens, 2053
**Wallington, J. S.,** *see* Jouhar, A. J., 617
**Walters, S. M.,** *see* Fricke, F. L., 868
**Wan, L. S. C.,** interaction of salicylic acid with quaternary ammonium compounds, 1903
**Wang, K. T.,** *see* Huang, J. T., 1620
**Ward, C. O.,** and Gautieri, R. F., effect of certain drugs on perfused human placenta VIII. Angiotensin-II antagonists, 287
**Warren, C. L.,** *see* Machatzke, H., 520
**Warren, R. J.,** *see* Eisdorfer, I. B., 195
**Warrington, H. P., Jr.,** *see* Browning, R. S., Jr., 2165
**Watkins, W. D.,** and Guess, W. L., toxicity of emetine to isolated embryonic chick-heart cells, 1968
**Watson, E. J.,** *see* Halliday, R. P., 430
**Watzman, N.,** Barry, H., III, Kinnard, W. J., Jr., and Buckley, J. P., some conditions under which pentobarbital stimulates spontaneous motor activity of mice, 1572
——Manian, A. A., Barry, H., III, and Buckley, J. P., comparative effects of chlorpromazine hydrochloride and quaternary chlorpromazine hydrochloride on the central nervous systems of rats and mice, 2089
**Wayland, L. G.,** and Weiss, P. J., identification of antibiotics in sensitivity disks, 806
**Weber, J. D.,** *see* Levine, J., 631
**Weddon, T. E.,** *see* Fletcher, H. P., 2101
**Weiner, N. D.,** Amanat, M., Blondo, D., Caprioli, R., Dinerman, N., and Felmeister, A., interaction of $NO_2$ with monolayers of phospholipids extracted from *E. coli* at 15 and 37°, 1398
——*see* Gibaldi, M., 787; 1072
——*see* Zatz, J. L., 1440
**Weinswig, M. H.,** *see* Burkman, A. M., 815
——*see* Wiley, M. R., 2011
**Weintraub, H.,** *see* Gibaldi, M., 832
**Weiss, P. J.,** *see* Wayland, L. G., 806
**Wertalik, F.,** and Bonorden, R., salivary levels of antibiotics from use of neomycin-gramicidin chewing troches, 530
**Wesolowski, J. W.,** Blaug, S. M., Chin, T.-F., and Lach, J. L., kinetics of degradation of glutethimide, 811
**Wesselman, H. J.,** assay of terpin hydrate and codeine elixir by gas chromatography, 1412
——and Koch, W. L., quantitative gas chromatographic determination of methapyrilene fumarate, ephedrine hydrochloride, and codeine phosphate in syrup, 845
**West, W. E.,** *see* Bowman, P. B., 470
**Westfall, B. A.,** *see* Bhargava, U. C., 1674; 1728
**Wheeler, L. M.,** *see* Aguiar, A. J., 1844
**White, G. R.,** *see* Machatzke, H., 520
**White, H. C.,** *see* Neely, W. B., 1176
**White, M.,** Bowman, F. W., and Kirshbaum, A., bacterial contamination in some nonsterile antibiotic drugs, 1061
**Whitworth, C. W.,** effect of various liquids on the diffusion of salicylic acid from ointment bases, 1540
**Wick, A. N.,** *see* Murphy, P. J., 1125
**Wilcox, C. J.,** *see* Hiestand, E. N., 1421
**Wiley, M. R.,** Burkman, A. M., and Weinswig, M. H., inhibition of liver-derived monoamine oxidase by several isopropyl hydrazides, 2011
**Wilkes, J. D.,** *see* Messmer, W. M., 1996
**Wilkinson, G. R.,** and Beckett, A. H., absorption, metabolism, and excretion of the ephedrines in man II. Pharmacokinetics, 1933
**Willard, P. W.,** and Powell, C. E., *in vivo* and *in vitro* activity of a vasoactive drug 9-(3,5-dimethylpyrazole - 1 - carboxamido) - 7-methyl - 4,6,6*a*,7,8,9,10,10*a* - octahydroindolo[4,3-*fg*]quinoline maleate, 1390
**Willette, R. E.,** *see* Counsell, R. E., 1657
**Willis, C. R., Jr.,** and Banker, G. S., polymer-drug interacted systems in the physiochemical design of pharmaceutical dosage forms I. Drug salts with PVM/MA and with a PVM/MA hemi-ester, 1598
**Willson, J. E.,** *see* Campbell, A. H., 2045
**Wilson, R. G.,** *see* Shah, M. A., 181
**Windheuser, J. J.,** *see* Albert, K., 2085
——*see* Zoglio, M. A., 2080
**Wiseman, E. H.,** and Federici, N. J., development of a sustained-release aspirin tablet, 1535
**Wolf, H. H.,** *see* Yeoh, P. N., 340
**Wolf, W.,** *see* Eisenmann, A., 1435
——*see* Koda, R. T., 2056
**Wolff, M. E.,** Ho, W., and Chang, H.-H., a cardioactive steroidal iodoacetate, 1450
**Wolkoff, H. N.,** Pinchuk, G., and Shapiro, P. H., evaluation of a miniature air-suspension coating apparatus, 317
**Woo, W.,** *see* Pernarowski, M., 1419
**Woo, W. S.,** *p*-methoxycinnamate and its metabolites in rabbit serum, 27
**Wurdack, P. J.,** *see* Stelzer, J. M., Jr., 1732
**Wynn, R. J.,** *see* Feldman, S., 1493
——*see* Gibaldi, M., 787

Y

**Yakatan, G. J.,** and Araujo, O. E., analog computer simulation of rheological systems I. Pseudoplastic flow, 155
——*see* Garrett, E. R., 1478
**Yale, T. J.,** *see* Martin, A. R., 166
**Yamamura, H. I.,** Lee, I. P., and Dixon, R. L., study of the sympathomimetic action of cyclohexylamine, a possible metabolite of cyclamate, 1132
**Yamashiro, D.,** *see* Luts, H. A., 1447
**Yamazaki, Y.,** *see* Ogura, H., 705
**Yeaglin, E. D.,** *see* Quintana, R. P., 230
**Yeoh, P. N.,** and Wolf, H. H., effects of some adrenergic agents on low frequency electroshock seizures, 340
**Yoder, D. S.,** *see* Bryant, R., 658
**Young, E.,** *see* Poulsen, B. J., 928
**Young, L.,** *see* Orth, R. E., 1814
**Yung, D. K.,** Chatten, L. G., and MacLeod, D. P., potential antiarrhythmic agents I. Synthesis and pharmacological evaluation of some piperazine and ethylenediamine analogs of procaine amide, 2073

Z

**Zagar, J. B.,** *see* Ascione, P. P., 1768
**Zalucky, T. B.,** *see* Kapadia, G. J., 254
**Zarembo, J. E.,** *see* Eisdorfer, I. B., 195
**Zatz, J. L.,** Weiner, N. D., and Gibaldi, M., monomolecular film properties of protective and enteric film formers I. Effect of polymer side chain on surface pressure-area isotherms, 1440
**Zelmer, J. E.,** *see* Aguiar, A. J., 1844
**Ziegler, H. W.,** *see* Cochran, E. M., 1215
**Zippie, K. G.,** *see* Beyer, W. F., 653
**Zoglio, M. A.,** Maulding, H. V., Haller, R. M., and Briggen, S., pharmaceutical heterogeneous system III. Inhibition of stearate lubricant-induced degradation of aspirin by the use of certain organic acids, 1877
——Windheuser, J. J., Vatti, R., Maulding, H. V., Kornblum, S. S., Jacobs, A., and Hamot, H., linear nonisothermal stability studies, 2080
——*see* Maulding, H. V., Jr., 1244; 1873
**Zvirblis, P.,** *see* Kondritzer, A. A., 1142

# Subject Index


A

**Abrasions,** inflicted—guinea pig back, 2045
**Abrus precatorius** seeds—lipids, 1442
**Absolute configuration**—analgesic activity, 711
**Absorbance**—analysis, turbidity, 1526
**Absorption**—apparent zero-order, 226
dissolution rate correlation—griseofulvin, 1383
effect—promazine-adsorbent preequilibration, 1604
elimination rates—pralidoximes salts, 1142
elimination rates—simultaneous administration, 1379
enhancing effect in goldfish, 101
ethanol, 158
excretion—calcium, 422
kinetics—griseofulvin, 984
lincomycin HCl, esters—intestinal loops, 2101
rate equations, 101
rate, intrinsic—drugs, 918
rate model—particle-size effects, 1825
rates—two compartmental, 117
translocation, residue — soybean plants, 764
**Accumulation** plateau—drug, multiple doses, 2162
**4-Acetamidophenyl 2,2,2-trichloroethyl carbonate,** 1146
(ATC)—synthesis, 752
**Acetaminophen,** procainamide HCl—test compounds, 2080
phenylephrine HCl, codeine $PO_4$, pyrilamine maleate—analysis, 644
prodrugs, 774; 780
**Acetarsone**—acid-base chemistry, 2105
**Acetic anhydride**–di- and tricarboxylic acid interaction, 239
**Acetone**—ethanol separation, 134
***N* - Acetyl - *p* - aminophenol** — absorption, 795
**Acetylcholine Cl**—autohydrolysis, 1025
**Acetylcholinesterase** inhibitors, 172; 418
**Acetylsalicylic acid**—*n*-methylglucamine salt distribution, 128
hydrolysis catalyzed by cyclodextrins, 44
salt—test compound, 918
***N*-Acetyitryptamines**—synthesis, 1998
**Achillea millifolium** essential oil—analysis, 2160
**Acid-base** extraction—phenylbutazone, 1952
titration—acetarsone, arsthinol, 2105
**Acid** hydrolysis, 142
**Acidic** components, *Juglans nigra*—antitumor activity, 1674
**Acridine** dithiocarbamates—synthesis, 1793
**2 - Acyl - 5 - alkyl - 5 - nitro - 1,3,2-dioxaphosphorinane 2-oxides**—synthesis, 1622.
**Adamantyl analogs**—synthesis, 1053
**Adenosine deaminase**—inhibitor binding site identified, 1070
**Adrenal gland** catecholamine output—physostigmine effect, 1741
effect—turbidimetric response, 1526
**Adrenergic** agent, 340
blocking agents—interaction mescaline, 72
**α-Adrenergic** blocking agents—test antagonists, 287
**β-Adrenergic** blocking agents, 340
blockade effect—bronchoconstrictor toxicity, 1543
receptors—relation to hyperglycemia, 1690
**Adsorbents,** effect—free salicylic acid analysis, 1685
**Aerosol foams**—bubble size analysis, 624
**Aerosols**—pharmaceutical, 488
volatile components, analysis, 966
**Agar overlay**—test procedure, 1061
**Aging** foam—bubble diameter effect, 624
rheological properties, 1796
tablet dissolution rate, 802
**Air-suspension** coating apparatus, miniature, 317
**Albumin** binding—inhibition, 245
bishydroxycoumarin interaction, 58
**Alcohol**—anhydride acylation reaction, 684
cumulative lethal dose—amitriptyline effect, 2005
effect—amitriptyline activity, 1900
**Alkali** elimination—peptide chain lengthening, 1514
**Alkaloid** production—seed callus cultures, 701
sulfate concentration, 342
isolation—*Thalictrum fendleri*, 262
**Alkaloids,** cactus—*Coryphantha runyonii*, 515
*Clitocybe dealbata*, 331
*Juglans nigra*—antitumor activity, 1674
*Ochrosia maculata*, 1720
*Peumus boldus*, 1023, 1619
quaternary—*Lophophora williamsii*, 254
quaternary — *Zanthoxylum elephantiasis*, 329
**Alkanolamine** esters, 1068
**2 - Alkoxy - 5 - alkyl - 5 - nitro - 1,3,2-dioxaphosphorinane 2-oxides**—synthesis, 1622
**2 - Alkylamino - 5 - alkyl - 5 - nitro - 1,-3,2 - dioxaphosphorinane 2 - oxides**—synthesis, 1809
**Alkylated** imido derivatives—synthesis, 2176
**Alkylating** ability—antitumor activity, 1112
**3 - Alkyl 2 - hydroxy - 1,4 - naphthoquinones**—synthesis, 520
**α-Alkyloximino acid thiol** esters—synthesis, 688
***S*-Alkyl phosphorothioates**—intermediate products, 455
**Allenic amines**—synthesis, 430
**Allopurinol**—analysis, 335, 649
tablets—analysis, 649
**Aluminum** foil package—tablet stability, 893
**Amine** interference—5-hydroxytryptamine analysis, 1568
**Amines,** aliphatic—identification, 1789
spectroscopy review, 195
substituted—diazonium derivatives, 1257
**γ-Aminoalcohols**—synthesis, 1487
**3 - ω - Aminoalkyl 2 - hydroxy - 1,4-naphthoquinones**—synthesis, 520
**4 - Aminoanhydrotetracyclines** — tetracycline intermediates, 1633
**4-Aminoantipyrine** uptake—goldfish, 1354
**7-Aminocephalosporanic** acid (7-ACA), related compounds—analysis, 2172
**4 - Amino - 6 - chloro - *m* - benzenedisulfonamide,** diazotized—color reagent, 1386
estradiol analysis, 1257
**β-Aminoethyl diphenylborate**—color reagent, 705
**β-Aminoketones,** 1801
synthesis, 1251, 1487
**Aminolysis,** benzylpenicillin—base catalysis, 1209
reaction, 791
**Aminophenones,** concentration—diffusion rate, 949
**Aminophylline** suppositories—*in vivo* absorption rate, 698
**4′-Aminopropiophenone**—diffusion, 944
**Aminopteridines**—solubilization, 878
**Aminopyrine**—renal metabolism, 1301
**3-Aminothiophene** carbamates—electrophilic substitution, 2003
**2 - Amino - 5 - trifluoromethylbenzoxazole**—synthesis, 1763
**Amitriptyline,** alcohol, effects—motor activity, 1900
alcohol interaction, 2005
**Amobarbital**—internal standard, 845
**Amphetamine** hypermotility effect—antagonism, 709
**Ampicillin,** anhydrous, trihydrate—thermodynamic properties, 1945
**Anagestone acetate**—analysis, 882
**Analgesia** rat tail flick method, 989
**Analgesic** activity, 884
activity—acetaminophen prodrugs, 774
tablets, powders—analysis, 1218
**Analgesics**—adamantyl analogs, 1053
**Analog computer** diagram, 155
**Analogs,** lincomycin—characterized, 693
**Analysis**—dienestrol-methyltestosterone combination, 868
phenylephrine in drug mixtures, 467
specificity—interference elimination, 871
**Androst - 4 - ene - 3,17 - dione - 4-$^{14}$C**—*in vitro* metabolism, 1962
**Anemopsis californica**—essential oil, 1020
**Anesthesia,** corneal—relation to charge density, 378
local—screening, 784
**Anesthetic activity,** local—3-quinuclidinol esters, 684
**Anesthetics,** topical—*in vivo* evaluation, 2045
**Angiotensin** activity—antagonized, 733
effect—serotonin activity, 1966
II antagonists, 287
**Anhalotine,** lophotine, and peyotine—isolation, 254
**Anhydride** transfer—buffer hydroxy substituent effect, 239
**Anionic-exchange** resin—separation, 811
**Anisamide** and substituted anisamide—riboflavin systems, 183
**Anisotropine methylbromide,** 36
human urinary excretion, 1375
**Anthraquinones**—isolated, identified, 1996
**Antiarrhythmic** agents, 2073
**Antibacterial activity,** 39
β-aminoketones, 1251; 1801
*in vitro*, 1017
phenyl pyridyl ethers, 151
**Antibiotic** addition—uropygial gland homogenates, 1962
combinations—microbial analysis, 871
preparations—bacterial contamination, 1061
**Antibiotics**—chewing troches, 530
in sensitivity disks—identity, 806
**Anticancer** activity, 189
**Anticholinergic** activity—screening, 1586
agents, 534
**Anticonvulsant activity** against electroshock, pentylenetetrazol, 384
supramaximal electroshock seizure test, 1530
**Antifertility factors**—plant extracts, 1607
**Antifungal** activity—β-amino ketones, 1801
phenyl pyridyl ethers, 151
assay—*Microsporum gypseum*, 1993
preparations—bacterial contamination, 1061
**Anti-inflammatory** activity—*Mycobacterium butyricum* cell injection, 989
activity—screening method, 1526
pyrazoles, 537
**Antileukemic** activity—methylglyoxal bis(guanylhydrazone) pamoate, 1438
agent, 83
**Antimalarial activity,** 688
phenyl pyridyl ethers, 151
**Antimicrobial activity**—small tube, disk methods, 1546
vanillin oxime derivatives, 1244
**Antimonyl ion**—pyrazolone derivative interaction, 1056
**Antiparkinsonism agents,** synthetic, 137
**Antiphlogistic activity**—pedal carrageenin injection, 989
**Antiradiation** activity—quinuclidine derivative, 1725
compounds, 345; 1611; 1614; 1793
**Antiserotonin** activity—LSD analogs, 2157
**Antispasmodics**—potential, 578

**Antituburcular activity**—cupric, cobalt ions effect, 1255
**Antitumor agents**, 1948
*Juglans nigra*, 1674
*Bursera microphylla*, 696
carcinostatic pyrazoles, 537
activity—iodopurine derivatives, 2056
1,3,2-dioxaphosphorinane 2-oxides, 1809
hexahydropyrimidines, 1817
imidazoles, 1562
9-methoxyellipticine, 1720
mice, 1948
screening, 1812
**Antiviral activity**—*Catharanthus* alkaloids, 2174
pyrazoles, 537
**Anuria**—penile ligation, 1010
**Apparatus,** dissolution—photographs, 485
nuclear *in vitro* release rates, 1649
particle preparation—described, 584
tensile strength measurement, 1042
**Apparent molar absorptivity** values—diazonium reagents, 1257
**Aralkylamines,** 124
**Arsthinol**—acid-base chemistry, 2105
**2' - Arylamino - 5 - alkyl - 5 - nitro-1,3,2 - dioxaphosphorinane 2 - oxides**—synthesis, 1809
**$\alpha,\beta$ - Aryloxyacetic acid ketones,** unsaturated—synthesis, 737
**Ascorbic acid effect**—vitamins $B_1$, $B_{12}$ stability, 1854
stability—polysorbate 80 solutions, gels, 2119
**Aspirin,** bromine derivatives—test compounds, 338
buffered—heterogeneous catalysis of degradation, 1685
degradation, stearate-induced—inhibition, 1877
determination—analgesic mixture, 1218
hydrolysis—rat small intestine, 1449
hydrolysis—tablets, 1873
salicylic acid—separation, 1240
sustained-release tablets, 1535
tablets, buffered—free salicylic acid, 631
*N*-methylglucamine salt—i.v. administration, 1313
wound healing effect, 1042
stability—salicylic acid sublimation, 1850
**Aster pilosus** leaves, 1059
**Atomic** absorption spectroscopy—analysis, 1243
absorption spectrometry—calcium, strontium analysis, 1215
positional and thermal parameters, 175
**Atria,** guinea pig—antiarrhythmic activity determination, 2073
**Atropine** activity—cryptenamine effect, 1576
citric-$^{14}$C acid labeling of 2,3,4 positions, 1357
enterochromaffin cell granulation, 1906
hydrolysis catalyzed by cyclodextrins, 44
tropine labeled, 443
**Automated analysis**—dye-complex extraction, 852
fluorometric, 147
iron, 653
isoxsuprine HCl tablets, single, 658
norgestrel, 1857
single tablet, 1227
tablets, steroid mixtures, 1415
**Automated coating,** pan coating—comparison, 1223
**Autoradiography**—analysis, 764
**3-Azabicyclo[3.2.1]octane**—amine component, Mannich reaction, 1487
HCl—improved synthesis, 1785
**Azeotropic** distillation reaction—acid catalyzed, 784
***o*-Azidobenzaldehyde**—synthesis, 877

## B

**Bacterial** contamination — uropygia gland homogenates, 1962
**Bactericidal** activity—povidone-iodine solutions, 2013
**Baeocystin**—isolation, identification, 1667
**Barbiturates**—identification, 2096
**Barium sulfate**—analysis, 1215
**Basidiomycete** cultures—phosphate effect, 1661
**Belladonna** alkaloids, neomycin, kaolin, pectin suspension, 464
**Benzamide** and substituted benzamide—riboflavin and theophylline systems, 183
**Benzazole** derivatives—Mannich reaction synthesis, 1814
**Benzene**—diosgenin solution, 602
**Benzofurans**—synthesis, 192
**Benzoic acid** dissolution rates, 737
internal standard, terpin hydrate, 1412
solubilization, 79
***N*-(2-Benzoxazolyl)amino acids, esters**—synthesis, 1693
**Benzphetamine HCl activity**—reserpine–diluent effect, 613
***N*-Benzyl iminodiacetic acid,** iodinated derivatives—synthesis, 1710
**Benzylpenicillin**—aminolysis, 1209
hydrolysis—catalyst structure-activity relationship, 1916
**Betaine** salts, 1784
**Betulinic acid**—summer plant growth, 864
**Bicyclo[3.1.0]hexane** systems, 1523
**Bicyclo[3.1.0]hex - 2 - ene - 4 - one - 1-carboxylic acid,** related compounds—syntheses, 1520
**Bile salts**—drug uptake, activity potentiation, 1354
**Bilirubin** binding—ion-exchange resins, 1896
**Binders**—tablet dissolution rate, 802
**Bio-antagonistic** pyrazoles, 537
**Biologic half-life**—dose dependency, 1881
of bishydroxycoumarin, 68
pralidoxime salts, 1142
**Biologic** specimen—phenylbutazone analysis, 2053
**Biological** analysis—muscarine, 331
analysis—penicillins, 1606
action, sulfonamides—chemical structure, 1455
activity—mangiferin, 1039
assay—sensitivity, 605
factors—drug absorption, 357
**Biopharmaceutics,** 1075
drugs—parenteral, 357
**Biosynthetic** processes—tetracyclines, 1633
**Biotransformation,** *in vivo, in vitro*—thiazesim-$^{14}$C, 1497
salicylamide, sodium salicylate, 1330
**2 - (4 - Biphenylyl)ethylamines**—synthesis, 564
**Bisamines,** unsymmetrical—reaction effect, 1097
**5(or 4)-[3,3-Bis(2-chloroethyl)-1-(triazeno]-imidazole-4(or 5)-carboxamide**—syntheses, 83
**Bishydroxycoumarin** in plasma—analysis, 58, 68
distribution, elimination, 1881
**Bis-quaternary** ammonium compounds, 172
**Bis-(trimethylsilyl) ether,** alizarin—internal standard, 868
dienestrol—derivative, 868
**Blood levels**—aminophylline from suppositories, 698
fenfluramine, 1173
salicylate, 828
ampicillin, anhydrous, trihydrate, 1945
**Blue tetrazolium** reaction—assay, 1057
**Body** considered—one, two compartments, 918
fluids, tissue—phenaglycodol determination, 426
**Books**
Actinomycin: Nature, Formation, and Activities, 2018
Actualities Pharmacologiques, 2182
The Balkan Nephropathy, 2182
Advances in Chromatography. Vol. 4, 354
Advances in Pharmaceutical Sciences. Vol. 2, 1270
American Drug Index 1967, 2020
Amino Acid Determination: Methods and Techniques, 2020
Antilymphocytic Serum, 356
Apothecaries: A History of the Worshipful Society of Apothecaries of London, 1617–1967, 1632
Aromatic Amine Oxides, 1452
Atomic Absorption Spectroscopy, 2181
Biochemical Preparations. Vol. 12, 1632
Bibliography of Vitamin E, 2182
Cell Differentiation, 2182
Cell Physiology and Pharmacology 2019
Characterisation and Manipulation of Powders, 1454
Chemical - Medical Abstracts. Section D, Endocrinology, 194
Committee on Safety of Drugs. Annual Report for 1966, 1824
Decision Making in Natural Science Policy, 2020
Design of Active-Site-Directed Irreversible Enzyme Inhibitors, 193
Development of Safer and More Effective Drugs, 2183
Dictionary of Organic Compounds. Fourth Edition, Third Supplement, 194
Dictionary of Pharmaceutical Sciences and Techniques. Vol. 1, 2018
Directory of Government Agencies Safeguarding Consumer and Environment, 2182
Dispensatorium Hafniense 1658. (Dispensatory of Copenhagen, a facsimile edition.), 1632
Drugs Affecting the Central Nervous System, 1454
Drug Responses in Man, 2183
Einfuhrung in die Arzneibereitung, 2182
Emulsion Science, 1453
Encyclopedia of Plant Physiology, 1272
Fatty Acids and Their Industrial Applications, 2183
Febrile Convulsions, 1632
Fibrinogen, 1824
Food Additives and Contaminants Committee: Second Report on Cyclamates, 1824
Fractional Solidification. Vol. 1, 1452
Fundamentals of Immunology. 4th ed., 1453
Furopyrans and Furopyrones: The Chemistry of Heterocyclic Compounds, Vol. 23, 1272
Gamma Globulins: Structure and Control of Biosynthesis. Proceedings of the Third Nobel Symposium, June 1967, Sodergarn, Sweden, 1824
Ganglion-Blocking and Ganglion-Stimulating Agents, 354
Glass Electrodes for Hydrogen and Other Cations, 1271
Growth of the Nervous System, 2183
Hagers Handbuch Der Pharmazeutischen Praxis. Fur Apotheker, Arzneimittelhersteller, Arzte und Medizinalbeamte, 1632
Handbook of Chemistry. Rev. 10th ed., 354
Handbook of Preventive Medicine and Public Health, 1632
Handbuch der Pflanzenphysiologie [Encyclopedia of Plant Physiology] Vol. XVIII: Sexuality, Reproduction, Alteration of Generations, 356
The Human Adrenal Cortex: Its Function Throughout Life, 356
Immunochemistry and the Biosynthesis of Antibodies, 2182
Index of Antibiotics from Actinomycetes, 2020
Index Nominum 1966, 536; Supplementum 1967, 2183
Indol alkaloide in Tabellen, 2183
Industrielle Mikrobiologie, 356
Interferon, 2020
III International Pharmacological Congress—International Symposium on Vaso Active Polypeptides: Bradykinin and Related Kinins, 1824
Introduction to Chromatography, 2181
Les Hétérosides Cardiotoniques de la Digitale det Leurs Dérivés Semi-Synthétiques, 1632
Lipid Chromatographic Analysis, Vol. 1, 1272
Mass Spectrometry of Organic Compounds, 354
Matrix Algebra for the Biological Sciences, 536
Methods of Biochemical Analysis. Vol. 15, 1272
Microbial Transformation of Steroids and Alkaloids, 1823
Molecular Basis of Virology, 2183

Monoamine Oxidase Inhibitors: Relationship Between Pharmacological and Clinical Effects, 2183
Myotatic Kinesthetic and Vestibular Mechanisms, 536
Naming Organic Compounds. A Programmed Introduction to Organic Chemistry, 536
Nutrition and Infection, 2182
Oxidative Coupling of Phenols, 536
Peptides, 1453
Pharmaceutical Abstracts. Vol. VIII, 536; Vol. IX, 2183
Pharmaceutical Chemistry, Part I: Principles, 2182
The Pharmaceutical Industry: A Personal Study, 2182
Pharmazeutisches Taschenbuch, 2182
Poly-α-Amino Acids. Protein Models for Conformational Studies, 1272
Potential Carcinogenic Hazards from Drugs, 1270
Precis d'Anatomie et de Physiologie Humaines, 2182
Precis de Matiere Medicale [Summary of Materia Medica]. Vol. II, 356
Prescribed and Nonprescribed Medicines, Type and Use of Medicines, United States, July 1964–June 1965. (PHS Publication No. 1000, Series 10, No. 39.), 1632
Principles of Adsorption Chromatography: The Separation of Nonionic Organic Compounds, 1824
Principles of Physical Chemistry for Biology and Pharmacy, 2183
Problems and Prospects of LSD, 2183
Proceedings of the 3rd International Pharmacological Meeting, 1966 Sao Paulo, Brazil, 1824
Progress in Biophysics and Molecular Biology. Vol. 17, 194
Prostaglandins, 2182
Psychological Time in Health and Disease, 356
Pyridoxal Catalysis: Enzymes and Model Systems, 2182
Quimica Farmaceutica. Quintino Mingoia, 356
Rogers' Inorganic Pharmaceutical Chemistry. 8th ed., 1631
Russian Chemico-Pharmaceutical Journal. No. 1, January 1967, 1632
Russian Pharmacology and Toxicology. No. 3, Vol. 30, May–June 1967, 1632
Separation Techniques in Chemistry and Biochemistry, 194
Solvent Properties of Surfactant Solutions, 2182
Statistical Techniques for Collaborative Tests, 194
The Stereochemistry of Macromolecules, 2182
Steroid Hormone Analysis. Vol. 1, 1271
The Structural Basis of Antibody Specificity, 2019
Studies of a Core Curriculum, 2019
Submicro Methods of Organic Analysis, 194
Systemic Mycoses, 2183
Take as Directed, 1452
A Textbook of Pharmaceutical Analysis, 2181
Titration in Nonaqueous Media, 2020
Topics in Medicinal Chemistry. Vol. 1, 193
Topics in Pharmaceutical Sciences. Vol. 1, 2019
Toxikologie-Fibel. fur Arzte, Apotheker, Naturwissenschaftler, Juristen und Studierende, 1272
Treatise on Analytical Chemistry. Part III: Analytical Chemistry in Industry. Vol. 1, 1451
Treatise on Analytical Chemistry. Part I: Theory and Practice. Vol. 7. Section D-4, Classical Physical Methods, 2020; Vol. 8, 2183
**Boundary effect** on pyridine release as function of pH—w/o emulsions, 93
**Bovine serum albumin** interaction—*p*-hydroxybenzoic acid esters (parabens), 1370
xanthine derivative interaction, 245
**Brain,** mouse—analysis, 613
tissue synthesis—nicotinamide adenine dinucleotide, 527
**Bratton-Marshall test**—identity, 1044
**Bromide ion** measurement—bromide ion activity electrode, 1478
**Bromination** of pyrido[3,2,1-*kl*]phenothiazines, 166
**Bromocresol green**-gallamine triethiodide—complex, 1768
**Bromocresol purple**—dye reagent, 852
reagent—propoxyphene HCl, 1227
**Bromophenol blue**—indicator, 1768
**Bromothymol blue**—acid dye, 2140
alkaline, aqueous degradation, 494
concentration—salt extraction, 1199
isosbestic point, 112
morphine complex—extraction, 1975
reagent, 1249
**Bronchoconstrictors**—toxicity, 1543
**Bronchodilatory** effects—metaproterenol, 971
**B. subtilis** spores—ethylene oxide effect, 433
**Bubble size**—aerosol rheology, 624
**Buffer system**—"ternary," 1056
3 - carbomethoxy - 1 - methylpyridinium hydrolysis, 1677
**Burns,** controlled infliction—guinea pig back, 2045
***n*-Butyl lithium**—methoxy-substituted carboxylic acids synthesis, 1820

C

**Caffeine** - aspirin - chlorpheniramine-glyceryl guaiacolate formulation, 313
$^{14}C$—test compound, 1649
5-chlorosalicylic acid complex, 1163
crystal structure, 350
complexes, 861
increased partition coefficients, 1335
determination—analgesic mixture, 1218
in plasma—analysis, 1703
retardation—salicylamide transfer, 1342
**Calcium** carbonate, 422
effect—drug-altered palmitate uptake, $O_2$ consumption, 1304
**Can emptying**—bubble size, density, 624
**Candicine Cl,** laurifoline Cl, and xanthoxyletin—isolation, 329
**Capillary viscosimeter**—analysis, 824
**Capsule** coating, 317
fill weight—factors affecting, 660
silastic—drug diffusion, 1401
**3 - Carbomethoxy - 1 methylpyridinium cation**—reaction kinetics, 1677
**Carbon disulfide** reagent, 185
**β-Carbolines**—synthesis, 269
**Carbonate ester,** acetaminophen—hydrolysis, 780
acetaminophen—synthesis, 774
hydrolysis, 282
salicylic acid—synthesis, 828
**1 - Carboxy - 12 - benzo(*d*)quinazo-(2,3 - *b*)oxazole - 12 - one** — synthesis, 1445
**Carboxyl - $^{14}C$ - 2,3,5 - triiodobenzoic acid**—synthesis, 764
**Carboxylic acid** esters, acetaminophen—synthesis, 774
methoxy substituted—synthesis, 1820
**$^{14}C$-Carboxyl 2,3,5-triiodobenzoic acid,** 323
**Cardioactivity**—steroidal iodoacetate, 1450
**Cardiovascular** activity—ST-155, 594
effects—metaproterenol, 971
**Cassia reticulata** flowers—phytochemistry, 1996
**Catalase** activity—hydrogen peroxide decomposition, 1609
**Catalysts,** model—penicillinase simulation, 1916
**Catecholamine** depleting agents, 340
**Catechol** morpholinomethyl derivative—penicillin hydrolysis, 1916
oxidation detection—Doty reagent, 710
**Catharanthus** alkaloids, 2167; 2174
*lanceus* leaves—alkaloids, 1035
*roseus* plants, 589
**Cation-exchange resin**—separation, 644; 1020
**Cells,** *Chlorella*—size, growth rate, 2038
*P. aeruginosa*—water, broth-washed, 389
perfusion—emetine solution, 1968
permeability, cations—UV light effect, 2136
**Cellulose acetate phthalate**—coating solution, 317
**Central mediation**—ST-155 activity, 594
physostigmine activity, 1741
**Centrally acting** pyrazoles, 537
**Centrifugal force**—granule diameter, 478
**Cephaloglycin**—7-ACA determination, 2172
**Cerimetric** titration, direct—analysis, 1977
**Chalcone derivatives**—pharmacological activity, 733
**Chelate stability** constants, 418
**Chemical** analysis—muscarine, 331
media for *Fusarium graminearum*, 97
**Chloramphenicol** assay, 305
capsules, 1844
formulations, 305
**Chlordan** pretreatment—drug metabolism, 1351
**Chlorella** species—vitamin $B_{12}$ content, 1040
*vulgaris* mutants—UV-induced, 2038
**2 - Chloro - 12 - benzo(*d*)quinazo(2,3-*b*)oxazole-12-one**—synthesis, 1445
**5 - Chloro - 2 - (3-chloro - 2 - hydroxypropoxy) - benzhydrylamine,** related compounds—syntheses, 1447
**3′ - Chloro - 3 - nitrosalicylanilide,** tritium labeled—synthesis, 2068
**Chloroform**—aspirin-catalyzed degradation, 1685
diluent, 631
diosgenin solution, 602
extraction—droperidol, 451
**Chlorophyll** content—leaves, 589
**Chlorophyllous** cultures—*Datura* tissue, 701
**8 - Chlorotheophylline** effect — 3-carbomethoxy - 1 - methylpyridinium hydrolysis, 1677
***p*-Chloro-*m*-xylenol** (PCMX)—microbiological evaluation, 609
**Chlorpheniramine,** dealkylated metabolites—analysis, 2085
maleate—dextromethorphan, 124
urinary excretion, 856
**Chlorpromazine** HCl–lecithin film interaction, 178
HCl—quaternary, tertiary forms, 2089
potentiation—epinephrine hyperglycemia, 1690
test compound, 338
**Cholestane**—internal standard, codeine, 1412
**Cholestasis**—bile duct ligation, 1010
**Cholinergic** mechanism—effect on, 72 receptor, 511
**Cholinesterase** systems—human plasma 1025
**Cholinomimetic** activity, 511
**Chromatographic** development systems—coal tar dyes, 2132
**Chromatography,** adsorption, thick layer, paper—separation, 696
partition and adsorption—separation, 262
TLC, column—separation, identity, 874
**α-Chymotrypsin**-catalyzed hydrolysis, 282
**Cinchona alkaloids,** 342, 1195
**Cinnamamide** and substituted cinnamamide—theophylline systems, 183
**Cinnamic** compounds—xenon trioxide oxidation, 1706
**Cinnamoylation** rates—amine identification, 1789
**Circular dichroism**—absolute configuration, 447
**Citing** chemical abstracts, 2184
**Citric acid** buffer–acetic anhydride interaction, 239
effect—aspirin stability, buffered, 1685
solution—reserpine activity, 613
**$^{14}C$-Labeled** urea—test compound, 1192
creatinine—test compound, 1192
**Clitocybe** species—muscarine, aging effect, 331
**CMC mucilage** systems, 155
**CNS** activity—*N*-(2-cyanoethyl)cyclohexylamine *N*-acyl analogs, 1671
depressants—test drugs, 1010
**Coalescence,** aggregation—small particles, 436
**Coating** apparatus—schematic diagram, 317
processes—comparison, 1983
**Cocaine** derivatives, quaternary—synthesis, 1822
**Codeine,** terpin hydrate elixir—analysis, 145
**Collapse points,** 17
**Colloidal solubilizer** solutions—dissolution, 1072

**Color** additives, coal tar—separation, identification, 2132
**Colorimetric analysis,** 36; 49; 53; 147; 164; 309; 314; 325; 459; 464; 488; 642; 705; 819; 824; 836; 852; 1000; 1227; 1231
automated, 653
end-point determination, 137
excreta, 422
methyl orange reagent, 451
salicylamide — spectrophotometer, 1556
silica, 1215
spectrophotometry, 305; 1202; 1212; 1218; 1234; 1249; 1257; 1351; 1386; 1401; 1409; 1415; 1493; 1609; 1661; 1677; 1716; 1732; 1744; 1748; 1768; 1791; 1896; 2111; 2126; 2140; 2172
uptake time, 1354
urine—spectrophotometer, 1375
**Columbianetin**—structure, 741
**Columbianin** structure—revised, 747
**Column chromatography**—separation, 309; 329; 335; 447; 464; 467; 515; 520; 631; 642; 646; 747; 752; 865; 933; 940; 1020; 1023; 1035; 1037; 1059; 1125; 1135; 1184; 1263; 1398; 1442; 1497; 1505; 1520; 1619; 1873; 1996; 2080; 2167
TIBA identification, 399
**Compartment models,** open—one, two, 994
**Compartments,** consideration of body as one and two, 117
two *vs.* one—drug absorption, 918
**Complex formation,** 53
absorption, 235
DNA-aminopteridines, 878
effect on drug absorption, 101
PCMX activity, 609
reaction rate influence, 1677
small molecules, 1556
tryptophan-alkylxanthines, 1865
**Complexes**—starch, 404
structural studies, 1163
xanthine, 350
**Complexing numbers**—caffeine, 861
**Compressed air**—resuscitation, 1248
**Compression**—film, 230
film effect, 1440
force—determination, 1770
force starch grain damage, 393
solids, 677
**Computer flow chart**—theoretical slopes for pyridine release, 87
theoretical values of pyridine release, 93
**Condensation,** Mannich reaction—mechanism, 715
phosphorus oxychloride, sulfa compounds, 532
reaction, 39; 877
reaction alkylation, imido derivatives, 2176
**Conductance bridge**—analysis, 617
**Confinement** motor activity unit—modifications, 1900
**Consecutive** first-order reaction—Guggenheim method, 1805
**Contact angle** measurements, 217
**Continuous** flow apparatus—tablet, capsule dissolution, 149
**Contractions,** heart cells—emetine effect, 1968
**Copper**-catalyzed oxidation—ascorbic acid, 2119
**Core tablets**—drug coating, 1007
**Cornstarch grains,** 187; 393
channel formation, 1253
**Cortical** after-discharge duration—induced paralysis, 1782
**Cosmetic products**—antimicrobial activity, 1546
**Coumarins,** 741; 747; 2062
adsorption equilibrium—ion-exchange resins, 598
anticoagulants, 58; 68; 1881; 1888
*Lomatium nuttallii*, 865
**Countercurrent distribution,** 1023
with urea, 328
**Coupling constants**—bicyclo[3.1.0]hexane systems, 1523
**Critical perfusion pressure**—guinea pig lungs, 1543
**Cryptenamine,** 1576
**Crystal,** molecular structure—6-thiopurine riboside, 1157
structure, 1163
structure of thiolphthalide, 175
**Crystalline substance**—starch grain damage, 393
**Cucurbita maxima** seed oil, 328
**Cultures**—column, round-bottom flask techniques, 1040
liquid—*Claviceps zizaniae*, 889
**Cupric** chelate synthesis—1,3-diaminopropanol and 1,3-diaminopropane, 418
**Cyanoacetamides**—synthesis, 1530
**Cyanocobalamin** (vitamin $B_{12}$)—stability, 1854
*N*-**(2-Cyanoethyl)cyclohexylamine,** *N*-acyl analogs—synthesis, 1671
**Cyclamate**—instability, 1073
**Cyclodextrins** influence on alkaline hydrolysis of esters, 44
**Cyclohexylamine** — sympathomimetic activity, 1132
**Cyclophosphamide** metabolism—chlordan effect, 1351
**Cytoplasm**—toxicant effects, 293
**Cytotoxicity**—lochnerinine, 2167
screening—tubercidin analogs, 1616

**D**

**Datura** tissue cultures, 701
**Deaggregation** rates, capsules—turbidity measurements, 1844
**Decomposition** products—phenylbutazone analysis, 1952
reactions—Mannich bases, 715
**Degradation,** imidazoles—light exposure, 1562
mestranol—detected, 1168
prednisolone, 1057
product—glutethimide, 811
products—acidic, alkaline media, 411
products of $^{14}$C-carboxyl 2,3,5-triiodobenzoic acid, 323
products—identity, 335
products—tolbutamide, 459
rate—dexamethasone tablets, 1231
rates—sterically hindered vitamin A esters, 1184
**Dehydroacetic acid,** 791
**21-Dehydroprednisolone** binding—calf thymus histones, 2116
**6 - Demethylchlortetracycline**—nitric acid transformation, 1046
**6-Demethyltetracycline** in 6-demethylchlortetracycline—analysis, 1046
**Densitometric** scanning—color quantitation, 2132
**Densitometry**—analysis, 646
spot area/concentration relationship 1048
**Density,** bulk, tapped—granules, 478
gradient, sucrose—association confirmed, 768
ionic—corneal amphoteric colloid, 378
**9 - (3 - Deoxyaldofuranosyl)adenines**—synthesis, 1697
**Deoxyalloxazines** (benzopteridines), 516
**Deoxycholate,** sodium—gastric emptying effect, rats, 1493
**Deoxypodophyllotoxin**—isolation, characterization, 696
**Depressant** activity, 884
**Depressor activity**—chalcone R-2803, 733
**Dermatological** lotions—rheological properties, 671
**Dermatomucosal** agents—antimicrobial activity, 1546
**Desipramine** HCl capsules, individual—analysis, 1979
**Deterioration**—nitroglycerin tablets, 893
**Deuterated** griseofulvin—antifungal activity, 1993
lomatin—mass spectra, 2062
**Deuterium** effect—*Penicillium* growth, antibiotic production, 2049
oxide—*P jancewskii* II cultures, 975
**Dexamethasone** tablets—stability, 1231
**Dextroamphetamine $SO_4$** activity—reserpine-diluent effect, 613
**Dextromethorphan** hydrobromide, terpin hydrate elixir—analysis, 145
**D-Glycero-D-gulo-heptose derivatives**—synthesis, 1263
**Diagram**—automated analyzer, 658; 852; 1227
automated apparatus, 1415; 1857; 1979
continuous flow dissolution apparatus, 1419
diffusion cell, 1583
extraction apparatus, 858
friction measurement apparatus, 1421
manifold flow system, automated, 653
particle coating apparatus, 1983
powder flowmeter, 2153
sampling apparatus, 966
tablet machine instrumentation, 1770
**2 - (*N*,*N* - Dialkylaminomethyl) - 7-phenylthioindoles**—synthesis, 979
**Dialysis** acceleration—surfactants, 1192
bovine serum albumin-parabens, 1370
protein binding determination, 1627
rates—polymer—drug system, 1598
studies, 79
separation, 658
**2,4 - Diamino - 6,7 - dimethylbenzo(g)-pteridine**—methylation, 516
**Diazotization**—analysis, 305
reaction—identity, 806
**Dichlorodiphenyldichloroethane** analogs—radioiodinated, 1657
**2 - (2,6 - Dichlorophenylamino) - 2-imidazoline HCl** (ST-155)—hypotensive activity, 594
**Die weight fill**—granule size, 497
**Dienestrol** analysis, 868
**Dies**—variables affecting wear, 1779
**Diester, 1,1-iminodi-2-propanol**—synthesis, 1068
**3 - Diethylaminomethyl - 1,2 - diphenylindolizine**—pharmacological screening, 1989
**Diethylstilbestrol** analogs—synthesis, 1265
analysis, 646
rat liver utilization *in vitro*, 1744
**2,2 - Diethyl - 3 - (3,4,5 - trimethoxybenzoyloxy)propyl carbamate**—synthesis, 707
**Differential** scanning calorimetry—analysis, 1868
**Diffuse** reflectance spectroscopy—analysis, 1653
**Diffusion** cell, steady state—diagram, 944
coefficients, 217; 959; 1583
coefficient, equations—homogeneous system, 87
constants—centrifuge, Schlieren optical system, 690
controlled model, 274
drug absorption, 357
drug from matrices, 1292
equations, one-dimensional, 93
ointment base effect, 1540
rates—salicylamide, caffeine, 1556
rate—tyloxapol concentration function, 836
small molecules from protein-containing compartment, 1627
steady state, 1401
steady state—membrane, pH, temperature, ethanol effect, 949
**Digital computer**—calculation, stability ratios, 557
**1,3 - Dihydro - 1 - hydroxy - 3 - oxo-1,2 - benziodoxole**—apparent reduction potential, 1435
**4,4′ - Dihydroxybibenzyl**—urinary metabolite *trans*-stilbene, 713
**Diluent** effect—drug release rates, matrices, 1292
**3,3-Dimercaptoacrylonitrile** derivatives—synthesis, 1611
**α - 5,9 - Dimethyl - 6,7 - benzomorphans,** *N*-substituted—synthesis, 884
**Dimethyl sulfoxide** effect—salicylic acid, sodium salicylate absorption, 1732
**Dimethylformamide** - tetraphenyl tin solution—internal standard, 1975
**Dimethylpolysiloxane** — determination in lotions, 1243
fluid, corn oil—vehicles, 1409
**5 - (Dimethyltriazeno) - imidazole - 4-carboxamide (DCI)**—pharmacokinetics, 2126
**Dimethyltubocurarine** iodide, 1782
**Diosgenin** stability, 602
**1,3-Dioxane** and 1,3-dioxolanes, basically substituted—synthesis, 784
**Dipalmitoyl lecithin** monomolecular films, 178
**Diphenhydramine** effect on mescaline activity, 72
**5,5-Diphenylhydantoin**—pKa′ value determination, 1434
**3,4 - Diphenyl - 4 - oxazolin - 2 - one** derivatives—synthesis, 1798
**3,4 - Diphenyl - 4 - oxazolin - 2 - thione**—derivatives, 1063
**Dipole moment**—sulfonamides, 1455
**Disintegration**—dissolution rates compared, 798
time—enteric-coated tablets, 1360
time—starch concentration, 1253
**Dispersant** effect on wax particle formation, 49
**Dissociation constants**—acid, 418
acid—diamines, 1209
betaine salts, 1784
**Dissolution** apparatus—multiple testing, 485
apparent nonsteady state, 1072

aspirin, sustained release, 1535
capsules—*in vitro*, 1844
kinetics—gastric fluid, 1322
profile determination—apparatus, 1419
rate—ampicillin, anhydrous, trihydrate, 1945
rate—reserpine–desoxycholic acid dispersion, 708
rates—parameters affecting, 1104
rates, phenobarbital tablets—factors affecting, 798; 802
rates—polymer-drug system, 1598
rates—salicylic acid–PVP, 832
rates—solid drugs, 959
study—rotating-disk method, 1629
water-insoluble drugs, 2143
**Distribution** coefficient, 79
excretion—griseofulvin, 984
factors, effect—elimination kinetics, 1991
rate constant equations, 128
volume—calculation errors, 128
**3,9 - Disubstituted - 2,4,8,10 - tetraoxa-3,9 - diphosphaspiro[5,5]undecane-3,9 - dioxides**—synthesis, 1812
**Diuretic activity**—$\alpha,\beta$-aryloxyacetic acid ketones, 737
**Divinylbenzene polymer** column, 134
**DMSO,** alcohol, water—diffusion effect, 1540
solutions, ointments—analysis, 651
**Dodecatriethylammonium bromide**—synthesis, 1431
**Dosage forms,** barbiturates—analysis, 2096
polymer–drug interacted system, 1598
**Dosage** variation—individual capsules, tablets, 1979
**Dose** dependence—bishydroxycoumarin elimination, 1888
**Dotriacontane**—internal standard, 2149
**Doty reaction**—validity confirmed, 710
**Droperidol,** fentanyl citrate solution—analysis, 451
**Drug** absorption, 235
absorption—complex formation effect, 1335; 1342
absorption, distribution, elimination—models, 918
absorption—intestinal mucosa, 795
accumulation — pharmacokinetics, 2162
administration—subcutaneous, intramuscular, 357
binding by plasma proteins—review, 895
degradation—Guggenheim method, 1805
diluent ratio, effect—core coating, 1007
distribution—perfusate to rat liver, 2000
distribution volume—two compartmental, 117
effect—$O_2$ consumption, 1304
estimation—biologic tissue, 1234
formulations—absorption, biological factors, 357
metabolism—intestinal microorganisms, 2021
metabolism—microsomal subfractions, 1027
mixtures—analysis, 644
particle-size relationship—absorption, activity, 1825
release, 274; 278
release—coated dosage forms, 317
release from wax prolonged-release particles, 49
release rates, 217
simultaneous administration—kinetics, 1379
stability in solid dosage forms, 23
**Dual-receptor site theory,** 1188
Ariens—basis for derivative structure, 534

E

**Eagle's basal medium** plus calf serum 293
**Echothiophate iodide** degradation, 411
**Editorials**
Article titles and abstracts (December)
Biological considerations in research design (April)
Changing the guard at FDA (July)
Drug expiration dating (March)
Efficacy review—a follow-up (September)
Goodbye, Gm.; hello, g. (May)
Keyphrases: an explanation (February)
Keyphrases: an innovation (January)
Our assessment is now confirmed (November)
Research support in the future (October)
Therapeutic orphans (June)
Toxicology: a new horizon (August)
**$ED_{50}$**—prodine enantiomers, 711
values—cyanoacetamides, 1530
**EDTA,** cupric ions effect—prednisolone degradation, 2116
effect—phenylmercuric nitrate activity, 389
**EEG** monitoring—after-discharge duration, 1782
**Effervescent** products, granular—preparation, 1776
**Egg shell calcium** *vs.* precipitated calcium carbonate USP—absorption, excretion, 422
**Ejection** force—determination, 1770
**Electrical barrier,** effect—coalescence, aggregation, 436
**Electrolyte** changes—smooth muscle, blood, 733
concentration—stability ratios, 557
effect—flocculation, 569
**Electrometric titration**—chloride ion analysis, 737
**Electron** impact—barbiturate fragmentation, 2096
**Electrophoresis**—separation, radioactive metabolites, 1497
paper—identity, metabolites, 1135
**Electroshock,** low frequency—seizure threshold effect, 340
**Electrostatic tester**—design, operation, 504
**Elimination** kinetics—perfusion rate effect, 1991
kinetics—salicylic acid, 891
rate constants, 226
**Ellagic acid**—antitumor activity, 1674
*Juglans nigra*, 1728
**Emetine** poisoning, chronic—effects, 1428
toxicity—embryonic chick-heart cells, 1968
**Emulsion** stabilization—polymers, 1836
systems—particle size, 1273
**Endecaphyllin** X—hiptagin, identical structures, 353
**Endothelial tissue**—drug absorption, 357
**Energy of interaction** potential—small particles, 436
**Enteric** coating effect—potassium release, 617
coating thickness—disintegration time, 1360
dosage forms—coating, 317
**Enterochromaffin** cell granulation—guinea pig duodenum, 1906
**Environment** effect—phenobarbital activity, 1572
**Enzyme inhibitors,** 1070; 1998
**Enzymes**, intestinal—aspirin hydrolysis effect, 1449
**Ephedrines**—pharmacokinetics, 1933
**Epinephrine** hypertensive effect—increased, 709
norepinephrine activity—cryptenamine effect, 1576
**Equilibrium** dialysis—PCMX, methylcellulose, polysorbate 80, 609
studies, 475
**Equipment**—pharmaceutical, 1075
**Ergot**—wild rice fungus, 889
**Errata,** 2184
**Erythrocytes**—photohemolysis determination, 2136
surfactant adsorption, 1246
**Escherichia coli B** cell-free extracts, 351
**Ester hydrolysis,** 44
**Esterification** and ammonolysis—reactions, 707
**Esters,** columbianetin—synthesis, 741
**Estrogens,** heterocyclic—synthetic, 1265
**Ethacrynic acid** related compounds, 737
**7,10 - Ethano - 1 - thia - 4,7 - diazaspiro[4,5]decane** dihydrochloride—synthesis, 1725
**Ethanol** in pharmaceuticals, 134
**Ethchlorvynol**—analysis, 185
**Ether vapor**—respiratory arrest, 1248
**Ethyl-(para, ortho, and meta) aminobenzoates** hydrolysis decelerated by cyclodextrins, 44
**Ethylcellulose**—coating solution, 317
**Ethylene** oxide sterilization, 12; 433
**Ethyl nicotinate,** *N*-ethyl nicotinamide –derivatives, 1004
**Ethyl substitution**—activity effect, 269
**17$\alpha$ - Ethynylestradiol - 3 - methyl ether** (mestranol) tablets, 147
anagestone acetate tablets, 882
**Euphorbia esula,** 933
**Equilibrium** constants controlling solubilization, 79
phenomena, 23
**Everted** intestine—experimental technique, 1335; 1342; 1449
sac—technique, 836
**Excretion,** TIBA—urine, milk, feces, 399
**Experimental methods,** 895
**Extraction**—single, multiple component dosage forms, 847
technique—microgram quantities, 858
thiamine dye salt, 1199
**Eye** irritation, 321
response—fluorometry, comparable, 333
rabbit, guinea pig—anesthesia testing, 2045

F

**Factor A**–vancomycin—TLC separation, 314
**Fasting,** satiation effects—phenobarbital activity, 1572
**Fatty acids,** effect—aspirin hydrolysis 1873
fractionation, 328
nonesterified—salicylate effect, 2111
starch affinity, 404
**Fenfluramine**—metabolism, 1173
**Fentanyl citrate,** droperidol—hydrolysis products, 451
**Ferrous** sulfate adjuvant reactions—aqueous dispersion, 1653
**Fetal** implantations, resorptions, mice—morphine effect, 1590
tissue—drug distribution, 1031
**Film-coated** multivitamin tablets—vitamin $B_{12}$ stability, 1854
**Film** coating—airless-spray, air-atomized systems, 1007
pressure, 17
substrate—water, 230
surface, pressure, area—determination, 1398
**Flame photometry**—analysis, 411
analysis, excreta, 422
sodium ion analysis, 737
**Flavins**—base-catalyzed hydrolysis, 841
**Flavonoids**—analysis, 705
**Flocculation**—suspensions, 569
**Flowability**—granule size, 497
**Flow,** powders—uniformity, 2153
rate—granulating process effect, 667
rate, perfusate—drug-distribution effect, 2000
rate, solids—glidant effect, 2015
**Fluocinolone acetonide** and its acetate—test compounds, 928
**Fluorene** derivatives, 348
***N*-Fluorenamides**—synthesis, 348
***N,N'* - (2,7 - Fluorenylene)bisacetamide** metabolites—synthesis, 1065
**Fluorescein** solution, 389
**Fluorescence** produced by sulfuric acid, 147
**Fluorescent** tagging, antibodies—stilbene isothiocyanates, 1938
**Fluoride electrode**—ion determination, 1260
**Fluorometry—analysis,** 112; 124; 169; 333; 984; 1168; 1240; 1313; 1360; 1677; 1857; 1938
brain tissue, 340
plasma, 1360
plasma griseofulvin, 1383
specificity — 5 - hydroxytryptamine, 1568
**Folin-Ciocalteu** reaction, 314
**Food deprivation**—mouse fetus, 1590
**Force transducer**—scale calibration, 481
**Formaldehyde** source—Mannich reaction, 715
**Formic acid**—preanalysis sample wetting, 631
**Friability**—granule size, 497
**Friction** measurements—powder beds, 1421
**Friedel-Crafts** acylation—synthesis method, 1910
**Fungal** free amino acid pool—hydroxytryptamine derivatives accumulation, 1661
**Furazolidone,** 325
**Furosemide**—analysis, 640
**Fusion** method—effervescent products, 1776

G

**Gallamine triethiodide**—analysis, 1768
**Gastric** absorption rate—*in situ* technique, 1335
fluid, HCl solution, compared—drug dissolution, 1322
irritation—salicylic acid hexylcarbonate, 1128
**Gastrointestinal** flora—normal, variables affecting, 2021
**Gelatin capsules,** hard—powder encapsulation, 660
**Gel filtration**—association confirmed, 768
**General pharmacy,** 1075
**Gentamicin complex**—differential analysis, 1319
separation, bioassay, 2170
**Gibberellic acid** effect—growth, alkaloid content, 589
**Glass**—entrapment, 12
**GLC** analysis, 134; 142; 145; 185; 411; 477; 470; 473; 475; 511; 524; 621; 693; 845; 847; 868; 882; 966; 1000; 1004; 1020; 1173; 1313; 1412; 1703; 1873; 1975; 2085; 2149; 2165
colorimetry, fluorometry—comparison, 1168
decomposition, 602
identity, 933; 1442; 2017
separation, identity, 1962; 2160
urine analysis, 856
**Glidant** action—bulk solid flow, 2015
flow rate, granules, 667
**Glucose** consumption—analysis, 97
succinic acid–ammonium hydroxide media, 97
**Glutethimide** degradation, 811
**Glyceryl guaiacolate** tablets, 313
**Glycol acetal dimethylcarbamates,** synthesis, 161
**Goldfish** overturn time—activity analysis, 1354
**Gramicidin** release—chewing troches, 530
**Granulation,** griseofulvin—bowl, dish methods, 478
**Granule flow**—factors affecting, 667
size—effect, physical properties, 497
strength, porosity, sizing, flow rate, 478
**Gravid mice**—morphine effects, 1590
**Gravimetric analysis**—barium chromate precipitation, 1215
**Griffin HLB numbers**—multiregressional analysis, 514
**Grisan derivatives**—synthesis, 230
**Griseofulvin,** 478
absorption, 984
absorption—human, 1383
distribution, 128
fully deuterated—isolation, 975
protio, fully and partially deuterated—comparison, 1993
test compound, 918
**Griseophenone A**—conversion to (±)-dehydrogriseofulvin, 874
**Guggenheim** method—kinetic utilization, 1805

H

**Half-life**—dexamethasone tablets, 1231
glutethimide—variable pH, 811
*p*-methoxycinnamate, 27
**5-Halouridines,** related nucleosides—solvolysis, 1478
**Hardness**—tablet dissolution rate, 802
testers, new, used—variation, comparison, 481
**HBr–phenylephrine HCl mixture,** 124
**Heat of compression,** measured—water temperature change, 677
effect, 181
effect—polypropylene alloy, 1552
transfer kinetics—fusion, 574
**Heart** cells, embryonic chick—test cultures, 1968
liver homogenates—oxidative determinations, 1428
**Heavy atom** technique—structure, 1157
**Hemolysis**—induced, 12
nonionic surfactants, 1246
**Hepatic glutathione** depletion—hind leg tourniquet, 989
***n*-Heptane** extraction, **58**
**Heptane** extraction, 68
**α-(*N*)-Heterocyclic** carboxaldehyde thiosemicarbazones Na salts—synthesis, 1948
**Heterocyclic amines,** 2003
**Heterodispersed systems,** 436
**Heterogeneous** systems—pharmaceutical, 1877
**Hexachlorophene** analysis—blood urine, 2165
**Hexadecane-water** emulsion—high mol wt. polymers, stabilization, 1836
**Hexahydropyrimidines**—synthesis, 1817
**Hexobarbital**—internal standard, 1703
metabolism—chlordan effect, 1351
sleep—prolonged, 815
sleep-time—chlorpromazines, 2089
**Hiptage madablota,** 1039
hiptagin, 353
**Histamine antagonism**—metaproterenol, 971
**Homatropine** HBr—stability determination, 1977
**Homogeneous** suspensions—theory, 1273
**Humidity,** effect—friction in powders, 1421
**Hydrochloric acid**—diosgenin solid, 602
**Hydrocortisone** diffusion, *in vitro*—rat intestine, 836
**Hydrolysis**—acid catalyzed, 1151
aspirin—concentration effect, 1449
ATC—pH, enzyme effect, 752
cholinesterase fractions, 1025
echothiophate iodide—temperature effect, 411
enzymatic, nonenzymatic, 780
and extraction, 634
flavins-amines, position 3 effect, 841
glutethimide—factors affecting, 811
homatropine HBr—detection, 1977
rate—aspirin, 631
rates—*in vitro*, 828
rates, *in vitro*—acetaminophen prodrugs, 774
**Hydrophilic** group, percent—HLB relation, 514
resin tablet formulations, 164
**Hydrophobic** group, mol. wt.—HLB relation, 514
**Hydrostatic pressure**—steady-state diffusion effect, 944
**9 - (1- Hydroxy - 2 - alkyl)adenines**—synthesis, 1070
**17β - Hydroxy - 7aα - 1,7α - dimethyl-B - homo - A - norestrane - 3,6-dione**—analysis, 1386
**2 - Hydroxy - 5 - alkyl - 5 - nitro - 1,3,2-dioxaphosphorinane 2-oxides**—synthesis, 1622
**Hydroxyindole - *O* - methyltransferase** inhibition—*N*-acyltryptamines, 1998
**Hydroxylamine HCl**—reactant, 1180
***N*-Hydroxy, *N*-acetoxy metabolites—*N,N′* - (2,7 - fluorenylene)bisacetamide,** 1065
***p*-Hydroxyphenoxy methyl penicillin**—analysis, 1606
**Hydroxypropyl methylcellulose** tablets—hydration layer, 1292
**4 - Hydroxypyrazolo[3,4 - *d*] - *v* - triazine**—synthesis, 1044
**5-Hydroxytryptamine** in tissue—analysis, 1568
**8-Hydroxyquinoline $SO_4$**—preservative, 605
**α- and β-Hydroxysuccinanilic acid**—hydrolysis product, 529
**Hyperglycemic** mechanism—chlorpromazine, epinephrine, 1690
**Hypoexcretion**—mortality effect, mice, 1010
**Hypoglycemic activity** mechanism—salicylates, 2111
pyrroles, indan amines, 1013
**Hypotensive activity,** antihypertensive, 430
chalcone R-2803, 733
lysergic acid derivatives, 1390
cryptenamine—mechanism, 1576
tolazoline analog, 594
**Hypothermic** activity, 884

I

**Identity test** color formation—furosemide, 640
**Ileum,** isolated—effect on tonus, contractility, 321
strips—spasmolytic testing, 1586
**Imidazoles**—synthesis, 1562
**Imidazolines**—synthesis, 1176
**Imidazolthiones**—synthesis, 1063
**Imipramine** HCl tablets, individual—analysis, 1979
**Indan amines**—synthesis, 1013
**Indoloquinoline** derivatives of lysergic acid, 1390
**Inhibition,** acetylcholinesterase—analysis, 418
MAO—screening, 1364
**Instrumentation**—powder flow, 2153
rotary tablet press, 1770
**Integrating** scanner—color intensity, 1319
**Interaction** index—amitriptyline-alcohol, 2005
**Interdependence,** surfactant, particle size—dissolution, 2143
**Interference threshold**—antibiotics, 871
**Intestinal** homogenates—lincomycin HCl, esters hydrolysis, 2101
homogenates and sacs—phenol red recovery, 1234
sac, everted—drug permeation, 1844
**Intravenous,** oral administration—excretion times, 1375
infusion—constant rate, 994
**In vitro** action on smooth muscle, 72
dissolution test—method, 798
*in vivo* absorption compared, 617
release studies, 49
**In vivo** determination of aralkylamines, 124
*in vitro* disintegration time—correlation, 1360
**Iodine** compounds, polyvalent—oxidizing agents, 1435
values, 328
**Iodometric** analysis, 411; 806
titration—acetarsone, arsthinol, 2105
titration—analysis, 1945
**Iodophors**—bactericidal activity testing, 2013
**Iodopurine** derivatives—synthesis, 2056
**Ion-exchange resins,** 598
binding, 1896
column chromatography—separation, amino acids, 701
cinchona alkaloids—equilibrium exchange, 1195
resins—alkaloids, exchange equilibria, 342
**Ionic strength,** phosphate buffer—oxidation rate, 1706
potentiometric titration, 1209
salt maintenance, 1206
steady-state diffusion effect, 944
**Ionic surfactants**—testosterone solubilization, 1394
**Ionization constants**—acetarsone, arsthinol, 2105
**Ion-pair** extraction, 36
partition chromatography—separation, 2085
**Iproniazid**—MAO inhibition standard, 2011
**Iron**—adjuvant interactions, 1653
**Iron-multivitamin** preparations—analysis, 653
**Irritation** reactions and testing, 1
**IR spectrophotometry**—analysis, 1370
identity, 640; 649; 696; 713; 819; 858; 1097; 1184; 1611; 1619; 1667; 1720; 1728; 1793; 1804; 1822; 1996; 2017; 2053; 2157
identity, chelate, 605
identity, purity, 1497
near—analysis, 2007
structure, 30; 83; 151; 161; 166; 189; 191; 195; 230; 254; 262; 269; 300; 311; 335; 345; 353; 384; 430; 447; 455; 473; 515; 516; 520; 524; 564; 711; 747; 757; 841; 864; 865; 874; 933; 940; 975; 979; 1020; 1023; 1029; 1035; 1037; 1039; 1044; 1053; 1059; 1063; 1151; 1125; 1251; 1265; 1364; 1445; 1514; 1520; 1614; 1622; 1671; 1693; 1697; 1710; 1725; 1755; 1763; 1785; 1798; 1809; 1812; 1817; 1820; 1910; 1922; 2056; 2176
**Isoboldine**—isolation, 1023
**Isomerization**—equilibrium, rate, 1308
effect—vitamin D assay, 1326
**Isonicotinoyl hydrazones**—synthesis, 1255
**Isopropyl** hydrazides—monoamine oxidase inhibition, 2011
**Isoproterenol**—absorption, elimination, *dl*-Isoproterenol - 7 - $^3$H—metabolic fate, 1135
aerosol—stability assay, 710
**Isothermal,** programmed temperature—GLC, 1412

J

**Jejunal loop**—Thiry-Vella fistula, 795
**Jejunum,** rat—ligated loops, 2101
**Juglone**—antitumor activity, 1674

K

**4 - Ketoanhydrotetracyclines**—dearomatization, 1633
**Ketosteroids,** conjugated—determination in pharmaceuticals, 1737
**Khusenol**—isolation, structure, 1029
**Kidney,** perfused—dog, monkey, 1301
**Kinetic equations**—degradation rates, 1117
drug absorption, 918
nonisothermal hydrolysis, 2080
multiple drug dosage forms, 1379
perfused organ system, 1991
three-compartmental model, 1888
zero-order plasma input, estimated maximum excretion, 994
**Kinetics**—bilirubin-resin binding, 1896
cinnamic compounds, oxidation, 1706
extraction of bishydroxycoumarin from plasma, 58

L

**Lachesine** derivatives—activity, 534
**Lacrimatory responses**—increased, 815
**Lactone ring**—cardioactive compounds, 1450
**Lactose** granules—wet granulation, 667
**Lag time**—constant urinary excretion rate, 994
**Lamprey** larvae—3′-chloro-3′-nitrosalicylanilide effect, 2068
**Laurolitsine** and laurotetanine—isolation, 1619
**Lawsone** derivatives, 520
**$LD_{50}$ values,** 172
acetaminophen carbonate esters, 1146
allenic amines, 430
biphenylethylamines, 564
cyclophosphamide and chlordan pretreated, 1351
particle size effect, 1269
phthalimidoaldehydes, 815
potassium perrhenate, rhenium trichloride, 321
quaternary ammonium compounds, 1431
**Lecithin** surface films, 17
**Light** scattering—particle concentration measurement, 1273
**Lincomycin**—analysis, 693
HCl, esters—absorption, 2101
**Lipid** solubility—antitumor activity, 1112
water partition coefficients, 621
**Lipids,** *A. precatorius*—components identified, 1442
**Lipoid** barrier—artificial, 235
**Liquid-liquid extraction**—ethanol–ether, 464
**Liquid scintillation** counting—analysis, 617; 768; 928; 1192
counting—radioactivity, 2068; 2126
counting—$^{14}C$, soybean plants, 764
spectrometry—analysis, 323; 351
**Lithium amide**—higher homolog synthesis, 384
**Liver** perfusion, isolated—experimental technique, 1881
rats—*in vitro* metabolism, 1505
**Local anesthesia**—guinea pig cornea, 378
effect on mescaline activity, 72
**Lochnerinine,** *C. pusillus*—isolation, identification, 2167
**Locomotor activity**—analysis, 613
depressed, 815
**Lomatin,** derivatives—mass spectra, 2062
**Lomatium nuttallii**—coumarins, isolated, identified, 865
**Lonicera ciliosa** extract—mouse litter reduction, 1607
**LSD** analogs—synthesis, 2157
antagonism—serotonin, 1188
**Lumiflavin** and derivatives—synthesis, 841
**Lyophilized substances**—moisture in vials, 887

M

**Macromerine**—isolation, 515
**Macromolecules**—solubilizing effects, 878
**Magnesium** pemoline—radioprotective effect, 1033
phosphate, secondary—column adsorbent, 309
stearate interference—strychnine $PO_4$ analysis, 1249
stearate lubricant effect, 181
**Malformations**—fetal, mice, 1590
**Malic acid**–acetic anhydride interaction, 239
**DL-Malic acid phenylimide**—alkaline hydrolysis, 529
**Mammillary model,** 117
**Manganese**—alkaloid growth in cultures, 701
**Mangiferin**—isolation, identification, 1039
**Mannich bases**—5-cycloalkyl, 5-dialkylaminomethyl vanillin oxime derivatives, 1244
centrally acting, 1814
synthesis, 1989
**Mannich reaction,** 384; 1487
mechanism, 1097
review, 715
**Mansa oil**—*Anemopsis californica,* 1020
**Mass spectroscopy,** 30; 191; 195; 335; 515
identity, 470; 696; 856; 940; 1804; 2017; 2096
mol. wt., 1035
structure, 713; 741; 747; 1505; 1667; 2096
lomatin, derivatives, fragmentation patterns, 2062
**Mathematical interrelation** of calculation methods, 128
**Matrices**—compressed, hydrophilic, 1292
inert, 217
wax, 274; 278
**Mechanism**—1-naphthol reaction, 305
hypotensive activity, 1390
sulfonamides, 1455
technology—Mannich reaction, 715
**Membrane** filter technique—bactericidal activity test, 2013
effect on pyridine release—w/o emulsions, 93
permeability, 101
permeation—goldfish, 226
permeation, nylon—complex formation determination, 1556
plasma—toxicant effects, 293
sensitivity to pH, 158
**Menadione** stability, 1409
**Meperidine adamantyl analog**—analgesic activity, 1053
**Mercaptan** decomposition of acyl alkyl carbonates, 688
**α-Mercaptoacetamidinium chlorides**—synthesis, 455
**Mercuric acetate T.S.** and mercuric acetate plus crystal violet T.S. indicators, 137
**Mescaline**—nicotinamide adenine dinucleotide synthesis, 527
(trimethoxyphenylethylamine), 72
**Mestranol**—analysis, 1415
tablets—analysis, 1168
**Metabolic** activity, 1031
activity—gastrointestinal flora, 2021
fate, TIBA—lactating cow, goats, 399
**Metabolism**—excretion rates, two compartmental, 117
partition coefficient ratios—correlated, 1027
pheniramine, chlorpheniramine, brompheniramine compared, 621
**Metabolites**—administration route effect, 1135
chlorpheniramine—isolated, identified, 856
diethylstilbestrol monoglucuronide, 1744
ephedrines—formation, elimination, 1933
formation—constant rate, 994
furazolidone—analysis in urine, 325
isolated, identified, 1125
phenacetin, 524
thiazesim—isolated, identified, 1505
**Metal–8-hydroxyquinoline chelates**—activity effect, 605
**Metallic ions**-isonicotinoyl hydrazones—complexes, 1255
**Metalloporphyrins**—synthesis, 300
**Metaproterenol**—β-adrenergic stimulant, 971
**Metered bottling machine**—rheological effect, 671
**Methanol**—internal standard in NMR, 651
chloroform extraction—fentanyl citrate, 451
reagent, 887
sulfuric acid—color reagent, 1000
vapor effect—vitamins $B_1$, $B_{12}$ stability, 1854
**Methapyrilene**—test drug, 1598
fumarate, ephedrine HCl, codeine $PO_4$ syrup—analysis, 845
**Methotrexate**—analysis, 2002
***p*-Methoxybenzoate** identified as metabolite, 27
***p*-Methoxycinnamate,** 27
**9-Methoxyellipticine**—isolation, identity, 1720
**8 - Methoxypsoralen** — photosensitizer, 1236
**Methoxysulfanilamidodiazines**—hydrolyses, 1151
**Methyl** and methoxy substitution—activity effect, 269
***N*-Methyl-$^{14}C$-atropine** and -tropine—synthesis, 443
**Methylcellulose**—reserpine activity, 613
***N* - Methyl - 14 - *O* - desmethylepiporphyroxine**—identification, 30
***cis* - 2 - Methyl - 4 - dimethylaminomethyl - 1,3 - dioxolane methiodide** analogs—synthesis, 511
**Methylenebisamine**—reaction intermediate, 1097
**Methyleugenol,** thymol, piperitone—isolated, identified, 1020
**Methylglyoxal** bis(guanylhydrazone) pamoate—synthesis, 1438
***N* - Methylnicotinamide — 8 - chlorotheophyllinate** complex, 1206
***N*-Methyl-2-phenylsuccinimide** derivatives—synthesis, 384
**Methyl red** and methyl red plus crystal violet T.S. indicators, 137
**Micellar solubilization,** 79
effect—dissolution rate, 959
**Michaelis constants**—acetylcholine Cl hydrolysis, 1025
**Microanalysis,** 39; 151
belladonna alkaloids, 464
identity, 578
**Microbiological** analysis, 314
analysis—gentamicin complex, 2170
analysis—parabens-sucrose esters, 2093
screening, 784
**Microcrystalline cellulose** (MCC) gels-carboxymethylcellulose (CMC) gels, 1927
tablets, 181
**Microextraction** from chromatograms, 858
**Microorganism** metabolism, intestinal—drugs, 2021
**Microsomal particles,** smooth, rough—metabolism rates, 1027
**Minimum inhibitory concentration**—PCMX, 609
**Miotic** activity, 172
**Model,** intestinal absorption—lincomycin HCl, esters, 2101
mathematical—thiopental distribution, 1346
**mathematical**—variables *vs.* capsule characteristics, 660
single compartment—ephedrines, pharmacokinetics, 1933
**Moisture effect,** 181
aspirin degradation, 1877
tablet dissolution rate, 802
**Molecular** binding determinations—optical activity measurements, 1865
conformation effect on complex formation, 183
structure, 1163
weight — approach - to - equilibrium method, 690
weight determination—starches, 404
**Molluscicides**—structure-activity relationship, 1202; 1609
**Monoamine oxidase**—liver derived, 2011
inhibitors, 269; 430; 1364
**Monoester,** 1,1′-iminodi-2-propanol—synthesis, 1068
**Monomolecular** films—polymeric film formers, 1440
**Morphine**—analysis, 1386
analysis—kaolin–pectin formulations, 1975
teratology, mice, 1590
**Motor activity**—phenobarbital administration, 1572
spontaneous, forced—chlorpromazines, 2089
test—mice, 1900
**Mucopolysaccharide,** granulation tissue—vitamin A effect, 1238
**Muscarine**—isolation, 331
**Muscarinic activity,** 511
**Musculotropic agents,** negative—test antagonists, 287
**Mutation** indices—*Chlorella,* 2038

N

**NAD,** NADH effect—emetine-dosed cells, 1968
**1-Naphthol**—reagent, 305
**2 - (2 - Naphthylamino)benzoxazole**—synthesis, 1445
**Neomycin** release—chewing troches, 530
**Nephelometry**—plasma analysis, 1128
**Neurotoxicity**—adrenergic agents, 340
**Neutralization value,** 328
**Neutron activation analysis,** 1788
metal identity, 605
derivative, 338
**Niacin**—analysis, 1004
**Niacinamide**—analysis, 1004
**Nicotinamide adenine dinucleotide,** 527
**Nicotine** effect on mescaline activity, 72
**Nicotinic** activity, 511
**Ninhydrin,** *n*-butylamine—color formation, 459
color reagent, 1319; 2170; 2172
reagent, 642, 1568
test—identity, 806
**Nitrate** effect on analysis accuracy, 147
**Nitriles,** aminonitriles—sulfur derivatives, 1614
*p*-**Nitrobenzoyl Cl**—acylating agent, 1068
**Nitrogen** consumption—analysis, 97
**Nitroglycerin** tablets, 893
**Nitrofurazone-**DES suppositories—analysis, 646
**NMR spectroscopy,** 30; 39; 151; 191; 254; 262; 329; 335; 353; 455; 515; 516; 520; 1023
analysis confirmation, 1868
chemical shifts, 1523
identity, 447; 651; 747; 864; 865; 940; 975; 979; 1029; 1037; 1125; 1176; 1616; 1693; 1804; 1822
mass spectroscopy—structure, 1619
structure, 195; 711; 874; 1265; 1445; 1505; 1520; 1710; 1755; 1763; 1820; 1910; 1922; 1958; 2003
$NO_2$ atmosphere—phospholipid film, 1398
**Nonaqueous titration**—acetous perchloric acid, 1051
**Nonionic surfactant** effect—*in vivo* absorption rate, 698
**Nonisothermal** method—stability prediction, 2080
**Nonsteady-state diffusion,** 949
(±)-**Norargemonine**—synthesis, 1922
**Norbaeocystin**—isolation, identification, 1667
**Norcaperatic acid**—*Polyporus fibrillosus,* 1804
**Norepinephrine** activity—antagonized, 733
**Norgestrel** tablets—analysis, 1857
**Noscapine-related** compounds—synthesis, 1755
**Nozzle orifice** size—dissolution rate, 584
**Nuclear** *in vitro* method—continuous evaluation, release rates, 1649
**Nucleosides**—D-*glycero*-D-*gulo* heptose derivatives, 1263
**Nucleus**—toxicant effects, 293
**Nuttallin**—new coumarin, isolated, 865

O

$O_2$ consumption—ventricle slices, 1304
**Octaphenylcyclotetrasiloxane** — standard, 1243
**Oil,** essential, *A. millifolium*—constituents, 2160
**Ointment** preparation—salicylic acid, sodium salicylate, 1732
**Open-model** system—two compartmental, 128
**Operating instructions**—dissolution apparatus, 485
**Opium alkaloids,** 30
benzylisoquinoline isolated, 940
**Optical rotation,** 353
identity, 329; 757; 864; 865; 874; 933; 1037; 1263; 1514; 1697
reaction rate, 1209
structure, 711
**Optical rotatory dispersion**—analysis, 1865
absolute configuration, 447
**Organic** acids effect—stearate degradation, aspirin, 1877
**Organophosphorus pesticides**—analysis, 1620
**Osmotic** coefficient—calculated, equation, 861
properties—aqueous solutions, 861
**Overturn end point,** 226
**Oxazepam,** 311
renal metabolism, 1301
**Oxidation,** tetracyclines—final biosynthetic step, 1633
**Oxime** formation rate—sugar identification, 1180
**Oxygen** ignition—iodine release, 634

P

**PABA antagonists**—chemical reactivity, 1455
**Palaudine**—isolated, structure confirmed, 940
**Palladium - on - carbon** — hydrogenation, 877
**Palmitate** uptake—rabbit heart slices, 1304
**Paper chromatography**—analysis, 27; 325; 701; 1357; 2002; 2068
degradation monitoring, 1117
identity, 443; 747; 1125; 1614
purity test, 649
radiochemical purity, 1357
separation, 313; 1478; 1606
separation, analysis, 1319
separation, degradation products, 338
separation, identity, 1511; 2170
**Paper disk method**—analysis, 1801
agar plate, 39
antiviral testing, 2174
**Parabens,** antimicrobial activity—binding effect, 1370
in gels, creams—analysis, 1760
methyl, propyl-sucrose esters—interaction, 2093
**Paralyzation** — dimethyltubocurarine, 1782
**Paramethasone acetate**—blue tetrazolium reagent, 1227
**Pargyline** effect—cyclohexylamine activity, 1132
**Partial molar area,** 17
**Particle** bonding—tablet compression, 574
coating—apparatus, method, 1983
concentration—stability ratios, 557
**Particle size**—analysis methods, 1273
dissolution, water-insoluble drug, 2143
distribution—emulsions, 1836
drugs—review, 1825
effect—absorption, excretion, toxicity, 1146
flow rate effect, 667; 2015
modifiers effect, 1748
stability ratios, 557
trichloroethyl carbonate toxicity, 1269
wax, nozzle size effect, 1104
**Partition coefficients**—bromothymol blue, 2140
isopropyl myristate-propylene glycol system, 928
pyridine, 87
transfer rates—comparison, 1342
**Pendular bond** strength—particle size, 478
**Penicillium** *janczewskii* II—cultures, 975
species—deuterium effect, 2049
**Pentachlorophenyl esters,** *N*-protected—peptide, amino acid coupling, 1514
**Pepsin** effect on starch, 187
**Peptide** synthesis, 1514
**Perchloric acid** in dioxane titrant, 137
titrant, 1768
**Perfused** organ system—drug elimination, 1991
**Perfusion** technique—drug administration, 1031
**Peritoneal dialysis,** 1192
**Permeation rate**—lipoid barrier, 235
solvent, 217
**Peroxidase** activity—*p*-phenylenediamine oxidation, 1609
horseradish, hydrogen peroxide—catalyzed conversion, 874
**Pesticidal** pyrazoles, 537
**Peyonine** structure determination, 191
**Peyophorine**—identity confirmation, 2017
**Peyote alkaloids,** 191; 254; 2017
**pH dependence**—oxidation rate, 1706
hydrolysis, 282
absorption rate in guppies, 158
**pH effect**—acetylcholinesterase inhibition, 418
albumin binding, 245
complex formation, 53
corneal ionic density, 378
cyclamate instability, 1073
echothiophate iodide degradation, 411
extraction efficiency, 58
flocculation, 569
pyridine release—w/o emulsions, 87
salt extraction, 1199
stability, 1117
**pH** independence of absorption rate in goldfish, 158
profile—colored complex, 705
solubility profile, 878
**Phagocytosis**—drug absorption, 357
**Pharmaceutical** aspects—antibiotics, radiopharmaceuticals, 1075
solids—electrostatic characteristics, 504
technology, 1075
**Pharmaceutics**—1967 literature review, 1075
**Pharmacokinetic behavior**—protein binding, 895
**Pharmacokinetics**—aspirin, salicylic acid, 1313
bishydroxycoumarin elimination, 68; 1881; 1888
drug absorption, 117
ephedrines absorption, metabolism, excretion, 1933
equations—plasma clearance, DIC, 2126
equations—drug accumulation, 2162
flow rate-drug distribution, 2000
thiopental, 1346
**Pharmacological activity**—biphenylethylamines, 564
imidazolines, 1176
pralidoxime salts, 1142
procaine amide analogs, 2073
salicylic acid hexylcarbonate, 1128
**Pharmacological screening,** 578; 1063; 1445
benzazoles, 1814
CNS depressant activity, 707
5,9 - dimethyl - 5,7 - benzomorphans, 884
3,4-diphenyl-4-oxazolin-2-one derivatives, 1798
ellagic acid, 1728
3-substituted-2-benzoxazoles, 1763
**Pharmacology**—ethanol extract, *Euphorbia esula,* 933
**Phase-contrast microscopy,** 293
**Phenacetin,** 524
dissolution rates, 1322
impurities determination, 2181
**Phenaglycodol,** 426
**Phenethylamine** analogs—analysis, 1788
β-**Phenethylbiguanide (C-14 labeled)**—metabolism, 1125
**Pheniramine**—urinary excretion, 621
**Phenobarbital**—dissolution rates, 1322
effects—motor activity, mice, 1572
**Phenolic disinfectants**—activity mechanism, 768
**Phenol red**—sodium deoxycholate delayed gastric emptying, 1493
**Phenothiazine** derivatives—3-azabicyclo[3.2.1]octane HCl, 1785
**Phenoxyamine** effect—cyclohexylamine activity, 1132
**Phenoxymethyl penicillin** fermentations—*p*-hydroxyphenoxymethyl penicillin determination, 1606
α-**Phenyl-α-(2,3-cyclohexenyl) acetic acid** derivatives—synthesis, 578
**Phenyl ethers**—synthesis, 151
**Phenylacetic acid** effect—*Penicillium* cultures, 2049
**Phenylalanine** analogs, radioiodinated—synthesis, 1958
$^{14}$**C-Phenylalanine** incorporation—inhibition, 351
**Phenylbutazone**—analysis, 2053
tablets—analysis, 1952
*p*-**Phenylenediamine**—color reagent, 1202
**Phenylephrine** dosage forms—analysis, 467
**3-Phenylglutaric acid,** iodinated derivatives—synthesis, 1710
**2-Phenylindolizine** derivatives—Mannich bases, 1989
**Phenylmercuric nitrate**—preservative activity, 389
**Phosphate** effect—trichloroacetic acid-soluble, insoluble nitrogen metabolites, 1661
**Phospholipids**—*E. coli* extracted, 1398
**Phosphorus-nitrogen compounds,** 189; 532
synthesis, 1625
**Photodegradation,** menadione—vehicle effect, 1409
**Photohemolysis** induction—tetrachlorosalicylanilide, 2136

**Photomicrographs**—coated particles, 1983
drug particles, 2143
technique—bubble size determination, 624
**Photosensitivity** reactions, 1
testing, 1
**Photosensitization**—relation to chlorpromazine HCl penetration, 178
**Phthalimidoaldehydes**—synthesis, pharmacology, 815
**Physical** parameters, effect—coating core tablets, 1007
pharmacy, 1075
**Physostigmine**—catecholamine output, 1741
**Phytochemistry**—aerial parts, *Euphorbia esula*, 933
**Picric acid** reagent, 36
**Pituitary gland** effect—turbidimetric response, 1526
**pKa values**—titration, 1616
**pKa′ value,** first—bromothymol blue, 2140
**Placenta**—perfused human, 287
**Plasma** – *N* - acetyl - *p* - aminophenol—analysis, 795
analysis—caffeine, 1703
binding—competitive inhibition, 895
concentration—aspirin, sustained release, 1535
concentration — bishydroxycoumarin 1888
extraction of ethchlorvynol from, 185
griseofulvin analysis, 984
levels—acetaminophen, 1146
levels, griseofulvin—single, multiple doses, 1383
**Plastics**—entrapment, 12
**Plastic film** package—tablet stability, 893
**PMR spectrometry,** 183
identity, 1616
**Polarimetry**—identity, 747
**Polarization bonding**—complex formation effect, 350
**Polarographic study**—complex formation, 1056
**Polyketide** theory—tetracycline biosynthesis, 1633
**Polymeric membranes**—drug diffusion, 944; 949; 1401
**Polymers,** effect—emulsion particle size, 1836
compressed, hydrophilic matrices, 1292
**Poly (methyl, vinyl ether/maleic anhydride)** and hemi-ester—test polymers, 1598
**Polymyxin B formulations**—analysis, 642
**Polyoxyethylene** glycol monododecyl ethers—hemolysis, 1246
polyoxypropylene surfactants, 514
**Polypropylene-polyisobutylene alloy**—stability, 1552
**Polysorbate 80** effect—ascorbic acid oxidation, 2119
effect on lipoid barrier, 101
pretreatment effect on secobarbital absorption, 101
**Polyvinylpyrrolidone** determination—weight-loss method, 832
solution—binder, 478
**Porphyrins**—synthetic, 300
**Potassium** absorption, 617
$^{42}K$ chloride solution and tablets—*in vivo* testing, 617
chloride tablets—*in vitro* testing, 617
iodoplatinate reagent, 30
perrhenate—pharmacology, toxicology, 321
**Potato-dextrose broth,** 97
**Potential** vitamin D content—calciferol and precalciferol concentration, 1326
**Potentiometric** analysis, 488; 1051; 1260
measurements—reduction potential, 1435
end point determination, 137
titration—analysis, 311
titration—pKa determination, 1916
titration—pKa values, 1401
titration—procedure, 1434
titration—reactivity analysis, 1598
**Powder,** sucrose-acacia solution—coating, 1007
flow studies, 2153
**Powders** for encapsulation—physical properties, 660
**Pralidoxime salts**—absorption, elimination, 1142
**Prasinomycins**—molecular association, 690
**Preequilibration**—promazine, adsorbent, 1604
**Prednisolone**—degradation products, 2116
stability in CMP, 1057
**Preservative**—tuberculin solution, 605
**Pressor** activity—cyclohexylamine, 1132
depressor activity—ST-155, 594
response, 287
**Pressure** effect—drug release, 217
relation—thermal effects, 677
**Pretetramids**—tetracycline precursors, 1633
**Procaine**—interaction with corneal surface, 378
amide analogs—synthesis, 2073
penicillin G suspension, 1796
**Prodine** enantiomers—absolute stereochemistry, 711
**Prodrugs**—acetaminophen carbonate esters, 1146
acetaminophen, trichloroethyl carbonate ester, 752
**Product identity** (published) questioned, 192
**Progesterone** and estradiol benzoate aqueous suspension, 169
testosterone propionate, and estradiol benzoate in oil, 169
**Prolonged-release** dosage forms—spray congealed, 1104
**Promazine** absorption—adsorbent effect 1604
**Propantheline** bromide—human urinary excretion, 1375
**Propellants**—aerosol analysis, 966
foam bubble size, 624
**Propoxyphene HCl**—paramethasone acetate on aspirin core, 1227
**Propyl substitution**—activity effect, 269
**Propyl** tosylthiocarbamate—hypoglycemic activity, 1791
**Propylene glycol**-water-Carbopol 934—vehicles, 928
**Protection index**—rat paw weights, 1236
**Protein binding,** 1370; 1627
drug distribution, 895
thiopental, 1346
**Protein-phenol** disinfectant—association, 768
**Protio** nutrient media—*Penicillium* cultures, 2049
**Protoveratrine A, B** activity—cryptenamine effect, 1576
**Prunus emarginata** extract—mouse litter reduction, 1607
**Pseudomonas aeruginosa**—fluorescein solution, 389
**Pseudoplastic flow** simulated by analog computer, 155
**Psilocybin** analogs—*Psilocybe baeocystis*, 1667
**Pulmonary resistance,** compliance—determined, 971
**Punch,** lower—pulldown force, 1770
variables affecting wear, 1779
**Purity** determination, drugs—differential scanning calorimetry, 1868
test—furosemide, 640
**Pyrazoles,** 1044
biologically active—review, 537
**Pyrazolone** derivatives, 1056
**Pyridine-3-aldoxime esters, ethers**—synthesis, 1586
**Pyridine dithiocarbamates**—synthesis, 345
**Pyridine** release from emulsions, 87; 93
**Pyridoxine** HCl—analysis, 1386
**Pyrimidine dithiocarbamates**—synthesis, 345
**Pyrogallol** morpholinomethyl derivative—penicillin hydrolysis, 1916
**Pyrroles**—synthesis, 1013
**Pyrrolizidine alkaloids,** 1112
**Pyrrolo[2,3 - *d*]pyrimidines** — synthesis, 1616
**Pyruvate,** lactate oxidation—emetine poisoning effect, 1428

Q

**Quantitative determination**—single multiple components, 847
**Quasi-steady-state diffusion,** 949
cell—diagram, 944
**Quaternary** ammonium compounds chain length—toxicity effect, 1431
tertiary chlorpromazine HCl—activity compared, 2089
**Quercetin - 3 - β - D - mono - galactoside**—isolated, 1059
**Quinaldine** dithiocarbamates—synthesis, 1793
**Quinestrol**—analysis, 1000
**Quinine** reference units—fluorescence determination, 1938
azonaphthalene sulfonic acid dye aluminum chelate, reference source 333
**3-Quinuclidinol dibasic acid esters**—synthesis, 684

R

**Radiation protective** activity—3,3-dimercaptoacrylonitrile derivatives, 1611
activity—screening, 1793
agent, 1033
agent—quinuclidine derivative, 1725
properties, 345
**Radioactive** compounds—release rates, 928
phenol derivates—test compounds, 768
**Radioactivity** determination—relative, specific, 1125
distribution—blood, urine, 1135
**Radiochromatography**—analysis, 2068
identity, 1962
purity, 1958
**Radioiodination**—iodide-125, 1657
phenylalanines—tissue distribution, 1958
**Raman spectroscopy,** 195
**Rate constants**—flavin hydrolysis, 841
**Reactivity index**—molecular orbital technique, 1176
**Reagents**—colorimetric analysis, 1257
**α-Receptor** blockage—lysergic acid derivative, 1390
**Receptors** proposed—serotonin, 1188
**Record card**—punches, 1779
**Refractive index,** 688
identity, 2157
**Release,** availability—chloramphenicol capsules, 1844
rates—compressed hydrophilic matrices, 1292
rates, drug—particle size, 1825
rates—solid dosage forms, 1649
**Renal** artery constriction—serotonin activity, 1966
clearance—DIC, 2126
metabolism—*in situ* determination, 1301
**Renovascular** hypertension—experimental, 1966
**Reserpine** activity—antagonism, 709
activity—diluent effect, 613
–desoxycholic acid dispersions—solid state, 708
effect—cyclohexylamine activity, 1132
enterochromaffin cell granulation, 1906
**Resorcinol** monoacetate composition, 475
resorcinol mono- and diacetate combination—confirmed, 475
**Respiratory activity**—3-quinuclidinol esters, 684
**Resuscitation method**—rats, 1248
**Retention times,** 50 drugs—relative to pentobarbital, 847
**(+)-Reticuline**—isolation, 1023
**Reversibility**—Mannich reaction, 715
**Rhenium trichloride**—pharmacology, toxicology, 321
**Rheology,** 155
lotion—changes during aging, 671
MCC-CMC gels, 1927
penicillin G suspension, 1796
salicylic acid-quaternary ammonium compounds, 1903
**Rhodamine B**—fluorescence standard, 333
**Rose bengal**—aralkylamine complex, 124
**Rotating disk**—dissolution apparatus, 959
**Rotary** tablet machine, 1770

S

**Salicylamide,** acetaminophen determination—analgesic mixture, 1218
caffeine complex—transfer rate, 1342
effect—salicylic glucuronide formation, 1330
**Salicylamine-caffeine**—complexing system, 1556
**Salicylate** activity—mechanism, 1238

sodium, effect—salicylamide glucuronide formation, 1330
**Salicylates**—action mechanism, 1042
hypoglycemic activity, 2111
**Salicylic acid,** 891
carbonate esters—prodrugs, 828
diffusion—ointment bases, 1540
disks—dissolution rates, 1072
free—analysis, 631; 1685
hexylcarbonate, 1128
*n*-methylglucamine salt distribution, 128
*N*-methylglucamine salt—i.v. administration, 1313
PVP—compressed mixtures, 832
quaternary ammonium compounds—interaction, 1903
retardation—caffeine transfer, 1335
sodium salicylate absorption—ointments, 1732
sublimation—aspirin tablets, 1850
**Salicylurate excretion**—salicylate administration, 1330
**Salivary levels**—antibiotics, 530
**Salt effects**—complex formation, 1206
**Salt formation** effect—peptide chain lengthening, 1514
methapyrilene, polymers, 1598
**Salvia triloba**—phytochemical investigation, 1037
**Salvigenin**—new flavone, isolated, 1037
**Sampling** device—aerosol analysis, 488
techniques—aerosols, 966
**Saponification equivalents,** 328
**Schematic diagram**—electrostatic tester, 504
solution kinetics apparatus, 494
**Schiff's base transformation** *N*-phenethyllutidone, 791
**Schistosoma**—infecting organism, 1202
**Scintillation** counting—analysis, 1649
counting—whole body, 399
spectrometry—analysis, 105
**Secobarbital**—polysorbate 80 system, 101
**Sedative** activity—noscapine-related compounds, 1755
**Sedimentation** coefficients—schlieren, interference optical systems, 690
redispersibility—suspensions, 569
**Self-association**—caffeine, 1335
**Semicarbazone,** phenaglycodol—analysis, 426
**Sensitivity** reactions, testing, 1
threshold—antibiotics, 871
**Sephadex gels,** aspirin, salicylic acid separation, 1240
**Serotonin** infusions—rats, 1966
mescaline interaction, 72
preferred conformation, 1188
**Serum** levels of *p*-methoxycinnamate, 27
turbidimetric response—heat application, 1526
**Shear** rate, stress range, effect—gels, 1927
strength—powders, 1421
**Shock** avoidance—chlorpromazines, 2089
**Sialic acid** content—sputum viscosity, 824
**Silastic membranes**—aminophenones, diffusion, 949
diffusion rates, 1401
permeability, 944
**Silica gel chromatopile**—separation, 975
**Silicon** analysis, 1243
**Silver** complexes—phenethylamine analogs, 1788
membrane filter—diffusion coefficients, 1583
**Simulated** gastric fluid, 164
intestinal fluid, 164
system—CMC mucilage comparison flow curves, 155
**Simultaneous determination,** 845
**Single-energy preferred conformation**—serotonin, 1188
**β-Sitosterol**—isolated, identified, 1996
**Skin** irritation, 321
reactions—incidence, 1
**$^{35}$S-Labeled thiothixene**—synthesis, 105
**Snails,** *Schistosoma masoni* infection—analysis, 1609
species of *Biomphalaria, Bulinus,* 1202
**Sodium** borohydride reduction—steroid analysis, 1737
carbonate solution—diosgenin solid, 602
fluorescein–polyvinylpyrrolidone system, 53
methoxide titration—analysis, 649
**Solid** particles—membrane transport, 1401
solution effect—purity determination, 1868
state dispersions—pharmacologic activity effect, 708
**Solubility**—ampicillin, anhydrous, trihydrate, 1945
complex formation analysis, 404
diethylstilbestrol, 1744
drug—simultaneous administration, 1379
in phthalic esters, 12
method—parabens-sucrose esters interaction, 2093
propylene glycol-water, 928
salicylic acid carbonate esters, 828
salicylic acid—PVP, 832
**Solubilization** with *n*-alkylpolyoxyethylene surfactants—temperature effect, 79
**Solution kinetics** apparatus, 494
**Solvent** effect adsorption equilibrium, 598
**Solvents,** solids—water determination, 2007
**Solvolysis** — halogen - substituted uridines, 1478
**Sorbitan monooleate**—dissolution rate, 584
**Soybean lecithin** lipids—interaction, 17
**Spasmogenic activity**—evaluated, 815
**Specific rotation**—identity, 447
**Spectral properties**—sulfonamides, precursors, 1455
**Spectrophotometry**—analysis, 768; 1046; 1246
cell count determinations, 609
turbidity analysis, 404
**Spectropolarimetry**—dissociation constants, 1784
**Speed of compression**—thermal effects, 677
**Spheres,** unequal—attractive energy, retardation, 436
**Spin-spin coupling,** long-range—bicyclo-[3.1.0]hexane systems, 1523
**Spray** coating—automated airless system, 1223
congealed formulations, 1748
congealed particles, 584
congealed products—*in vitro* dissolution model, 1104
**Sputum viscosity,** 824
**Stability**—alkaline solution, 335
assay—quinestrol dosage forms, 1000
constants, 183
constants—equations, 1556
constants—tryptophan-alkylxanthine complexes, 1865
emulsions—aging, polymer effect, 1836
menadione—nonaqueous vehicles, 1409
prediction—pharmaceuticals, 1117
ratios—flocculating monodisperse systems, 557
ratio—suspensions, 569
studies—linear, nonisothermal, 2080
**Staph. aureus**—ethylene oxide resistant, 433
**Starch** grain diameter determination, 187
in simulated gastric fluid, 187
starch-fraction sols—complexing behavior, 404
swelling—tablet disintegration, 393
**Static** conditions—Danckwerts' model, 1629
conditions—dissolution rates, 787
electrification—positive, negative, applied, 504
friction—powder beds, 1421
**Stearic acid** monomolecular films—grisan effect, 230
**Steric factors**—Mannich reaction mechanism, 1097
**Sterilization,** ethylene oxide—variables affecting, 433
of plastic devices, 12
**Steroid mixtures**—analysis, 169
**Steroidal iodoacetate,** 1450
**Steroids**—analysis, 1737
**Stilbene** isothiocyanates—synthesis, 1938
***trans*-Stilbene**—conversion in rabbits, 713
**Stimulant effects**—phenobarbital, 1572
**Stimuli application**—anesthesia determination, 2045
**Stirred conditions**—diffusion layer model, 1629
dissolution rates, 787
**Stirrer, propeller-driven**—dissolution apparatus, 959
**Stoichiometric balance,** 112
**Stoichiometry,** 282
cinnamic compounds, oxidation, 1706
**Stomach** weight—sodium deoxycholate effect, 1493
**Stress distribution,** solids—solubility, 574
**Strontium,** lead extraction—gastrointestinal fluids, 1215
**Structure–activity relationships,** 737; 1013
analgesic, 1176
cyanoacetamides, 1530
LSD analogs, 2157
procaine amide analogs, 2073
salicylates, 2111
sulfanilamide analogs, 1017
**Structure,** basic—tetracyclines, 1633
**Strychnine phosphate** tablets—analysis, 1249
**3 - Substituted - 2 - benzoxazolinones**—synthesis, 1763
**2-Substituted indazoles**—synthesis, 877
**2-(4′-Substituted phenyl)-Δ$^1$-pyrrolines**—synthesis, 1910
***N*-Substituted phosphoric triamide,** phosphorodiamidic acid derivatives—synthesis, 532
**Succinic acid** buffer—acetic anhydride interaction, 239
**Sugars**—identification, 1180
**Sulfacetamide** solutions—stability, 1212
co-administration, 1379
combination, 142
**Sulfaethidole–wax**—prolonged release formulations, 1748
**Sulfaethylthiadiazole–wax** formulations, 584; 1104
particle preparation, 49
**Sulfanilamide** formation—sulfacetamide solutions, 1212
thiophene analogs, 1017
wax system, 278
**Sulfate,** total—equilibrium mixture, 342
**Sulfinpyrazone**—analysis interference, 2053
**Sulfobromophthalein** solutions—analysis, 819
**Sulfonamide** suspensions—direct analysis, 250
**Sulfonamides**-phosphorus tri- and oxychloride—condensation, 1625
structure, activity relationship, 1455
**Sulfuric acid–methanol** color reagent, 147; 1168
**Sunscreen preparations**—testing, 1236
**Surface** pressure-area isotherms—determination, 1440
pressure—effect on film, 178
tension-concentration curves—purity determination, 1431
tension—dissolution effect, 1322
**Surfactant** concentration effect—*Z* values, 1394
concentration—dissolution effect, 1322
physiologic—dissolution, water-insoluble drug, 2143
effect on starch, 187
effect on wax particle formation, 49
effect—wetting, 217
solution—benzoic acid solubility, 787
stability ratios, 557
**Surfactants**—flocculation, 569
in dialysis solutions, 1192
**Suspending** adjuvants, effect—gels, 1927
**Suspensions**—oral, 250
**Sustained-release** tablets—double layer, 1535
**Sympathomimetic amines**—analysis, 1048
**Synthesis** of 3-substituted benzoxazolinones, 39
of *N*-methyl-14-*O*-desmethylepiporphyroxine derivatives, 30

**T**

**Tablet** coating, 317
compression, 574
density, 164
disintegration—starch grain damage, 393
formulation dissolution, 164
formulation effect—disintegration time, 1360
friability, 181
hardness, 164; 181

weight variation—powder flow effect, 2153
**Tablets**—compressed, 802
compressed—crushing-strength, 481
furosemide—analysis, 640
heat of compression, 677
physical properties—granule effect, 497
sugar coating, 1223
**Tableting** tool life records—evaluation, 1779
**Tachysterol**—elimination, 1308
**Tartaric acid** buffer–acetic anhydride interaction, 239
**Taurodeoxycholate, sodium**—potentiating effect, 1354
**Temperature** effect—aspirin tablets stability, 1850
effect—drug release rates, matrices, 1292
effect—hemolysis, 1246
effect—stability, 1117
indicating pigments—heat of compression, 677
rheological properties, 1796
**Tensile** properties—polypropylene alloy, 1552
strength—healing incision, 1042; 1238
**Terpenes**—relative retention times, 473
**Terpin hydrate**-codeine elixir—analysis, 1412
elixirs, 145
formulations—analysis, 473
**Tertiary amines**—automated analysis, 852
**Testosterone** butyrate and estradiol benzoate aqueous suspension, 169
micellar solubilization, 1394
**Tetrabutylammonium hydroxide**—titrant, 311
**Tetracycline** analogs, 351
antibiotics—biosynthesis review, 1633
phenothiazines, 166
**Tetradecatriethylammonium bromide**—synthesis, 1431
**α-Tetradecylcitric acid**—isolated, identified, 1804
**Tetrahydro-β-carbolines,** *N*-2(9)-substitutes—synthesis, 1364
**Tetraphenylborate salt** formation, 137
*meso*-**Tetraphenylporphyrins,** *para*-substituted metal chelates, 300
**Thalictrum alkaloids,** 262
**Thalidomide,** D and L—synthesis, 757
**Theophylline** combinations—nonaqueous titrations, 1051
**Therapeutic** aspects—particle size, 1825
**Thermal** analysis—differential, 1552
stability, menadione—vehicle effect, 1409
**Thermodynamic effects**—compression, 677
**Thermodynamics**—stressed solids, 574
**Thermoelectric osmometer**—improved, 861
**Thiamine,** 112
bromothymol blue salt, 1199
bromothymol blue salt formation, 112
bromothymol blue salt physical properties, 112
**Thiazesim-$^{14}$C**—excretion, distribution, 1497
metabolism—*in vivo, in vitro,* 1505
**Thick-layer chromatography**—component identification, 399
separation, 1231
**Thiolphthalide,** 175
**Thiopental**—distribution, 1346
**6-Thiopurine riboside,** 1157
**Thiothixene** excretion, melanin interaction, metabolism, 105
**Thiry-Vella fistula** dog—biologic model, 795
**Thixotropy**—agitation type, duration, 671
**Thymotic acid** and homologs—activity, 989
**Thyroid** preparations—analysis, 634
uptake—TIBA, 399
**Thyroxine**—quantitative determination, 634
**Time-lapse cinematography,** 293
**Tissue** analysis—5-hydroxytryptamine, 1568
compartment—estimation, 117
culture, 12
culture—mouse fibroblast cells, 293
distribution—radioiodinated dichlorodiphenyldichloroethane analogs, 1657
distribution thiothixene, 105
**Titration, nonaqueous**—analysis, 1768
**Titrimetric analysis**—EDTA, $MgCl_2$, 1215
**Titrimetry, nonaqueous**—quantitative analysis, 137
**TLC**—analysis, 411; 515; 524; 764; 791; 1023; 1231; 1716; 1744
analysis confirmation, 1168; 1868
analysis, decomposition, 602
analysis, identity, 2181
analysis, radiochemical purity, 1357
analysis, separation, 710
analysis of urine, 105
densitometric scanning, 314
determination of free tocopherol, 23
identity, 443; 451; 646; 696; 713; 747; 806; 811; 864; 865; 889; 1037; 1151; 1398; 1922; 1996
and paper chromatography—separation, 262
polyamide—analysis, 1620
separation, 30; 83; 124; 169; 323; 335; 459; 475; 757; 856; 940; 975; 1048; 1263; 1308; 1616; 1716; 1720; 1857; 1962; 2017
separation, degradation products, 338
separation, identification, 2167
separation, identity, 634; 819; 933; 1035; 1059; 1212; 1364; 1497; 1505; 1511; 1562; 1619; 1661; 1667; 1952; 2116; 2132
separation monitoring, 1020
separation, plastic pigments, 2038
UV light fluorescence, 516
**α-Tocopheryl acetate**—analysis, 470
**Tolbutamide** dosage forms—analysis, 459
tablets—disintegration, 1253
**2-o-Tolylcyclohexanols,** *trans* and *cis*, 447
**Toothpaste**—fluoride ion analysis, 1260
**Topical** testing, toxicity—review, 1
**Tortuosity values**—apparent, 278
**Tosylbiurets,** thiocarbamates—synthesis, 1791
**Toxicity**—DNA-aminopteridines, 878
of ethylene oxide, 12
*in vivo, in vitro,* 1017
oral—acetaminophen prodrugs, 774
testing—X-ray contrast agents, 1710
**Transacetalation** of di- and trihydric alcohols, 161
**Triazene** transformation product, 83
**Trichloroethyl carbonate**—toxicity, 1269
**Triethyl citrate** toxicity, 293
**Trifluoperazine** metabolites—nonpolar, 1511
**5-Trifluoromethyl-2-benzoxazolinone**—synthesis, 1763
**5-Trifluoromethyl-2′-deoxyuridine**—hydrolysis, 1117
*m*-**Trifluoromethylhippuric acid,** deethylated fenfluramine—metabolites, 1173
**2,3,5-Triiodobenzoic acid** (TIBA), 399
**Triiodothyronine**—quantitative determination, 634
*N*-**3,4,5-Trimethoxybenzoyl heptamethylenimine**—antidepressive activity, 709
**Trimethylsilyl ether**—lincomycin, 693
**Trisulfapyrimidine** tablets analysis, 142
**Triterpenic constituents**—*Lepechinia chamaedryoides,* 864
**Tritium foil** electron capture detector—GLC analysis, 2165
**Tropaeolin OO**—indicator, 137
**Tropine-labeled atropine**—synthesis, 1357
**Tryptophan-alkylxanthines** — interaction, 1865
**Tuberculin analogs,** 1616
**Tuberculin solution**—stability, 605
**Tumor** inhibition, $ED_{50}$—deoxypodophyllotoxin, 696
inhibition—pyrrolizidine alkaloids, 1112
localizing agents, 1958
localizing agents—synthesis, 1657
**Turbidimetric response,** heat—anti-inflammatory agents, 1526
**Two-compartmental** open system—pharmacokinetic model, 1313
**Tyloxapol,** effect—cortisol diffusion, 836
**Tyramine HCl** oxidation—isopropyl hydrazide inhibition, 2011

**U**

**Urethan** derivatives—phosphorylated, 189
**Urinary excretion,** 36
acetaminophen, 1146
fenfluramine and metabolites, 1173
—quaternary ammonium compounds, 1375
rates, 994
rats—trifluoperazine metabolites, 1511
**Urine**—chlorpheniramine, metabolites, separation, determination, 2085
extraction of ethchlorvynol from, 185
furazolidone analysis procedure, 325
phenacetin metabolites, analysis, 524
**Uropygial** gland homogenates, chicken—17β-hydrogenase, 1962
**Ursolic acid**—spring plant growth, 864
**Uterine-placental-fetal preparation**—*in situ,* 1031
**UV densitometry** on TLC—analysis, 1760
**UV determination** of hydrolysis, 142
**UV irradiation**—*Chlorella* cultures, 2038
of film, 178
photohemolysis, 2136
effect—polypropylene alloy, 1552
**UV light**—identity, 1562
methotrexate spot detection, 2002
nucleoside visualization, 1478
phototube detector—scanning, 1760
reaction irradiation, 1447
spot fluorescence, 2181
spot visualization, 1857; 2132
α-tocopherol zone visualization, 1716
vitamin A fluorescence, 309
**UV photodegradation** of $^{14}$C-carboxy 2,3,5-triiodobenzoic acid, 323
**UV spectrophotometry**—analysis, 23; 27; 44; 58; 68; 79; 169; 195; 274; 278; 313; 411; 426; 451; 467; 488; 527; 598; 644; 658; 698; 752; 780; 798; 841; 1048; 1135; 1195; 1206; 1212; 1218; 1231; 1292; 1308; 1313; 1322; 1330; 1335; 1342; 1401; 1535; 1540; 1511; 1556; 1598; 1609; 1649; 1737; 1850; 1873; 1877; 1952; 1962; 1979; 2002; 2053; 2080; 2085; 2093; 2105; 2119;
analysis, decomposition, 602
analysis, identity, 640; 649
analysis, salicylic acid, 832
complex stability, 183
continuous—analysis, 282
degradation monitoring, 1117
identity, 631; 713; 806; 1184; 1263; 1616; 1619; 1667; 1720; 1728; 1793; 1996
identity, chelate, 605
iodine analysis, 634
kinetic analysis, 791
oxime formation monitoring, 1180
solvolysis monitoring, 1478
pKa determination, 1916
procedure, 1434
reaction monitoring, 1789
structure, 30; 83; 166; 191; 230; 254; 262; 269; 300; 311; 329; 348; 515; 516; 529; 737; 864; 865; 874; 940; 975; 1023; 1029; 1035; 1037; 1039; 1044; 1065; 1125; 1151; 1438; 1505; 1614; 1671; 1910; 1922; 2056
structure, analysis, 335

**V**

**Vagal** stimulation—enterochromaffin cell granulation, 1906
**Vancomycin HCl,** 314
**Vanillin oxime** derivatives—synthesis, 1244

**Vaporphase chromatography**—identity, 430; 713
**Vasomotor activity**—3-quinuclidinol esters, 684
**Vehicles,** topical—steroid release, 928
**Vetiver oil,** Angola—khusenol isolation, 1029
**Vials**—moisture determination, 887
**Vibration, effect**—shear force, 1421
**Vincaleukoblastine** content—gibberellic acid, 589
**Vindolinine,** yohimbine, perivine—isolation, 1035
**Viscosity**—salicylic acid-quaternary ammonium compounds, 1903
shear rate relation, 671
**Visible spectrophotometry**—structure, 300
**Vitamin A** decay, 23
effect—aspirin retarded healing, 1238
esters, α,α-dialkyl-substituted—synthesis, 1184
**Vitamin $B_{12}$**, 1040
**Vitamin D** analysis, 309; 1308; 1326
**Vitamin E** analysis—multivitamin products, 1716; 2149
decay, 23
effect—aspirin retarded healing, 1238
—interference elimination, 309
**Vitamin (multiple) dosage forms,** 470
**Volume of distribution,** 128
apparent, 68
DIC, DIC-$2^{14}C$, 2126

W

**Water** of crystallization—moisture source, 1776
determination, 2007
**Waxes**—dissolution rate, 584
**Weight,** tablets—granule size, 497
variation, capsules—factors affecting, 660
**Wetting effect**—drug release, 217
**Wild rice,** *Zizania aquatica*—phytochemical properties, 889

X

**Xanthine** complexes—bonding mechanism, 350
derivatives, 245
**Xanthoxime esters, ethers**—synthesis, 1586
**Xenon** trioxide oxidation—organic compounds, 1706
**X-Irradiation** exposure—mice, 1033
**X-Ray** analysis—crystal structure, 175
contrast agents—synthesis, X-ray intensity, 1710
crystallography—analysis, 1157
crystallography—identity, 1720
diffractometry—analysis, 250
emission spectrometry—analysis, nonautomated, 653

Y

Z

**Z values**—determination, 1394
**Zero first-order process**—salicylic acid elimination, 891
**Zero-order infusion** method, 128
**Zeta potential**—suspensions, 569
**Zirconium chloride**—color reagent, 705